<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Janus kinase inhibitors for the treatment of COVID‐19 - Kramer, A - 2022 | Cochrane Library</title> <meta content="Janus kinase inhibitors for the treatment of COVID‐19 - Kramer, A - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015209/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Janus kinase inhibitors for the treatment of COVID‐19 - Kramer, A - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015209/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015209" name="dc.identifier" scheme="DOI"/> <meta content="Janus kinase inhibitors for the treatment of COVID‐19" name="citation_title"/> <meta content="Andre Kramer&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Carolin Prinz&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University Medical Center Göttingen, Georg August University" name="citation_author_institution"/> <meta content="Falk Fichtner&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Anna-Lena Fischer" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Volker Thieme" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Felicitas Grundeis" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Manuel Spagl" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Christian Seeber" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Vanessa Piechotta" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Maria-Inti Metzendorf" name="citation_author"/> <meta content="Medical Faculty of the Heinrich-Heine-University Düsseldorf" name="citation_author_institution"/> <meta content="Martin Golinski" name="citation_author"/> <meta content="University Medical Center Göttingen, Georg August University" name="citation_author_institution"/> <meta content="Onnen Moerer" name="citation_author"/> <meta content="University Medical Center Göttingen, Georg August University" name="citation_author_institution"/> <meta content="Caspar Stephani" name="citation_author"/> <meta content="University Medical Center Göttingen, Georg August University" name="citation_author_institution"/> <meta content="Agata Mikolajewska" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="Stefan Kluge" name="citation_author"/> <meta content="Medical Center Hamburg Eppendorf (UKE)" name="citation_author_institution"/> <meta content="Miriam Stegemann&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="miriam.stegemann@charite.de" name="citation_author_email"/> <meta content="Sven Laudi&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leipzig Medical Center" name="citation_author_institution"/> <meta content="Nicole Skoetz&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD015209" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/06/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015209/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015209/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015209/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antiviral Agents [therapeutic use]; *Coinfection; *COVID-19 Drug Treatment; *Janus Kinase Inhibitors [therapeutic use]; Oxygen; Randomized Controlled Trials as Topic; SARS-CoV-2; United States" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015209&amp;doi=10.1002/14651858.CD015209&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Qh5938oe";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015209\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015209\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015209\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015209",title:"Janus kinase inhibitors for the treatment of COVID\\u201019",firstPublishedDate:"Jun 13, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015209&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015209';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015209/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015209/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015209%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015209/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015209/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015209/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015209/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015209" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015209/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015209" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015209/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015209/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5476 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015209" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015209/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/appendices#CD015209-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/supinfo/CD015209StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/supinfo/CD015209StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015209/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015209/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015209/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015209/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015209/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Janus kinase inhibitors for the treatment of COVID‐19</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Contributed equally: first authors"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0004">Andre Kramer</a><sup>a</sup></li> <li class="author custom-tooltip" title="Contributed equally: first authors"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0005">Carolin Prinz</a><sup>a</sup></li> <li class="author custom-tooltip" title="Contributed equally: first authors"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0006">Falk Fichtner</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0007">Anna-Lena Fischer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0008">Volker Thieme</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0009">Felicitas Grundeis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0010">Manuel Spagl</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0011">Christian Seeber</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0012">Vanessa Piechotta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0013">Maria-Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0014">Martin Golinski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0015">Onnen Moerer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0016">Caspar Stephani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0017">Agata Mikolajewska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0018">Stefan Kluge</a></li> <li class="author custom-tooltip" title="Contributed equally: last authors"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0019"><i class="icon corresponding-author fa fa-envelope"></i>Miriam Stegemann</a><sup>a</sup></li> <li class="author custom-tooltip" title="Contributed equally: last authors"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0020">Sven Laudi</a><sup>a</sup></li> <li class="author custom-tooltip" title="Contributed equally: last authors"><a href="/cdsr/doi/10.1002/14651858.CD015209/information#CD015209-cr-0021">Nicole Skoetz</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015209/information/en#CD015209-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 June 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015209/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015209">https://doi.org/10.1002/14651858.CD015209</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015209-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015209-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015209-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015209-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015209-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD015209-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015209-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015209-abs-0001" lang="en"> <section id="CD015209-sec-0001"> <h3 class="title" id="CD015209-sec-0001">Background</h3> <p>With potential antiviral and anti‐inflammatory properties, Janus kinase (JAK) inhibitors represent a potential treatment for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. They may modulate the exuberant immune response to SARS‐CoV‐2 infection. Furthermore, a direct antiviral effect has been described. An understanding of the current evidence regarding the efficacy and safety of JAK inhibitors as a treatment for coronavirus disease 2019 (COVID‐19) is required. </p> </section> <section id="CD015209-sec-0002"> <h3 class="title" id="CD015209-sec-0002">Objectives</h3> <p>To assess the effects of systemic JAK inhibitors plus standard of care compared to standard of care alone (plus/minus placebo) on clinical outcomes in individuals (outpatient or in‐hospital) with any severity of COVID‐19, and to maintain the currency of the evidence using a living systematic review approach. </p> </section> <section id="CD015209-sec-0003"> <h3 class="title" id="CD015209-sec-0003">Search methods</h3> <p>We searched the Cochrane COVID‐19 Study Register (comprising MEDLINE, Embase, ClinicalTrials.gov, World Health Organization (WHO) International Clinical Trials Registry Platform, medRxiv, and Cochrane Central Register of Controlled Trials), Web of Science, WHO COVID‐19 Global literature on coronavirus disease, and the US Department of Veterans Affairs Evidence Synthesis Program (VA ESP) Covid‐19 Evidence Reviews to identify studies up to February 2022. We monitor newly published randomised controlled trials (RCTs) weekly using the Cochrane COVID‐19 Study Register, and have incorporated all new trials from this source until the first week of April 2022. </p> </section> <section id="CD015209-sec-0004"> <h3 class="title" id="CD015209-sec-0004">Selection criteria</h3> <p>We included RCTs that compared systemic JAK inhibitors plus standard of care to standard of care alone (plus/minus placebo) for the treatment of individuals with COVID‐19. We used the WHO definitions of illness severity for COVID‐19. </p> </section> <section id="CD015209-sec-0005"> <h3 class="title" id="CD015209-sec-0005">Data collection and analysis</h3> <p>We assessed risk of bias of primary outcomes using Cochrane's Risk of Bias 2 (RoB 2) tool. We used GRADE to rate the certainty of evidence for the following primary outcomes: all‐cause mortality (up to day 28), all‐cause mortality (up to day 60), improvement in clinical status: alive and without need for in‐hospital medical care (up to day 28), worsening of clinical status: new need for invasive mechanical ventilation or death (up to day 28), adverse events (any grade), serious adverse events, secondary infections. </p> </section> <section id="CD015209-sec-0006"> <h3 class="title" id="CD015209-sec-0006">Main results</h3> <p>We included six RCTs with 11,145 participants investigating systemic JAK inhibitors plus standard of care compared to standard of care alone (plus/minus placebo). Standard of care followed local protocols and included the application of glucocorticoids (five studies reported their use in a range of 70% to 95% of their participants; one study restricted glucocorticoid use to non‐COVID‐19 specific indications), antibiotic agents, anticoagulants, and antiviral agents, as well as non‐pharmaceutical procedures. At study entry, about 65% of participants required low‐flow oxygen, about 23% required high‐flow oxygen or non‐invasive ventilation, about 8% did not need any respiratory support, and only about 4% were intubated. We also identified 13 ongoing studies, and 9 studies that are completed or terminated and where classification is pending. </p> <p><b>Individuals with moderate to severe disease</b> </p> <p>Four studies investigated the single agent baricitinib (10,815 participants), one tofacitinib (289 participants), and one ruxolitinib (41 participants). </p> <p>Systemic JAK inhibitors probably decrease all‐cause mortality at up to day 28 (95 of 1000 participants in the intervention group versus 131 of 1000 participants in the control group; risk ratio (RR) 0.72, 95% confidence interval (CI) 0.57 to 0.91; 6 studies, 11,145 participants; moderate‐certainty evidence), and decrease all‐cause mortality at up to day 60 (125 of 1000 participants in the intervention group versus 181 of 1000 participants in the control group; RR 0.69, 95% CI 0.56 to 0.86; 2 studies, 1626 participants; high‐certainty evidence). </p> <p>Systemic JAK inhibitors probably make little or no difference in improvement in clinical status (discharged alive or hospitalised, but no longer requiring ongoing medical care) (801 of 1000 participants in the intervention group versus 778 of 1000 participants in the control group; RR 1.03, 95% CI 1.00 to 1.06; 4 studies, 10,802 participants; moderate‐certainty evidence). They probably decrease the risk of worsening of clinical status (new need for invasive mechanical ventilation or death at day 28) (154 of 1000 participants in the intervention group versus 172 of 1000 participants in the control group; RR 0.90, 95% CI 0.82 to 0.98; 2 studies, 9417 participants; moderate‐certainty evidence). </p> <p>Systemic JAK inhibitors probably make little or no difference in the rate of adverse events (any grade) (427 of 1000 participants in the intervention group versus 441 of 1000 participants in the control group; RR 0.97, 95% CI 0.88 to 1.08; 3 studies, 1885 participants; moderate‐certainty evidence), and probably decrease the occurrence of serious adverse events (160 of 1000 participants in the intervention group versus 202 of 1000 participants in the control group; RR 0.79, 95% CI 0.68 to 0.92; 4 studies, 2901 participants; moderate‐certainty evidence). JAK inhibitors may make little or no difference to the rate of secondary infection (111 of 1000 participants in the intervention group versus 113 of 1000 participants in the control group; RR 0.98, 95% CI 0.89 to 1.09; 4 studies, 10,041 participants; low‐certainty evidence). Subgroup analysis by severity of COVID‐19 disease or type of JAK inhibitor did not identify specific subgroups which benefit more or less from systemic JAK inhibitors. </p> <p><b>Individuals with asymptomatic or mild disease</b> </p> <p>We did not identify any trial for this population.</p> </section> <section id="CD015209-sec-0007"> <h3 class="title" id="CD015209-sec-0007">Authors' conclusions</h3> <p>In hospitalised individuals with moderate to severe COVID‐19, moderate‐certainty evidence shows that systemic JAK inhibitors probably decrease all‐cause mortality. Baricitinib was the most often evaluated JAK inhibitor. Moderate‐certainty evidence suggests that they probably make little or no difference in improvement in clinical status. Moderate‐certainty evidence indicates that systemic JAK inhibitors probably decrease the risk of worsening of clinical status and make little or no difference in the rate of adverse events of any grade, whilst they probably decrease the occurrence of serious adverse events. Based on low‐certainty evidence, JAK inhibitors may make little or no difference in the rate of secondary infection. Subgroup analysis by severity of COVID‐19 or type of agent failed to identify specific subgroups which benefit more or less from systemic JAK inhibitors. </p> <p>Currently, there is no evidence on the efficacy and safety of systemic JAK inhibitors for individuals with asymptomatic or mild disease (non‐hospitalised individuals). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015209-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015209-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015209-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015209-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015209-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015209-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015209-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015209-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD015209-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015209-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015209-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015209-abs-0002" lang="en"> <h3>Are systemic Janus kinase inhibitors an effective treatment for people with COVID‐19?</h3> <p><b>Key messages</b> </p> <p>We found moderate‐ to high‐certainty evidence from 6 studies to conclude that systemic Janus kinase (JAK) inhibitors are an effective treatment for coronavirus disease 2019 (COVID‐19) in hospitalised people, because they resulted in fewer deaths and a lower rate of clinical deterioration. Evaluation of systemic JAK inhibitors is ongoing in 13 studies whilst the results of 9 further studies are awaiting publication. We will update this review and may adapt our conclusions when their results become available. </p> <p><b>What are JAK inhibitors?</b> </p> <p>JAK inhibitors are medicines that block the activity of certain parts of the immune system that are sometimes problematic. They are taken orally (systemic) and usually are taken by people who suffer from autoimmune diseases, where the immune system attacks the body itself. JAK inhibitors might also be administered by inhalation but since this was not our focus, we refer to 'systemic JAK inhibitors' throughout the review. </p> <p><b>How might JAK inhibitors treat COVID‐19?</b> </p> <p>In COVID‐19, the immune system sometimes overreacts, which can lead to a severe course of disease. JAK inhibitors can block parts of the immune system and counteract any clinical deteriorations. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know whether systemic JAK inhibitors, in addition to usual care, are effective for people with COVID‐19 when compared to usual care with or without a placebo (a treatment that looks and tastes the same as the study drug but with no active ingredient), and whether they cause unwanted effects. We were particularly interested in:<br/>• number of deaths from any cause up to 60 days after treatment, or longer if reported;<br/>• whether people got better or worse after treatment, based on their need for breathing support;<br/>• unwanted effects of the treatment and infections acquired in hospital. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that reported on people with COVID‐19 who received systemic JAK inhibitors together with usual care, or usual care alone (plus/minus placebo). We compared and summarised the results of the studies and rated our confidence in the evidence, based on common criteria about the reliability of the evidence. </p> <p><b>What did we find?</b> </p> <p>We found 6 suitable studies involving 11,145 people with COVID‐19. All studies compared systemic JAK inhibitors (baricitinib in 4 studies, tofacitinib in 1 study and ruxolitinib in 1 study) to usual care (in addition to placebo), and were performed in hospitalised people. We did not find studies performed in outpatients. Most participants needed oxygen supplementation through low‐flow devices (7220 participants) and few (463 participants) were mechanically ventilated at the study entry. We also identified 13 ongoing studies and 9 studies that are completed/terminated but unpublished yet. </p> <p><b>Main results</b> </p> <p>Systemic JAK inhibitors plus usual care compared to usual care alone probably lead to fewer deaths from all causes at up to day 28 and lead to fewer deaths from all causes up to day 60 in the studies. It was not possible to identify subgroups of participants (according to severity of illness) who might benefit most from treatment with JAK inhibitors. Systemic JAK inhibitors probably make little or no difference in improvement in clinical status. They probably decrease the risk of worsening of clinical status. Systemic JAK inhibitors probably make little or no difference in the rate of unwanted effects, and probably decrease slightly the occurrence of serious unwanted effects. Systemic JAK inhibitors may result in little or no difference in the rate of infections acquired in hospital. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>As current studies on systemic JAK inhibitors in outpatients are lacking, evidence is limited in this group of people with COVID‐19. Studies used different ways to assess and report unwanted effects, especially in regard to infections acquired in hospital. </p> <p>In accordance with the living approach of this review, we will continually update our search and include eligible trials to fill this evidence gap. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to February 2022. We monitor newly published studies weekly using the Cochrane COVID‐19 Study Register, and have incorporated all new trials identified from this source until the first week of April 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015209-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015209-sec-0105"></div> <h3 class="title" id="CD015209-sec-0106">Implications for practice</h3> <section id="CD015209-sec-0106"> <p>Systemic Janus kinase (JAK) inhibitors probably decrease all‐cause mortality of hospitalised people with coronavirus disease 2019 (COVID‐19), with a number needed to treat (NNT) for an additional beneficial outcome of 28. Moderate‐certainty evidence suggests that they probably make little or no difference in improvement in clinical status but decrease the risk of worsening of clinical status. Moderate‐certainty evidence also suggests that JAK inhibitors probably make little or no difference in the rate of adverse events of any grade, while they probably decrease the occurrence of serious adverse events. Based on low‐certainty evidence, JAK inhibitors may make little or no difference in secondary infections. </p> <p>Baricitinib was the most often evaluated JAK inhibitor. Most studies evaluated participants with a need for oxygen or non‐invasive mechanical ventilation. Subgroup analysis of severity of COVID‐19 disease or type of agent could not identify whether specific subgroups are more or less likely to benefit from systemic JAK inhibitors.  </p> <p>Currently, there is no evidence on the efficacy and safety of systemic JAK inhibitors for individuals with asymptomatic infection or mild disease (non‐hospitalised individuals).  </p> </section> <h3 class="title" id="CD015209-sec-0107">Implications for research</h3> <section id="CD015209-sec-0107"> <p>There is an urgent need for high‐quality evidence regarding (1) the effects of systematic JAK inhibitors in specific subgroups of disease severity, and (2) the safety profile of systemic JAK inhibitors against COVID‐19 disease. Within the 13 ongoing studies identified by our review, most included hospitalised participants with COVID‐19 without further discriminating disease severity. Hence, data from future studies that differentiate subpopulations by disease severity are urgently awaited. More studies which analyse separately the effects in participants with moderate and severe disease at baseline should be initiated. Safety data acquisition should focus on high‐quality assessment of major short‐term (major adverse cardiac events and venous thrombosis) and long‐term (malignancies) harms that have already been attributed to treatment strategies using JAK inhibitors to treat chronic inflammatory conditions. Future studies also need to include outpatients with COVID‐19. Finally, there is a particular lack of studies on combination or sequence of immunomodulatory treatments against COVID‐19. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015209-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015209-sec-0008"></div> <div class="table" id="CD015209-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">JAK inhibitors plus standard of care compared to standard of care (plus/minus placebo) in individuals with moderate to severe COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>JAK inhibitors plus standard of care compared to standard of care (plus/minus placebo) in individuals with moderate to severe COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: hospitalised people with confirmed SARS‐CoV‐2 infection</b> <br/><b>Setting: hospitalised participants</b> <br/><b>Intervention: Janus kinase inhibitors plus standard of care</b> <br/><b>Comparator: standard of care alone (plus/minus placebo)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes<br/><i>(Time frame of absolute effects)</i> </b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>95% CI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Plain language summary</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard of care alone (plus/minus placebo)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Janus kinase inhibitors</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality (<i>up to day 28)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/>(75 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72<br/>(0.57 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,145 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably decrease all‐cause mortality at up to day 28</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality <i>(up to day 60)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(102 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69<br/>(0.56 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1626 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors decrease all‐cause mortality at up to day 60</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care </p> <p><i>(up to day 28)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>778 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>801 per 1000<br/>(778 to 824) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03<br/>(1.00 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,802 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably make little or no difference in improvement in clinical status (discharged alive or hospitalised, but no longer requiring ongoing medical care) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsening of clinical status: new need for invasive mechanical ventilation or death</p> <p><i>(at day 28)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000<br/>(141 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90<br/>(0.82 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9417 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably decrease the risk of worsening of clinical status (new need for invasive mechanical ventilation or death at up to day 28) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any grade)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>427 per 1000<br/>(388 to 476) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97<br/>(0.88 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1885 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably make little or no difference in the rate of adverse events (any grade) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/>(138 to 186) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79<br/>(0.68 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2901 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably decrease the occurrence of serious adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary infection</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/>(100 to 123) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98<br/>(0.89 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,041 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊖ ⊖<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors may make little or no difference to the rate of secondary infections</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><b>CI:</b> confidence interval; <b>JAK inhibitors:</b> Janus kinase inhibitors; <b>NE:</b> not estimable; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. <br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Reasons for downgrading:</b> </p> <p><sup>a</sup>Downgraded one level for serious risk of bias, because of unblinded trial design, deviation from the intended interventions (only 91% of participants allocated to baricitinib received treatment) in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> </p> <p><sup>b</sup>Downgraded one level for serious indirectness, because of expected dissimilarities between outcome measurement between studies impacting the transferability of results; no further downgrade for serious risk of bias (unblinded trial design and deviation from the intended interventions in the largest study (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>), since the result of this study did not change pooled effect estimate of the outcome but only narrowed 95% confidence interval </p> <p><sup>c</sup>Downgraded one level for serious risk of bias, because of unblinded trial design (bias in measurement of the intervention provider decision outcome: invasive mechanical ventilation) and deviation from the intended intervention (91% allocated to baricitinib received treatment) in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> </p> <p><sup>d</sup>Downgraded one level for serious risk of bias, because of missing data to adjust for competing risk of death </p> <p><sup>e</sup>Downgraded one level for serious indirectness, because of expected dissimilarities between outcome measurement (definitions of different types of infections) between studies and one level for serious risk of bias because of missing data to adjust for competing risk of death and deviations from intended intervention </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015209-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015209-sec-0009"></div> <p>This work is part of a series of Cochrane Reviews investigating treatments and therapies for coronavirus disease 2019 (COVID‐19). Reviews in this series share information in the background section and methodology based on the first published reviews about monoclonal antibodies (<a href="./references#CD015209-bbs2-0102" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>), and convalescent plasma (<a href="./references#CD015209-bbs2-0073" title="ChaiKL , ValkSJ , PiechottaV , KimberC , MonsefI , DoreeC , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub3]">Chai 2020</a>), and are part of the German research project 'CEOsys' (COVID‐19 Evidence‐Ecosystem; <a href="./references#CD015209-bbs2-0072" title="CEOsys. COVID-19 Evidence Ecosystem (CEOsys). www.covid-evidenz.de (accessed 26 August 2021).">CEOsys 2021</a>). </p> <section id="CD015209-sec-0010"> <h3 class="title" id="CD015209-sec-0010">Description of the condition</h3> <p>COVID‐19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Declared a pandemic on 11 March 2020 (<a href="./references#CD015209-bbs2-0156" title="World Health Organization. Timeline: WHO's COVID-19 response. www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline (accessed 17 March 2021).">WHO 2020a</a>), with respect to public health, socio‐economic conditions, and impact on healthcare facilities, COVID‐19 is unprecedented in comparison to previous coronavirus outbreaks, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), with 813 and 888 deaths, respectively (<a href="./references#CD015209-bbs2-0154" title="World Health Organization. Cumulative number of reported probable cases of SARS. www.who.int/csr/sars/country/2003_07_11/en (accessed 13 April 2020).">WHO 2003</a>; <a href="./references#CD015209-bbs2-0155" title="World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int/emergencies/mers-cov/en (accessed 13 April 2020).">WHO 2019</a>; <a href="./references#CD015209-bbs2-0160" title="World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia. www.who.int/emergencies/disease-outbreak-news/item/2021-DON333 (accessed 17 August 2021).">WHO 2021a</a>). Despite intensive international containment efforts, as of October 2021, there have been more than 237 million confirmed cases, including more than 4.8 million deaths (<a href="./references#CD015209-bbs2-0157" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 4 August 2020).">WHO 2020b</a>; <a href="./references#CD015209-bbs2-0161" title="World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 26 August 2021).">WHO 2021b</a>). </p> <p>SARS‐CoV‐2 is a positive‐sense, double‐stranded ribonucleic acid (RNA) virus that belongs to the <i>Coronaviridae</i> family (<a href="./references#CD015209-bbs2-0077" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2021;384:229-37. [DOI: 10.1056/NEJMoa2029849]">Chen P 2021</a>; <a href="./references#CD015209-bbs2-0103" title="KumarS , NyoduR , MauryaAK , SaxenaSK . Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In: SaxenaSK , editors(s). Coronavirus Disease 2019 (COVID-19). Singapore: Springer, 2020. [DOI: 10.1007/978-981-15-4814-7_3]">Kumar 2020</a>). There is widespread consensus that SARS‐CoV‐2 is closely related to a beta coronavirus detected in bat faeces. However, the host of origin and the intermediate host remain unclear (<a href="./references#CD015209-bbs2-0110" title="LundstromK , SeyranM , PizzolD , AdadiP , Mohamed Abd El-AzizT , HassanSS , et al. Viewpoint: origin of SARS-CoV-2. Viruses2020;12(11):1203. [DOI: 10.3390/v12111203]">Lundstrom 2020</a>; <a href="./references#CD015209-bbs2-0112" title="MalaiyanJ , ArumugamS , MohanK . An update on the origin of SARS-CoV-2: despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and O-linked glycan residues. Journal of Medical Virology2020;93(1):499-505. [DOI: 10.1002/jmv.26261]">Malaiyan 2020</a>; <a href="./references#CD015209-bbs2-0162" title="World Health Organization. Origins of the SARS-CoV-2 virus. www.who.int/health-topics/coronavirus/origins-of-the-virus (accessed 30 March 2021).">WHO 2021c</a>). SARS‐CoV‐2 binds to angiotensin‐converting enzyme 2 receptors, which are expressed in lung, heart, kidney, intestine, as well as endothelium, by means of its spike glycoprotein (<a href="./references#CD015209-bbs2-0169" title="YangL , LiuW , YuX , WuM , ReichertJM , HoM . COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Therapeutics2020;3(3):205-12. [DOI: 10.1093/abt/tbaa020]">Yang 2020</a>). Viral variants mainly present mutational changes in the spike glycoprotein (<a href="./references#CD015209-bbs2-0163" title="World Health Organization. Weekly epidemiological update on COVID-19 - Edition 49. www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-july-2021 (accessed 20 July 2021).">WHO 2021d</a>). Infection with SARS‐CoV‐2 results in an immune response involving cluster of differentiation (CD) 4<sup>+</sup> (CD4<sup>+</sup>) and 8<sup>+</sup> (CD8<sup>+</sup>) T cells, which may lead to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome through the release of pro‐inflammatory cytokines and chemokines. This is largely triggered by an inadequate type I/III interferon response to viral infection and followed by a maladaptive hypercytokinaemic cytokine storm, for which interleukin 6 (IL‐6) is the key prognostic biomarker (<a href="./references#CD015209-bbs2-0075" title="ChenLY , QuachTT . COVID-19 cytokine storm syndrome: a threshold concept. Lancet Microbe2021;2(2):e49-e50. [DOI: 10.1016/S2666-5247(20)30223-8]">Chen LY 2021a</a>; <a href="./references#CD015209-bbs2-0087" title="GalaniIE , RovinaN , LampropoulouV , TriantafylliaV , ManioudakiM , PavlosE , et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nature Immunology2021;22(1):32-40. [DOI: 10.1038/s41590-020-00840-x]">Galani 2021</a>; <a href="./references#CD015209-bbs2-0109" title="LiX , GengM , PengY , MengL , LuS . Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis2020;10(2):102-8. [DOI: 10.1016/j.jpha.2020.03.001]">Li X 2020</a>; <a href="./references#CD015209-bbs2-0150" title="Utrero-RicoA , Ruiz-HornillosJ , González-CuadradoC , RitaCG , AlmogueraB , MinguezP . IL-6-based mortality prediction model for COVID-19: validation and update in multicenter and second wave cohorts. Journal of Allergy and Clinical Immunology2021;47(5):1652-61. [DOI: 10.1016/j.jaci.2021.02.021]">Utrero‐Rico 2021</a>; <a href="./references#CD015209-bbs2-0170" title="ZhangQ , BastardP , BolzeA , JouanguyE , ZhangSY , et al, COVID Human Genetic Effort. Life-threatening COVID-19: defective interferons unleash excessive inflammation. Med (New York, NY)2020;1(1):14-20. [DOI: 10.1016/j.medj.2020.12.001]">Zhang 2020</a>). </p> <p>The median incubation time is five to six days, and 97.5% of symptomatic cases develop symptoms within 11.5 days of exposure (<a href="./references#CD015209-bbs2-0105" title="LauerSA , GrantzKH , BiQ , JonesFK , ZhengQ , MeredithHR , et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine2020;172(9):577–82. [DOI: 10.7326/M20-0504]">Lauer 2020</a>). Signs and symptoms can range from sore throat, cough, fever, headache, fatigue, myalgia, arthralgia, anosmia, and ageusia (<a href="./references#CD015209-bbs2-0147" title="StruyfT , DeeksJJ , DinnesJ , TakwoingiY , DavenportC , LeeflangMM , et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013665. [DOI: 10.1002/14651858.CD013665]">Struyf 2020</a>), to dyspnoea, chills, nausea or vomiting, diarrhoea, nasal congestion, haemoptysis, and conjunctival congestion (<a href="./references#CD015209-bbs2-0158" title="World Health Organization. Weekly epidemiological update - 27 October 2020. www.who.int/publications/m/item/weekly-epidemiological-update-27-october-2020 (accessed 2 November 2020).">WHO 2020c</a>). </p> <p>A large proportion of infected individuals remain asymptomatic throughout the course of the disease (<a href="./references#CD015209-bbs2-0078" title="ChenT , WuD , ChenH , YanW , YangD , ChenG , et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ2020;368:m1295. [DOI: 10.1136/bmj.m1295]">Chen T 2020</a>; <a href="./references#CD015209-bbs2-0086" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015209-bbs2-0124" title="PanA , LiuL , WangC , GuoH , HaoX , WangQ , et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA2020;323(19):1915-23. [DOI: 10.1001/jama.2020.6130]">Pan 2020</a>; <a href="./references#CD015209-bbs2-0167" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). The reported frequency of asymptomatic courses varies greatly and ranges between 6% and 96%, depending on the time of investigation and the cohort investigated (<a href="./references#CD015209-bbs2-0086" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015209-bbs2-0122" title="OranDP , TopolEJ . Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Annals of Internal Medicine2020;173(5):362-7. [DOI: 10.7326/M20-3012]">Oran 2020</a>). In a meta‐analysis, Buitrago‐Garcia and colleagues estimated the proportion of persistently asymptomatic infected individuals at 20%, with a prediction interval of 3% to 67% (<a href="./references#CD015209-bbs2-0071" title="Buitrago-GarciaD , Egli-GanyD , CounotteMJ , HossmannS , ImeriH , Ipekci AzizM , et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Medicine2020;17(9):e1003346.">Buitrago‐Garcia 2020</a>). Despite the absence of clinical signs, asymptomatic individuals show typical findings on chest computed tomography (CT) in up to 50% of cases (<a href="./references#CD015209-bbs2-0097" title="HuZ , SongC , XuC , JinG , ChenY , XuX , et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Science China Life Sciences2020;63:706-11. [DOI: 10.1007/s11427-020-1661-4]">Hu 2020</a>; <a href="./references#CD015209-bbs2-0114" title="MengH , XiongR , HeR , LinW , HaoB , ZhangL , et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. Journal of Infection2020;81(1):e33-9. [DOI: 10.1016/j.jinf.2020.04.004]">Meng 2020</a>). </p> <p>A smaller proportion of infected individuals are affected by severe (approximately 11% to 20%) or critical (approximately 1% to 5%) disease, with hospitalisation and intensive care unit (ICU) admittance due to respiratory failure, septic shock, or multiple organ dysfunction syndrome (<a href="./references#CD015209-bbs2-0086" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015209-bbs2-0167" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). In a case series from 12 New York hospitals, 14% of people hospitalised due to COVID‐19 were treated in ICU (<a href="./references#CD015209-bbs2-0133" title="RichardsonS , HirschJS , NarasimhanM , CrawfordJM , McGinnT , DavidsonKW , et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA2020;323(20):2052-9. [DOI: 10.1001/jama.2020.6775]">Richardson 2020</a>), as were 14% to 37% in evaluations of patients during the first COVID‐19 wave in Germany (<a href="./references#CD015209-bbs2-0136" title="SchillingJ , LehfeldAS , SchumacherD , UllrichA , DierckeM . Disease severity of the first COVID-19 wave in Germany using reporting data from the national notification system. Journal of Health Monitoring2020;5(S11):2-20. [DOI: 10.25646/7170]">Schilling 2020</a>; <a href="./references#CD015209-bbs2-0149" title="TolksdorfK , BudaS , SchulerE , WielerLH , HaasW . Higher lethality and long duration of ventilation distinguish COVID-19 from severe respiratory tract infections in influenza waves [Eine höhere Letalität und lange Beatmungsdauer unterscheidenCOVID-19 von schwer verlaufenden Atemwegsinfektionen inGrippewellen]. Epidemiologisches Bulletin2020;41:3-10. [DOI: 10.25646/7111]">Tolksdorf 2020</a>). In an observational study of 10,021 hospitalised adults in Germany with a confirmed COVID‐19 diagnosis, 17% received mechanical ventilation (non‐invasive and invasive). In this study, 27% of ventilated people required dialysis due to acute renal failure; mortality in ventilated people was 53% as opposed to 16% in people not receiving mechanical ventilation; and mortality in people receiving mechanical ventilation (non‐invasive and invasive) as well as dialysis was 73% (<a href="./references#CD015209-bbs2-0099" title="KaragiannidisC , MostertC , HentschkerC , VoshaarT , MalzahnJ , SchillingerG , et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respiratory Medicine2020;8:853-62. [DOI: 10.1016/ S2213-2600(20)30316-7]">Karagiannidis 2020</a>). In a systematic review and meta‐analysis of international studies, the proportion of people who died was estimated at 34% amongst those treated in ICU, and 83% amongst those receiving invasive mechanical ventilation (<a href="./references#CD015209-bbs2-0130" title="PotereN , ValerianiE , CandeloroM , TanaM , PorrecaE , AbbateA , et al. A higher mortality rate and long ventilation times differentiate COVID-19 from severe respiratory infections in flu waves [Eine höhere Letalität und langeBeatmungsdauer unterscheiden COVID-19 von schwerverlaufenden Atemwegsinfektionen in Grippewellen]. Critical Care2020;24(1):289. [DOI: 10.25646/7111]">Potere 2020</a>). The severity of this disease can be also classified according to a standardised scale established by the WHO (<a href="./references#CD015209-bbs2-0113" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>; <a href="#CD015209-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD015209-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="WHO clinical progression scale (from: Marshall 2020)ECMO: extracorporeal membrane oxygenation; FiO2:fraction of inspired oxygen; NIV: non‐invasive ventilation; pO2:partial pressure of oxygen; SpO2:oxygen saturation. *If hospitalised for isolation only, record status as for ambulatory patient." data-id="CD015209-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>WHO clinical progression scale (from: <a href="./references#CD015209-bbs2-0113" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>) </p> <p>ECMO: extracorporeal membrane oxygenation; FiO<sub>2</sub>:fraction of inspired oxygen; NIV: non‐invasive ventilation; pO<sub>2</sub>:partial pressure of oxygen; SpO<sub>2</sub>:oxygen saturation. *If hospitalised for isolation only, record status as for ambulatory patient. </p> </div> </div> </div> <p>The infection fatality ratio varies widely between countries and reporting periods (from 0.01% to more than 25%). However, these numbers may be misleading as they tend to overestimate the infection fatality ratio due to varying testing frequency, lag in reporting dates, and variations in case definitions, especially in the beginning of the pandemic, as clinicians were mainly focused on severe cases (<a href="./references#CD015209-bbs2-0157" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 4 August 2020).">WHO 2020b</a>; <a href="./references#CD015209-bbs2-0167" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). </p> <p>Risk for severe disease, hospitalisation, and mortality is higher for individuals aged 65 years or older, males, smokers, and individuals with certain underlying medical conditions, such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart conditions, an immunocompromised state, obesity, sickle cell disease, or type 2 diabetes mellitus (<a href="./references#CD015209-bbs2-0098" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506.">Huang 2020</a>; <a href="./references#CD015209-bbs2-0099" title="KaragiannidisC , MostertC , HentschkerC , VoshaarT , MalzahnJ , SchillingerG , et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respiratory Medicine2020;8:853-62. [DOI: 10.1016/ S2213-2600(20)30316-7]">Karagiannidis 2020</a>; <a href="./references#CD015209-bbs2-0106" title="LiangW , GuanW , ChenR , WangW , LiJ , XuK , et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology2020;21(3):335-7.">Liang 2020</a>; <a href="./references#CD015209-bbs2-0127" title="PetrilliCM , JonesSA , YangJ , RajagopalanH , O'DonnelL , ChernyakY , et al. Factors associated with hospital admissionand critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ2020;396:m1966. [DOI: 10.1136/bmj.m1966]">Petrilli 2020</a>; <a href="./references#CD015209-bbs2-0158" title="World Health Organization. Weekly epidemiological update - 27 October 2020. www.who.int/publications/m/item/weekly-epidemiological-update-27-october-2020 (accessed 2 November 2020).">WHO 2020c</a>; <a href="./references#CD015209-bbs2-0165" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584:430-6. [DOI: 10.1038/s41586-020-2521-4]">Williamson 2020</a>). C‐reactive protein (CRP), which is produced by the liver in response to release of IL‐6, is a major prognostic marker for poor outcomes, as reported in the large UK International Severe Acute Respiratory and Emerging Infections Consortium Coronavirus Clinical Characterisation Consortium (ISARIC 4C) model (<a href="./references#CD015209-bbs2-0101" title="KnightSR , HoA , PiusR , BuchanI , CarsonG , DrakeTM , et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ2020;370:m3339. [DOI: 10.1136/bmj.m3339]">Knight 2020</a>). </p> <p>Vaccination has been shown to be highly effective at reducing severe illness and death from COVID‐19. As of October 2021, more than 6.3 billion (6300 million) doses of COVID‐19 vaccines have been administered at the global level (<a href="./references#CD015209-bbs2-0161" title="World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 26 August 2021).">WHO 2021b</a>). However, the majority of vaccines have been administered in resource‐rich countries. The majority of the world's population still remains unvaccinated and therefore at risk of developing COVID‐19. Moreover, the duration and degree of protection of vaccines against severe disease, but also against infection and transmission, is still not well‐defined. Studies are still assessing the impact of SARS‐CoV‐2 variants on product‐specific vaccine efficacy and effectiveness. Equitable access to safe and effective vaccines is critical to mitigate the public health and economic impact of the pandemic (<a href="./references#CD015209-bbs2-0091" title="GrubaughND , HanageWP , RasmussenAL . Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell2020;182(4):794-5. [DOI: 10.1016/ j.cell.2020.06.040]">Grubaugh 2020</a>; <a href="./references#CD015209-bbs2-0138" title="SchwarzT , Tober-LauP , HillusD , HelbigET , LippertLJ , ThibeaultC , et al. Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany. Emerging Infectious Diseases2021;27(8):2174-8. [PMID: 10.3201/eid2708.211145]">Schwarz 2021</a>). </p> <p>In light of the extent of the pandemic, including evolving virus variants and a scarcity of effective treatments as well as issues related to the global availability of vaccines, the role of effective therapies is of utmost interest for combating COVID‐19. </p> </section> <section id="CD015209-sec-0011"> <h3 class="title" id="CD015209-sec-0011">Description of the intervention</h3> <p>Janus kinases (JAKs) are enzymes involved in cellular signal transduction and are related to cell proliferation, differentiation, apoptosis, haematopoiesis, and immune regulation (<a href="./references#CD015209-bbs2-0120" title="O'SheaJJ , KontziasA , YamaokaK , TanakaY , LaurenceA . Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases2013;72 Suppl 2(2):ii111-5. [DOI: 10.1136/annrheumdis-2012-202576]">O'Shea 2013</a>; <a href="./references#CD015209-bbs2-0168" title="XinP , XuX , DengC , LiuS , WangY , ZhouX , et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology2020;80:106210. [DOI: 10.1016/j.intimp.2020.106210]">Xin 2020</a>). Targeted by cytokines, members of the JAK family (JAK 1, JAK 2, JAK 3, tyrosine kinase 2 (TYK 2)) activate the signal transducer and activator of transcription (STAT) through phosphorylation and mediate intracellular communication between the cytokine receptors in the membrane and the cellular nucleus (<a href="./references#CD015209-bbs2-0117" title="MullerR . JAK inhibitors in 2019, synthetic review in 10 points. European Journal of Internal Medicine2019;66:9-17. [DOI: 10.1016/j.ejim.2019.05.022]">Muller 2019</a>). By activating the transcription of pro‐inflammatory protein genes in the nucleus, the JAK/STAT signalling pathway enhances recruitment and differentiation of T cells. It therefore plays an important role in initiating immune activation and inflammation, interfering in vital cellular functions, including signalling, growth, and survival (<a href="./references#CD015209-bbs2-0088" title="GhoreschiK , LaurenceA , O'SheaJJ . Janus kinases in immune cell signaling. Immunological Reviews2009;228(1):273-87. [DOI: 10.1111/j.1600-065X.2008.00754.x]">Ghoreschi 2009</a>; <a href="./references#CD015209-bbs2-0168" title="XinP , XuX , DengC , LiuS , WangY , ZhouX , et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology2020;80:106210. [DOI: 10.1016/j.intimp.2020.106210]">Xin 2020</a>). Indeed, a genetic variant on chromosome 19 close to the gene encoding for TYK 2 ‐ a target gene of JAK inhibitor ‐ was associated with an increased risk for severe/fatal progression of disease in a landmark genome‐wide association study (GWAS) (<a href="./references#CD015209-bbs2-0123" title="Pairo-CastineiraE , ClohiseyS , KlaricL , BretherickAD , RawlikK , PaskoD , et al. Genetic mechanisms of critical illness in COVID-19. Nature2021;591(7848)(7848):92-8. [DOI: 10.1038/s41586-020-03065-y]">Pairo‐Castineira 2021</a>). </p> <p>An overexpression of JAK/STAT components is associated with inflammatory arthritis and other hyper‐inflammatory conditions (<a href="./references#CD015209-bbs2-0152" title="WalkerJG , AhernMJ , ColemanM , WeedonH , PapangelisV , BeroukasD , et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases2006;65(2):149-56. [DOI: 10.1136/ard.2005.037929]">Walker 2006</a>). Pharmacological inhibition of JAKs therefore aims to disrupt the aberrant cycle of pro‐inflammatory and proliferating signalling, found in autoimmune diseases and malignancies (<a href="https://pubmed.ncbi.nlm.nih.gov/22403586/" target="_blank">Kontzias 2012</a>). Ruxolitinib was the first JAK inhibitor to be approved for the therapy of myeloproliferative neoplasms in 2011, followed by currently eight further JAK inhibitors with various indications, such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and graft‐versus‐host‐disease (<a href="./references#CD015209-bbs2-0143" title="SpinelliFR , MeylanF , O'SheaJJ , GadinaM . JAK inhibitors: ten years after. European Journal of Immunology2021;51:1615-27. [DOI: 10.1002/eji.202048922]">Spinelli 2021</a>). Among the ones approved and implemented in therapeutic regimes are non‐selective tofacitinib (JAK 1, JAK 2, JAK 3) as well as selective ruxolitinib and baricitinib (JAK 1 and JAK 2). Indeed, most recently, two phase 3 trials demonstrated efficacy of baricitinib in the treatment of severe forms of alopecia areata, another autoimmune disorder, in which Janus kinase signalling may play a role (<a href="./references#CD015209-bbs2-0100" title="KingB , OhyamaM , KwonO , ZlotogorskiA , KoJ , MesinkovskaNA , et al. Two phase 3 trials of baricitinib for alopecia areata. New England Journal of Medicine 2022 Mar 26 [Epub ahead of print]. [DOI: 10.1056/NEJMoa2110343] [PMID: 35334197]">King 2022</a>). </p> <p>Most of the data on adverse effects refer to chronic use of JAK inhibitors. Intervention in the JAK/STAT signalling pathway suppresses immune response, with infections being a major and potentially harmful side effect. Additionally, with JAKs playing a pivotal role in haematopoiesis, myelosuppression may occur. Further observed adverse events include elevation in liver enzymes, elevation in cholesterol, and intestinal perforation. An increased risk of malignancies such as lymphoma, serious cardiovascular events (myocardial infarction, stroke, venous thromboembolism, etc.), and death, observed in a large randomised study of long‐term tofacitinib against rheumatoid arthritis, led to a current drug safety warning by the US Food and Drug Administration (FDA) for tofacitinib to treat certain chronic inflammatory conditions, and marks the need for close examination of people undergoing JAK inhibitor therapy (<a href="./references#CD015209-bbs2-0084" title="US Food and Drug Administration. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib); December 2021. www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis?utm_medium=email&amp;utm_source=govdelivery (accessed 13 April 2022).">FDA 2021a</a>). This FDA warning also included baricitinib and upadacitinib, since both drugs belong to the same drug class and are used in the same clinical context of chronic inflammatory disease modulation. Ruxolitinib was exempted from the warning, since this drug is currently in clinically different situations of haematologic diseases such as myelofibrosis. </p> </section> <section id="CD015209-sec-0012"> <h3 class="title" id="CD015209-sec-0012">How the intervention might work</h3> <p>Impaired virus‐specific T cell response and profuse cytokine production (e.g. tumour necrosis factor (TNF), IL‐1B, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12, IL‐23, granulocyte colony stimulating factor (G‐CSF), and interferon (IFN)‐γ and associated chemokines, such as chemokine (CC motif) ligand (CCL)2, CCL8, CCL20, chemokine (CXC motif) ligand (CXCL)1, CXCL3, CXCL5, CXCL6, CXCL2, and CXCL16 (<a href="./references#CD015209-bbs2-0142" title="SolimaniF , MeierK , GhoreschiK . Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. European Journal of Immunology2021;51(5):1071-5.">Solimani 2021</a>)) are associated with the hyper‐inflammatory condition observed in people particularly with severe COVID‐19 (<a href="./references#CD015209-bbs2-0121" title="OjaAE , SarisA , GhandourCA , KragtenNA , HogemaBM , NossentEJ , et al. Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients. European Journal of Immunology2020;50(12):1998-2012. [DOI: 10.1002/eji.202048908]">Oja 2020</a>; <a href="./references#CD015209-bbs2-0142" title="SolimaniF , MeierK , GhoreschiK . Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. European Journal of Immunology2021;51(5):1071-5.">Solimani 2021</a>). JAK/STAT signalling has been identified as a possible indicator of a stronger immune response to SARS‐CoV‐2 infections and thus, JAK inhibitors may be able to modulate disease‐related pathological immunoreactions (<a href="./references#CD015209-bbs2-0070" title="BouwmanW , VerhaeghW , HoltzerL , Van de StolpeA . Measurement of cellular immune response to viral infection and vaccination. Frontiers in Immunology2020;11:575074. [DOI: 10.3389/fimmu.2020.575074]">Bouwman 2020</a>). JAK inhibitors block the inflammatory cytokine pathways intracellularly, while IL inhibitors only block the extracellular activity of the IL‐6/IL‐6‐R receptor complex (<a href="./references#CD015209-bbs2-0076" title="ChenLY , BiggsCM , JamalS , StukasS , WellingtonCL , SekhonMS . Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome. Cell Reports Medicine2021;2(5):100269. [DOI: 10.1016/j.xcrm.2021.100269]">Chen LY 2021b</a>). Indeed, people with psoriasis receiving immune treatments (i.e. anti‐IL‐17/anti‐IL‐23 monoclonal antibodies or phosphodiesterase 4 inhibitors) reportedly have a lower risk for adverse outcomes when infected with SARS‐CoV‐2 (<a href="./references#CD015209-bbs2-0142" title="SolimaniF , MeierK , GhoreschiK . Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection. European Journal of Immunology2021;51(5):1071-5.">Solimani 2021</a>). Additionally, and aside from their anti‐inflammatory and antiproliferative properties, JAK inhibitors have shown direct antiviral activity by targeting host proteins for their antiviral mechanisms and interfering with viral cell entry (<a href="./references#CD015209-bbs2-0144" title="StebbingJ , PhelanA , GriffinI , TuckerC , OechsleO , SmithD , et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infectious Diseases2020;20(4):400-2. [DOI: 10.1016/S1473-3099(20)30132-8]">Stebbing 2020</a>). </p> </section> <section id="CD015209-sec-0013"> <h3 class="title" id="CD015209-sec-0013">Why it is important to do this review</h3> <p>The clinical management of people with COVID‐19 generally should include supportive care and specific therapeutic interventions, depending on the severity of disease and the individual's disposition (<a href="./references#CD015209-bbs2-0104" title="LamontagneF , AgoritsasT , MacdonaldH , Leo Y-S, DiazJ , AgarwalA , et al. A living WHO guideline on drugs for COVID-19. BMJ2020;370:m3379. [DOI: 10.1136/bmj.m3379]">Lamontagne 2020</a>; <a href="./references#CD015209-bbs2-0119" title="National Institutes of Health. COVID-19 treatment guidelines - therapeutic management of patients with COVID-19 (version last updated on 9 October 2020). www.covid19treatmentguidelines.nih.gov/therapeutic-management (accessed 6 November 2020).">NIH 2020</a>; <a href="./references#CD015209-bbs2-0159" title="World Health Organization. Corticosteroids for COVID-19 - living guidance 2; September 2020. www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (accessed 5 November 2020).">WHO 2020d</a>). However, despite the rapid pace of research and numerous ongoing trials, there is still a deficit of effective therapeutic interventions for the clinical management of people with COVID‐19, and key uncertainties remain concerning treatment effects for patient‐relevant outcomes for all patients and specific subgroups. </p> <p>A robust body of evidence demonstrates the beneficial effect of systemic corticosteroids on mortality in people with severe COVID‐19 requiring supplemental oxygen or ventilator support. Remaining uncertainties include effects on long‐term mortality, efficacy in people with non‐severe COVID‐19, possible interactions with other immunomodulatory therapies, and the rate of subsequent opportunistic infections (<a href="./references#CD015209-bbs2-0065" title="AgarwalA , RochwergB , LamontagneF , SiemieniukRA , AgoritsasT , AskieL , et al. A living WHO guideline on drugs for covid-19. BMJ2020;370:m3379. [DOI: 10.1136/bmj.m3379]">Agarwal 2020</a>). For remdesivir, a novel nucleotide analogue with in vitro activity against SARS‐CoV‐2, initial studies showed some positive results in improving patient‐important outcomes, but no clinically relevant beneficial effect was reported in several subsequent studies. Thus, its optimal role remains uncertain (<a href="./references#CD015209-bbs2-0066" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>; <a href="./references#CD015209-bbs2-0068" title="BeigelJH , TomashekKM , DoddLE , MehtaAK , ZingmanBS , KalilAC , et al. Remdesivir for the treatment of COVID-19 — final report. New England Journal of Medicine2020;383:1813-26. [DOI: 10.1056/NEJMoa2007764]">Beigel 2020</a>; <a href="./references#CD015209-bbs2-0119" title="National Institutes of Health. COVID-19 treatment guidelines - therapeutic management of patients with COVID-19 (version last updated on 9 October 2020). www.covid19treatmentguidelines.nih.gov/therapeutic-management (accessed 6 November 2020).">NIH 2020</a>). Recently, guidelines addressed the use of a combination of the anti‐SARS‐CoV‐2 monoclonal antibodies casirivimab and imdevimab in non‐severe, severe, and critical COVID‐19 in varying dosing regimes (<a href="./references#CD015209-bbs2-0065" title="AgarwalA , RochwergB , LamontagneF , SiemieniukRA , AgoritsasT , AskieL , et al. A living WHO guideline on drugs for covid-19. BMJ2020;370:m3379. [DOI: 10.1136/bmj.m3379]">Agarwal 2020</a>; <a href="./references#CD015209-bbs2-0102" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>). Anti‐IL‐6 receptor monoclonal antibodies, such as tocilizumab, in addition to systemic corticosteroid therapy have been evaluated for the management of people with COVID‐19 who have systemic inflammation. Guideline recommendations on the use of this combination therapy focus on certain hospitalised individuals who are exhibiting rapid respiratory decompensation due to COVID‐19, but the guideline panels persistently struggle to define the specific patient populations that would benefit from this intervention. </p> <p>JAK inhibitors became subject to appropriate clinical testing due to their anti‐inflammatory and possibly antiviral properties. Additionally, oral dosing, short‐term use, and a reportedly acceptable profile of side effects are advantages of these immunomodulators, and theoretically make them applicable for different stages of the disease (<a href="./references#CD015209-bbs2-0144" title="StebbingJ , PhelanA , GriffinI , TuckerC , OechsleO , SmithD , et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infectious Diseases2020;20(4):400-2. [DOI: 10.1016/S1473-3099(20)30132-8]">Stebbing 2020</a>). </p> <p>Several systematic reviews have focused on non‐COVID‐19‐specific JAK inhibitors (e.g. <a href="./references#CD015209-bbs2-0074" title="ChenCY , ChenWC , HsuCK , ChaoCM , LaiCC . Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: a systematic review and meta-analysis of randomized controlled trials. International Immunopharmacology2021;99:108027. [DOI: 10.1016/j.intimp.2021.108027]">Chen CY 2021</a>; <a href="./references#CD015209-bbs2-0107" title="LimenRY , SedonoR , SugiartoA , HariyantoTI . Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Review of Anti-infective Therapy 2021 Sep 29 [Epub ahead of print]. [DOI: 10.1080/14787210.2021.1982695]">Limen 2021</a>), and various ongoing projects may feed into the undertaking: a research initiative supported by the World Health Organization (WHO) and Cochrane are mapping and evaluating all randomised trials for COVID‐19, including trials on JAK inhibitors (<a href="./references#CD015209-bbs2-0153" title="World Health Organization/Cochrane. COVID-NMA Initiative - a living mapping and living systematic review of COVID-19 trials. covid-nma.com (accessed 6 November 2020).">WHO/Cochrane 2020</a>), with a planned network meta‐analysis of all possible treatments (<a href="./references#CD015209-bbs2-0069" title="BoutronI , ChaimaniA , DevaneD , MeerpohlJJ , RadaG , HróbjartssonA , et al. Interventions for the prevention and treatment of COVID‐19: a living mapping of research and living network meta‐analysis. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD013769. [DOI: 10.1002/14651858.CD013769]">Boutron 2020</a>). </p> <p>In January 2022, WHO published the new version of its COVID‐19 clinical treatment guideline (<a href="./references#CD015209-bbs2-0164" title="World Health Organization guideline development group. Therapeutics and COVID-19 living guideline. Ninth version, published 3 March 2022. Available at www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.3.">WHO 2022</a>), including a strong recommendation for the use of baricitinib in addition to corticosteroids in people with severe or critical COVID‐19, and conditional recommendations against the use of ruxolitinib and tofacitinib in this setting. The recommendations were based on a network meta‐analysis, including data from about 3000 participants. However, the meta‐analysis did not include the results of the largest trial on baricitinib, RECOVERY, of which a preprint (reporting data of more than 8000 participants) was published in early March 2022 (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). </p> <p>To identify, track, evaluate, and update quickly the information on current research efforts on JAK inhibitors in people with COVID‐19, we plan to conduct this systematic review as a living evidence synthesis. It will include information on the effects of systemic JAK inhibitors on people infected with SARS‐CoV‐2 in every stage of clinical development, as well as provide information on the effectiveness and safety of these JAK inhibitors from randomised controlled trials (RCTs) to gain a complete picture of the field. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015209-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015209-sec-0014"></div> <p>To assess the effects of systemic JAK inhibitors plus standard of care compared to standard of care alone (plus/minus placebo) on clinical outcomes in individuals (outpatient or in‐hospital) with any severity of COVID‐19, and to maintain the currency of the evidence using a living systematic review approach. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015209-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015209-sec-0015"></div> <section id="CD015209-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015209-sec-0017"> <h4 class="title">Types of studies</h4> <p>The main description of methods is based on a template from the Cochrane Haematology working group in line with the series of Cochrane Reviews investigating treatments and therapies for COVID‐19 (e.g. <a href="./references#CD015209-bbs2-0102" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>; <a href="./references#CD015209-bbs2-0129" title="PoppM , StegemannM , Metzendorf M-I, GouldS , KrankeP , MeybohmP , et al. Ivermectin for preventing and treating COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]">Popp 2021</a>; <a href="./references#CD015209-bbs2-0146" title="StroehleinJK , WallqvistJ , IannizziC , MikolajewskaA , Metzendorf M-I, BenstoemC , et al. Vitamin D supplementation for the treatment of COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD015043. [DOI: 10.1002/14651858.CD015043]">Stroehlein 2021</a>). We made specific adaptations related to the research question, if necessary. The original protocol for this review was registered with PROSPERO on 11 August 2021 (CRD42021272973). As this review and the other reviews of the Cochrane Review series are living systematic reviews during the COVID‐19 pandemic, specific adaptions related to the research question, including participants, interventions, comparators, outcomes, and methods were necessary. Relevant protocol changes were transparently reported in the section <a href="#CD015209-sec-0117">Differences between protocol and review</a>. </p> <p>To assess the effectiveness and safety of systemic JAK inhibitors for treating people with COVID‐19, we included randomised controlled trials (RCTs), as this study design provides the best evidence for experimental therapies in highly controlled therapeutic settings. For RCT data, we used the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015209-bbs2-0094" title="HigginsJP , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021a</a>). Non‐standard RCT designs, such as cluster‐randomised and cross‐over trials, were not eligible for the review. </p> <p>To track the development of JAK inhibitors, we included all prospectively registered trials on systemic JAK inhibitors in humans infected with SARS‐CoV‐2. We excluded controlled non‐randomised interventional and observational studies, animal studies, pharmacokinetic studies, and in vitro studies. </p> <p>We included the following formats if sufficient information was available on study design, characteristics of participants, interventions, and outcomes: </p> <p> <ul id="CD015209-list-0001"> <li> <p>full‐text publications;</p> </li> <li> <p>preprint articles;</p> </li> <li> <p>abstract publications;</p> </li> <li> <p>results published in trials registries; and</p> </li> <li> <p>personal communication with investigators.</p> </li> </ul> </p> <p>We decided to include preprints and conference abstracts to have a complete overview of ongoing research, especially for tracking newly emerging studies on JAK inhibitors. We did not apply any limitation with respect to the length of follow‐up. </p> </section> <section id="CD015209-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies investigating adults with a confirmed diagnosis of COVID‐19 (reverse transcription polymerase chain reaction (RT‐PCR) or antigen testing) irrespective of age, gender, ethnicity, disease severity, or setting. If studies had included participants with both suspected and confirmed COVID‐19 diagnoses, we would have used only the data for the participant population with confirmed COVID‐19 diagnosis. If data had not been reported separately for participants with confirmed or suspected COVID‐19 diagnosis, we would have included the mixed population. If mixed population studies had contributed data to meta‐analyses, we would have excluded these studies in sensitivity analysis to test the robustness of the results. </p> </section> <section id="CD015209-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following interventions:</p> <p> <ul id="CD015209-list-0002"> <li> <p>participants who received systemic JAK inhibitors in addition to standard of care.</p> </li> </ul> </p> <p>We included the following comparisons for studies with a control arm:</p> <p> <ul id="CD015209-list-0003"> <li> <p>standard of care alone (plus/minus placebo).</p> </li> </ul> </p> <p>Standard of care included application of oxygen via low‐flow or high‐flow devices, invasive or non‐invasive ventilation. Other medication could be steroids or remdesivir, for example. </p> <p>We would have included studies that compared several JAK inhibitors with each other and another treatment, as well as studies that compared several doses of one type of JAK inhibitor with another treatment, placebo, or no treatment. However, we did not identify such studies. If they are published in the future, we will include them in future updates of this review. </p> </section> <section id="CD015209-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes based on the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for people with COVID‐19 (<a href="./references#CD015209-bbs2-0080" title="COMET Initiative. Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020). [DOI: www.comet-initiative.org/Studies/Details/1538]">COMET 2020</a>; <a href="./references#CD015209-bbs2-0113" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>), and additional outcomes that have been prioritised by consumer representatives and the German guideline panel for therapy of hospitalised people with COVID‐19. </p> <p>We defined outcome sets with primary and secondary outcomes for two populations:</p> <p> <ul id="CD015209-list-0004"> <li> <p>hospitalised individuals with moderate to severe COVID‐19; and</p> </li> <li> <p>non‐hospitalised individuals with asymptomatic SARS‐CoV‐2 infection or mild COVID‐19.</p> </li> </ul> </p> <p>Primary outcomes were used to inform the <a href="./full#CD015209-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015209-sec-0021"> <h5 class="title">Hospitalised individuals with moderate to severe COVID‐19</h5> <section id="CD015209-sec-0022"> <h6 class="title"><i>Primary outcomes</i> </h6> <p> <ul id="CD015209-list-0005"> <li> <p>All‐cause mortality at day 28, day 60 and at hospital discharge</p> </li> <li> <p>Clinical status at day 28, day 60, and up to longest follow‐up, including:</p> <ul id="CD015209-list-0006"> <li> <p>improvement of clinical status; i.e. participants discharged alive. Participants should be discharged without clinical deterioration or death. </p> </li> <li> <p>worsening of clinical status; i.e. participants with clinical deterioration, defined as new need for invasive mechanical ventilation or death. </p> </li> </ul> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any event </p> </li> <li> <p>Serious adverse events during the study period, defined as number of participants with any event </p> </li> <li> <p>Specific adverse events: secondary infection</p> </li> </ul> </p> </section> <section id="CD015209-sec-0023"> <h6 class="title"><i>Secondary outcomes</i> </h6> <p> <ul id="CD015209-list-0007"> <li> <p>All‐cause mortality, time to event</p> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHO Quality of Life 100‐question patient‐reported questionnaire (WHOQOL‐100)) at up to 7 days, up to 28 days, and longest follow‐up available </p> </li> <li> <p>Adverse events grades 3 and 4</p> </li> <li> <p>Adverse events of special interest, including anaemia, lymphocytopenia, thrombocytopenia, and intestinal perforation </p> </li> <li> <p>Ventilator‐free days (defined as days alive and free from mechanical ventilation)</p> </li> <li> <p>Viral clearance, assessed with reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days </p> </li> </ul> </p> </section> </section> <section id="CD015209-sec-0024"> <h5 class="title">Non‐hospitalised individuals with asymptomatic SARS‐CoV‐2 infection or mild disease</h5> <section id="CD015209-sec-0025"> <h6 class="title"><i>Primary outcomes</i> </h6> <p> <ul id="CD015209-list-0008"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and up to longest follow‐up</p> </li> <li> <p>Admission to hospital or death within 28 days</p> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days, up to 28 days, and longest follow‐up available </p> </li> <li> <p>Specific adverse events: occurrence of signs of bone marrow suppression (anaemia, low lymphocyte or platelet count, pancytopenia) or secondary infection or intestinal perforation </p> </li> <li> <p>Serious adverse events during the study period, defined as number of participants with any event </p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any event </p> </li> </ul> </p> </section> <section id="CD015209-sec-0026"> <h6 class="title"><i>Secondary outcomes</i> </h6> <p> <ul id="CD015209-list-0009"> <li> <p>Viral clearance, assessed with RT‐PCR for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days </p> </li> </ul> </p> </section> </section> <section id="CD015209-sec-0027"> <h5 class="title">Timing of outcome measurement</h5> <p>We collected information on outcomes from all time points reported in the publications.</p> <p>In case of time‐to‐event analysis (e.g. for mortality), we included the outcome measure based on the longest follow‐up time and measured from randomisation. We also collected information on outcomes from all other time points reported in the publications. If only a few studies contributed data to an outcome, we would have pooled different time points, provided the studies produced valid data and pooling was clinically reasonable. </p> <p>We included (serious) adverse events occurring during active treatment, and long‐term adverse events as well. A grouping of the measurement time points of eligible outcomes (e.g. adverse events and serious adverse events) into those measured directly after treatment (up to 7 days after treatment), medium‐term outcomes (up to 15 days after treatment) and longer‐term outcomes (more than 30 days after treatment) was not possible due to a lack of available data. </p> </section> </section> </section> <section id="CD015209-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015209-sec-0029"> <h4 class="title">Electronic searches</h4> <p>Our Information Specialist (MIM) conducted systematic searches in the following sources from the inception of each database to 24 February 2022 (date of last search for all databases) and did not place restrictions on the language of publication. </p> <p> <ul id="CD015209-list-0010"> <li> <p>Cochrane COVID‐19 Study Register (CCSR) (<a href="https://covid-19.cochrane.org" target="_blank">covid19.cochrane.org</a>), comprising: </p> <ul id="CD015209-list-0011"> <li> <p>MEDLINE (PubMed), weekly updates;</p> </li> <li> <p>Embase, weekly updates;</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), daily updates; </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>), weekly updates; </p> </li> <li> <p>medRxiv (<a href="https://www.medrxiv.org/" target="_blank">www.medrxiv.org</a>), weekly updates; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), monthly updates.</p> </li> </ul> </li> <li> <p>Web of Science Core Collection:</p> <ul id="CD015209-list-0012"> <li> <p>Science Citation Index Expanded (1945 to present);</p> </li> <li> <p>Emerging Sources Citation Index (2015 to present).</p> </li> </ul> </li> <li> <p>WHO COVID‐19 Global literature on coronavirus disease (<a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/" target="_blank">https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/</a>). </p> </li> <li> <p>US Department of Veterans Affairs Evidence Synthesis Program (VA ESP) Covid‐19 Evidence Reviews (<a href="https://www.covid19reviews.org/" target="_blank">https://www.covid19reviews.org/</a>). </p> </li> </ul> </p> <p>We monitor newly published RCTs weekly using the Cochrane COVID‐19 Study Register and have incorporated all new trials from this source until the first week of April 2022. </p> <p>For detailed search strategies, see <a href="./appendices#CD015209-sec-0111">Appendix 1</a>. </p> <p>We did not conduct separate searches of the databases required by the Methodological Expectations of Cochrane Intervention Reviews (MECIR) standards (<a href="./references#CD015209-bbs2-0096" title="HigginsJP , LassersonT , ChandlerJ , ToveyD , ThomasJ , FlemyngE , et al. Methodological Expectations of Cochrane Intervention Reviews (MECIR). Version February 2022. Available from community.cochrane.org/mecir-manual.">Higgins 2021c</a>), since these databases are already being regularly searched for maintenance of the CCSR. </p> </section> <section id="CD015209-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We searched for other potentially eligible studies or ancillary publications by checking the reference lists of included studies, systematic reviews, and meta‐analyses. In addition, we contacted the investigators of included studies to obtain additional information on the retrieved studies. </p> <p>We compared our identified studies with results from projects that aim to track COVID‐19 intervention research; namely, <a href="http://www.covid-trials.org" target="_blank">www.covid-trials.org</a> and <a href="https://covid-nma.com/dataviz/" target="_blank">covid-nma.com/dataviz</a>. </p> </section> <section id="CD015209-sec-0031"> <h4 class="title">Living systematic review considerations</h4> <p>The signal for updating this review will stem from the weekly monitoring of published RCTs via the CCSR, as described under <a href="#CD015209-sec-0029">Electronic searches</a>. Once the decision to update the review has been made, the methods mentioned in this section will be incorporated in the review update. </p> </section> </section> <section id="CD015209-sec-0032"> <h3 class="title" id="CD015209-sec-0032">Data collection and analysis</h3> <section id="CD015209-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Two out of five review authors (AK, CP, MG, AM, NS) independently screened the results of the search strategies for eligibility for this review by reading the abstracts using Covidence software (<a href="./references#CD015209-bbs2-0081" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed after 21 December 2020. Available at covidence.org.">Covidence</a>). Following the living review approach, we immediately screened any new citations retrieved by the weekly searches. Abstracts that both review authors found eligible, or abstracts that we disagreed upon or rated as uncertain, were obtained as full‐text publications for further discussion. Two review authors assessed the full‐text articles of selected studies. If the two review authors were unable to reach a consensus, we consulted all review authors who were involved in study selection to reach a final decision. </p> <p>We documented the study selection process in a flow chart, as recommended in the PRISMA statement (<a href="./references#CD015209-bbs2-0116" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>), and showed the total numbers of retrieved references and the numbers of included and excluded studies (<a href="#CD015209-fig-0002">Figure 2</a>). We listed all studies that we excluded after full‐text assessment and the reasons for their exclusion in the <a href="#CD015209-sec-0066">Excluded studies</a> section. </p> <div class="figure" id="CD015209-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD015209-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> <section id="CD015209-sec-0034"> <h5 class="title">Living systematic review considerations</h5> <p>Two review authors will screen records derived from CCSR weekly to identify new studies.</p> </section> </section> <section id="CD015209-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We conducted data extraction according to the guidelines proposed by Cochrane (<a href="./references#CD015209-bbs2-0108" title="LiT , HigginsJP , Deeks JJ (editors). Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Li T 2021</a>). For each outcome, two out of five review authors (AK, CP, FG, VT, MSp) independently and in duplicate extracted the data using a customised data extraction form developed in Microsoft Excel (<a href="./references#CD015209-bbs2-0115" title="Mircosoft Excel. Microsoft Corporation. Microsoft Corporation, 2018. office.microsoft.com/excel.">Microsoft 2018</a>). We solved disagreements by discussion. When no agreement could be obtained, we involved a third review author to solve the disagreement. </p> <p>Two out of five review authors (AK, CP, FG, VT, MSp) independently assessed eligible studies obtained in the process of study selection (as described above) for methodological quality and risk of bias. If we were unable to reach a consensus, we consulted a third review author. </p> <p>We extracted the following information, if reported.</p> <p> <ul id="CD015209-list-0013"> <li> <p>General information: author(s), title, source, publication date, country, language, duplicate publications. </p> </li> <li> <p>Study characteristics: trial design, setting and dates, source of participants, inclusion/exclusion criteria, comparability of groups, treatment cross‐overs, compliance with assigned treatment, length of follow‐up, funding. </p> </li> <li> <p>Participant characteristics: age, gender, ethnicity, number of participants recruited/allocated/evaluated, additional diagnoses, severity of disease, previous treatments, concurrent treatments, comorbidities (e.g. diabetes, respiratory disease, hypertension, immunosuppression, obesity, heart failure), time since symptom onset. </p> </li> <li> <p>Interventions: type of JAK inhibitor, dose, frequency, timing, duration, and route of administration, setting (e.g. hospitalised, non‐hospitalised), duration of follow‐up. </p> </li> <li> <p>Control interventions (placebo or standard of care alone): dose, frequency, timing, duration, and route of administration, setting, duration of follow‐up. </p> </li> <li> <p>Outcomes: as specified under <a href="#CD015209-sec-0020">Types of outcome measures</a>. </p> </li> </ul> </p> <section id="CD015209-sec-0036"> <h5 class="title">Living systematic review considerations</h5> <p>Two review authors will extract, evaluate, and integrate studies identified through the weekly searches following the guidance for Cochrane living systematic reviews (<a href="./references#CD015209-bbs2-0079" title="Cochrane. Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode. Version December 2019. www.community.cochrane.org/review-production/production-resources/living-systematic-reviews (accessed 2 November 2020).">Cochrane 2019</a>). </p> </section> </section> <section id="CD015209-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Risk of Bias 2.0 (RoB 2) tool (beta version 7) to analyse the risk of bias of study results (<a href="./references#CD015209-bbs2-0145" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898]">Sterne 2019</a>). For this review, the effect of the assignment to the intervention (the intention‐to‐treat (ITT) effect) was relevant, thus we performed all assessments with RoB 2 on this effect. The outcomes that we assessed were those specified for inclusion in the summary of findings table (<a href="./full#CD015209-tbl-0001">summary of findings Table 1</a>). </p> <p>Two out of seven review authors (AK, CP, FG, VT, CSt, ALF, MSp) independently assessed the risk of bias for each outcome. In case of discrepancies among our judgements and inability to reach consensus, we consulted a third review author to reach a final decision. We assessed the following types of bias as outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015209-bbs2-0095" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>). </p> <p> <ul id="CD015209-list-0014"> <li> <p>Bias arising from the randomisation process.</p> </li> <li> <p>Bias due to deviations from the intended interventions.</p> </li> <li> <p>Bias due to missing outcome data.</p> </li> <li> <p>Bias in measurement of the outcome.</p> </li> <li> <p>Bias in selection of the reported result.</p> </li> </ul> </p> <p>To address these types of bias, we used the signalling questions recommended in RoB 2 and made a judgement using the following options. </p> <p> <ul id="CD015209-list-0015"> <li> <p>'Yes': if there is firm evidence that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'Probably yes': a judgement has been made that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No': if there is firm evidence that the question is unfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'Probably no': a judgement has been made that the question is unfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No information': if the study report does not provide sufficient information to allow any judgement. </p> </li> </ul> </p> <p>We used the algorithms proposed by RoB 2 to assign each domain one of the following levels of bias. </p> <p> <ul id="CD015209-list-0016"> <li> <p>Low risk of bias.</p> </li> <li> <p>Some concerns.</p> </li> <li> <p>High risk of bias.</p> </li> </ul> </p> <p>Subsequently, we derived an overall 'risk of bias' rating for each prespecified outcome in each study in accordance with the following suggestions. </p> <p> <ul id="CD015209-list-0017"> <li> <p>'Low risk of bias': we judge the trial to be at low risk of bias for all domains for this result. </p> </li> <li> <p>'Some concerns': we judge the trial to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain. </p> </li> <li> <p>'High risk of bias': we judge the trial to be at high risk of bias in at least one domain for the result, or we judge the trial to have some concerns for multiple domains in a way that substantially lowers confidence in the results. </p> </li> </ul> </p> <p>We used the RoB 2 Excel tool to implement RoB 2 (available from <a href="https://www.riskofbias.info/" target="_blank">riskofbias.info</a>), and stored our detailed RoB 2 assessments as supplementary online material. The link to our RoB 2 Excel sheet can be obtained by personal request to the authors via email. </p> <p>For domain three of the tool ('bias due to missing outcome data'), we considered death as a competing risk factor, especially for dichotomous outcomes. We judged adverse events to be at risk of bias due to missing data because it is likely that death during follow‐up impeded occurrence of adverse events. </p> </section> <section id="CD015209-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We performed meta‐analyses based on the recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015209-bbs2-0094" title="HigginsJP , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021a</a>). We used RevMan Web software to perform statistical analyses (<a href="./references#CD015209-bbs2-0132" title="Review Manager Web (RevMan Web). Version 4.5.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). </p> <p>For continuous outcomes, we recorded mean difference (MD) with 95% confidence intervals (CIs). </p> <p>For dichotomous outcomes, we recorded the number of affected participants and the number of participants per group in both treatment and control groups. We reported the pooled risk ratio (RR) with a 95% confidence interval (CI) using the Mantel‐Haenszel method under a random‐effects model (<a href="./references#CD015209-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). </p> <p>If available, we extracted and reported hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to death) and the corresponding 95% CIs. As HRs were available, there was no need to estimate the HR as accurately as possible from available data using the methods proposed by <a href="./references#CD015209-bbs2-0125" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34. [DOI: 10.1002/(SICI)1097-0258(19981230)17:24&amp;lt;2815::AID-SIM110&amp;gt;3.0.CO;2-8]">Parmar 1998</a> and <a href="./references#CD015209-bbs2-0148" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16]">Tierney 2007</a>. </p> </section> <section id="CD015209-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The aim of this review was to summarise studies that analyse data at the level of the individual. We collated multiple reports of one study so that the study, and not the report, was the unit of analysis. </p> <section id="CD015209-sec-0040"> <h5 class="title">Studies with multiple treatment groups</h5> <p>As recommended in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015209-bbs2-0094" title="HigginsJP , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021a</a>), for studies with multiple treatment groups of the same intervention (i.e. dose, route of administration), we would have evaluated whether study arms were sufficiently homogeneous to be combined. If arms could not be pooled, we would have compared each arm with the common comparator separately. For pairwise meta‐analyses, we had planned to split the ‘shared’ group into two or more groups, depending on the number of treatment arms, and included two or more (reasonably independent) comparisons. For this purpose, for dichotomous outcomes, both the number of events and the total number of participants would have been divided, and for continuous outcomes, the total number of participants would have been divided with unchanged means and standard deviations (SDs). </p> </section> </section> <section id="CD015209-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> suggests a number of potential sources for missing data, which we took into account: at study level, at outcome level, and at summary data level (<a href="./references#CD015209-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). At all levels, it is important to differentiate between data 'missing at random', which may often be unbiased, and 'not missing at random', which may bias study and thus review results. </p> <p>If data were missing, we requested these data from the principal investigators. If, after this, data were still missing, we assumed data to be missing at random if missing outcomes were balanced across study arms and the method of detecting outcomes was comparable across study arms. In that case, we made no assumptions about the missing outcome data and performed a complete case analysis and excluded the participants with missing outcome data from the analysis (<a href="./references#CD015209-bbs2-0092" title="GuyattGH , EbrahimS , Alonso-CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017;87:14-22. [DOI: https://doi.org/10.1016/j.jclinepi.2017.05.005]">Guyatt 2017</a>). When we assumed that data were not missing at random, and we identified no supporting evidence that the results were not biased by missing outcome data, we planned to exclude these data from meta‐analysis and discuss the potential impact of their absence on the results. </p> </section> <section id="CD015209-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of treatment effects between trials using a Chi² test with a significance level at P &lt; 0.1, and visual examination of forest plots. We used the I² statistic (<a href="./references#CD015209-bbs2-0093" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), to quantify possible statistical heterogeneity (I² statistic &gt; 30% to signify moderate heterogeneity; I² statistic &gt; 75% to signify considerable heterogeneity; <a href="./references#CD015209-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). If heterogeneity was above 80%, we explored potential causes through sensitivity analyses. </p> <p>If we could not find a reason for heterogeneity, we did not perform a meta‐analysis, but commented on results from all studies and presented these in tables. </p> </section> <section id="CD015209-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>Missing studies can introduce bias to the analysis. Hence, we had planned to include completed non‐published trials in trial registers meeting our predefined eligibility criteria. We contacted authors to seek assurance that the results will be made available, classified them as 'awaiting classification' while waiting for the clarification of our questions and more detailed baseline characteristic information, and reported the number of completed non‐published trials. We planned to investigate risk of reporting bias (publication bias) in pairwise meta‐analyses using contour‐enhanced funnel plots, in case of 10 or more relevant studies pooled in a meta‐analysis. In the current review, there are no meta‐analyses including ten or more studies. For future review updates, if funnel plot asymmetry is suggested by a visual assessment, we plan to perform exploratory analyses (e.g. Rücker’s arcsine test for dichotomous data (<a href="./references#CD015209-bbs2-0134" title="RückerG , SchwarzerG , CarpenterJ . Arcsine test for publication bias in meta-analyses with binary outcomes. Statistics in Medicine2008;27(5):746-63. [DOI: 10.1002/sim.2971]">Rücker 2008</a>), and Egger’s linear regression test for continuous data (<a href="./references#CD015209-bbs2-0083" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997 Sep 13;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629]">Egger 1997</a>)) to further investigate funnel plot asymmetry. A P value of less than 0.1 will be considered as the level of statistical significance. </p> </section> <section id="CD015209-sec-0044"> <h4 class="title">Data synthesis</h4> <p>We analysed trial data including different severities of disease separately, grouping them by severity of respiratory insufficiency (no oxygen supplementation, low oxygen supplementation, non‐invasive ventilation (NIV), oxygen supplementation via high‐flow nasal cannula (HFNC), invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO) at baseline), as these are different populations in different settings, resulting in different outcome sets (see <a href="#CD015209-sec-0020">Types of outcome measures</a>). We only analysed trials whose populations consisted of hospitalised individuals with moderate to severe COVID‐19. We would have analysed separately those trials reporting on non‐hospitalised individuals with asymptomatic infection or mild COVID‐19, but we did not find such studies. </p> <p>If clinical and methodological characteristics of individual studies were sufficiently homogeneous, we pooled the data in meta‐analysis, according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015209-bbs2-0082" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). We used RevMan Web software for meta‐analyses (<a href="./references#CD015209-bbs2-0132" title="Review Manager Web (RevMan Web). Version 4.5.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). One review author entered the data into the software, and a second review author checked the data for accuracy. When meta‐analysis was feasible, we used the random‐effects model as we assume that the intervention effects are related but are not the same for the included studies. For dichotomous outcomes, we performed meta‐analyses using the Mantel‐Haenszel method under a random‐effects model to calculate the summary (combined) intervention effect estimate as a weighted average of the intervention effects estimated in the individual studies. For continuous outcomes, we used the inverse‐variance method. </p> <p>We planned to present descriptive statistics only, if we deemed meta‐analysis inappropriate for a certain outcome because of heterogeneity or because of serious study limitations leading to considerably high risk of bias. This was not the case for the current review version. Where meta‐analysis was possible, we would have assessed the effects of potential biases in sensitivity analyses; however, our considerations were not applicable. We have investigated heterogeneity in subgroup analyses (see <a href="./references#CD015209-fig-0014" title="">Analysis 2.1</a>, <a href="./references#CD015209-fig-0015" title="">Analysis 3.1</a>). For future review updates, if we cannot find a cause for heterogeneity, we plan to omit meta‐analysis, and instead to comment on the results narratively with the results from all studies presented in analyses. We used forest plots to visualise meta‐analyses of primary outcomes only, including risk of bias assessment. We reported secondary outcomes narratively. </p> <section id="CD015209-sec-0045"> <h5 class="title">Living systematic review considerations</h5> <p>Whenever we identify new evidence (studies, data, or information) that meets the review inclusion criteria, we will immediately assess risk of bias and extract the data and incorporate them in the synthesis, as appropriate. We will not adjust the meta‐analyses to account for multiple testing, given that the methods related to frequent updating of meta‐analyses are under development (<a href="./references#CD015209-bbs2-0139" title="SimmondsM , SalantiG , McKenzieJ , ElliottJ , Living Systematic Review Network. Living systematic reviews: 3. Statistical methods for updating meta-analyses. Journal of Clinical Epidemiology2017;91:38-46. [DOI: 10.1016/j.jclinepi.2017.08.008]">Simmonds 2017</a>). </p> </section> </section> <section id="CD015209-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To further explore the effects of JAK inhibitors, we performed subgroup analyses of the following characteristics: </p> <p> <ul id="CD015209-list-0018"> <li> <p>type of JAK inhibitor substance;</p> </li> <li> <p>severity of condition.</p> </li> </ul> </p> <p>In addition, we would have conducted subgroup analyses according to the following characteristics: </p> <p> <ul id="CD015209-list-0019"> <li> <p>age of participants (divided into applicable age groups; e.g. 18 to 65 years, 65 years and older); </p> </li> <li> <p>pre‐existing conditions (diabetes, respiratory disease, hypertension, immunosuppression);</p> </li> <li> <p>timing of first dose administration with illness onset;</p> </li> <li> <p>duration since symptom onset;</p> </li> <li> <p>duration of JAK inhibitor application.</p> </li> </ul> </p> <p>We used the tests for interaction to test for differences between subgroup results.</p> </section> <section id="CD015209-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses of the following characteristics for our primary outcome (all‐cause mortality up to day 28): </p> <p> <ul id="CD015209-list-0020"> <li> <p>comparison of preprints versus peer‐reviewed articles; </p> </li> <li> <p>comparison of studies with a low risk of bias or some concerns versus studies with a high risk of bias; </p> </li> <li> <p>comparison of studies with placebo versus no placebo;</p> </li> <li> <p>comparison of the fixed‐effect versus random‐effects statistical model.</p> </li> </ul> </p> <p>We had planned to perform sensitivity analyses of the following characteristics for our primary outcomes: </p> <p> <ul id="CD015209-list-0021"> <li> <p>assessment of statistical heterogeneity (I² &gt; 80%);</p> </li> <li> <p>comparison of premature termination of studies with completed studies.</p> </li> </ul> </p> <p>As we identified no heterogeneity above 80%, and there was no study with a high risk of bias, nor a prematurely ended study, we did not conduct sensitivity analysis concerning those characteristics. </p> </section> <section id="CD015209-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD015209-sec-0049"> <h5 class="title">Summary of findings</h5> <p>We created a summary of findings table for people with moderate to severe disease using MAGICapp software (<a href="./references#CD015209-bbs2-0111" title="MAGIC authoring and publication platform (MAGICapp). MAGIC (Making Grade the Irresistible Choice), Version 10.6. Oslo: MAGIC Evidence Ecosystem Foundation, 2020. Available at magicapp.org/.">MAGICapp</a>), and evaluated the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for interventions evaluated in RCTs (<a href="./references#CD015209-bbs2-0090" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed after 21 December 2020. Available at gradepro.org.">GRADEpro GDT</a>), as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015209-bbs2-0137" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>). </p> <p>For time‐to‐event outcomes, we calculated absolute effects at specific time points, as recommended in the GRADE guidance 27 (<a href="./references#CD015209-bbs2-0141" title="SkoetzN , GoldkuhleM , Van DalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles. Journal of Clinical Epidemiology2020;118:124-31. [DOI: 10.1016/j.jclinepi.2019.10.015]">Skoetz 2020</a>). For participants with asymptomatic infection and mild disease, we will create a separate summary of findings table, when study findings become available. </p> <p>According to Chapter 14 of the updated <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, the “most critical and/or important health outcomes, both desirable and undesirable, limited to seven or fewer outcomes” should be included in the summary of findings table(s) (<a href="./references#CD015209-bbs2-0137" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>). We included outcomes prioritised according to the Core Outcome Set for intervention studies (<a href="./references#CD015209-bbs2-0080" title="COMET Initiative. Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020). [DOI: www.comet-initiative.org/Studies/Details/1538]">COMET 2020</a>), and patient‐relevant outcomes. These are: </p> <section id="CD015209-sec-0050"> <h6 class="title">Hospitalised individuals with moderate to severe COVID‐19</h6> <p> <ul id="CD015209-list-0022"> <li> <p>All‐cause mortality:</p> <ul id="CD015209-list-0023"> <li> <p>up to day 28</p> </li> <li> <p>up to day 60</p> </li> </ul> </li> <li> <p>Clinical status at day 28</p> <ul id="CD015209-list-0024"> <li> <p>Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care </p> </li> <li> <p>Worsening of clinical status: new need for invasive mechanical ventilation or death</p> </li> </ul> </li> <li> <p>Adverse events (any grade)</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Secondary infection (a specific adverse event)</p> </li> </ul> </p> </section> <section id="CD015209-sec-0051"> <h6 class="title">Non‐hospitalised individuals with asymptomatic SARS‐CoV‐2 infection or mild disease</h6> <p> <ul id="CD015209-list-0025"> <li> <p>All‐cause mortality</p> <ul id="CD015209-list-0026"> <li> <p>up to day 28</p> </li> <li> <p>up to day 60</p> </li> </ul> </li> <li> <p>Admission to hospital or death within 28 days</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Adverse events (any grade)</p> </li> </ul> </p> </section> </section> <section id="CD015209-sec-0052"> <h5 class="title">Assessment of the certainty in the evidence</h5> <p>We used the GRADE approach to assess the certainty of the evidence for the outcomes listed in the previous section. </p> <p>The GRADE approach uses five domains (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each prioritised outcome. </p> <p>We downgraded the certainty of the evidence for:</p> <p> <ul id="CD015209-list-0027"> <li> <p>serious (−1) or very serious (−2) risk of bias;</p> </li> <li> <p>serious (−1) or very serious (−2) inconsistency;</p> </li> <li> <p>serious (−1) or very serious (−2) uncertainty about directness;</p> </li> <li> <p>serious (−1) or very serious (−2) imprecise or sparse data;</p> </li> <li> <p>serious (−1) or very serious (−2) probability of reporting bias.</p> </li> </ul> </p> <p>The GRADE system uses the following criteria for assigning grades of evidence.</p> <p> <ul id="CD015209-list-0028"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We followed the current GRADE guidance for these assessments in its entirety as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapter 14 (<a href="./references#CD015209-bbs2-0137" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>). </p> <p>We used the overall risk of bias judgement, derived from the RoB 2 Excel tool, to inform our decision on downgrading for risk of bias. We phrased the findings and certainty in the evidence as suggested in the informative statement guidance (<a href="./references#CD015209-bbs2-0135" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [DOI: 10.1016/j.jclinepi.2019.10.014]">Santesso 2020</a>). Our RoB table can be obtained from the review authors through a personal request via email. </p> </section> <section id="CD015209-sec-0053"> <h5 class="title">Methods for future updates: living systematic review considerations</h5> <p>We will use the CCSR to monitor newly‐published results of RCTs on JAK inhibitors on a weekly basis. Two review authors will screen, extract, evaluate, and integrate the data following the guidance for Cochrane living systematic reviews (<a href="./references#CD015209-bbs2-0079" title="Cochrane. Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode. Version December 2019. www.community.cochrane.org/review-production/production-resources/living-systematic-reviews (accessed 2 November 2020).">Cochrane 2019</a>). </p> <p>We will manually check platform trials that were previously identified and listed as 'studies awaiting classification' for additional treatment arms. </p> <p>We will wait until the accumulating evidence changes one or more of the following components of the review before republishing the review: </p> <p> <ul id="CD015209-list-0029"> <li> <p>findings that substantially change the estimated effect of one or more primary outcomes;</p> </li> <li> <p>findings that substantially change the credibility (e.g. GRADE rating) of the estimated effect of one or more prioritised outcomes; </p> </li> <li> <p>new settings, populations, interventions, comparisons, or outcomes studied.</p> </li> </ul> </p> </section> <section id="CD015209-sec-0054"> <h5 class="title">When review methods will be reviewed</h5> <p>We will check the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID‐19 research (e.g. when additional comparisons, interventions, subgroups, or outcomes, or new review methods become available). </p> </section> <section id="CD015209-sec-0055"> <h5 class="title">Conditions under which the review will no longer be maintained as a living systematic review </h5> <p>In our regular review of the scope, we will decide whether to continue or stop updating the review. Decisions to stop may be that the conclusions for our main outcomes and populations of interest are unlikely to change with future studies included in the review, no new evidence is expected, or the review question is no longer a priority for policy and practice. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015209-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015209-sec-0056"></div> <section id="CD015209-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD015209-sec-0058"> <h4 class="title">Results of the search</h4> <p>We performed database searches for RCTs according to predefined search strings and identified 494 records. After removing duplicates, we screened 474 records based on title and abstract, of which 406 did not meet the prespecified inclusion criteria. We screened full texts or, if applicable, trial register entries of the remaining 68 references. We excluded 37 published records (36 studies) that did not meet our prespecified inclusion criteria. Reasons for exclusion of studies at full‐text stage are listed in <a href="#CD015209-tbl-0002">Table 1</a> ‐ Characteristics of excluded studies. We classified 13 ongoing studies as possibly eligible studies (see <a href="#CD015209-tbl-0003">Table 2</a> ‐ <a href="./references#CD015209-sec-0127" title="">Characteristics of ongoing studies</a>). Overall, we included six studies (eight records) in our narrative analysis and six studies in our meta‐analyses. We searched ClinicalTrials.gov and the WHO ICTRP for additional and ongoing trials that met our inclusion criteria. Details of our search strategy are provided in <a href="./appendices#CD015209-sec-0111">Appendix 1</a>. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD015209-fig-0002">Figure 2</a>). </p> <div class="table" id="CD015209-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number</b> </p> <p><b>of participants (ITT)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Severity of condition in regard to respiratory support, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age, years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time from symptom onset to randomisation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ruxolitinib 5 mg twice a day orally (duration not reported)</p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo twice a day (vitamin C) orally + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 20</p> <p>Control: 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supplemental oxygen<br/>through low‐flow devices = 36 (87.8) </p> <p>Supplemental oxygen<br/>through high‐flow devices / NIV = 5 (12.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (range) 63 (58 ‐ 68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 20 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tofacitinib 10 mg twice a day orally (reduced dose: 5 mg twice a day) for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo twice a day orally + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 144</p> <p>Control: 145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen = 71 (24.6)</p> <p>Supplemental oxygen<br/>through low‐flow devices = 181 (62.6) </p> <p>Supplemental oxygen<br/>through high‐flow devices = 37 (12.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 56 (± 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4 mg once a day (reduced dose: 2 mg once a day) for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC (including remdesivir in all participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo once a day + SoC (includig remdesivir in all participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 515</p> <p>Control: 518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen = 142 (13.7)</p> <p>Supplemental oxygen<br/>through low‐flow devices = 564 (54.6) </p> <p>Supplemental oxygen<br/>through high‐flow devices / NIV = 216 (20.9) </p> <p>IMV = 111 (10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 55.4 (± 15.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 8 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4 mg once a day orally (reduced dose: 2 mg once a day) for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo once a day orally + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 764</p> <p>Control: 761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen = 186 (12.2)</p> <p>Supplemental oxygen<br/>through low‐flow devices = 962 (63.1) </p> <p>Supplemental oxygen<br/>through high‐flow devices / NIV = 370 (24.3) </p> <p>Unknown = 7 (0.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 57.6 (± 14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 7 days in 83.5% of participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4 mg once a day (reduced dose when GFR ≥ 30 to<br/>&lt; 60 mL/min/1.73 m<sup>2</sup> : 2 mg once a day) by nasogastric tube delivery (or<br/>given orally when feasible); for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo once a day by nasogastric tube delivery (or<br/>given orally when feasible) + SoC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 51</p> <p>Control: 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMV = 101 (100)</p> <p>ECMO = 4 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 58.6 (± 13.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 7 days in 93.9% of participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4mg once a day for up to 10 days or until hospital discharge (reduce dose if eGFR ≥30 &lt;60 mL/min/1.73m2: 2 mg once daily, if eGFR ≥15 &lt;30 mL/min/1.73m2: 2 mg on alternate days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 4148</p> <p>Control: 4008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen: 465 (6%)</p> <p>Simple oxygen: 5513 (68%)</p> <p>NIV: 1927 (24%)</p> <p>IMV: 251 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>intervention: 58.5 (15.4) vs control 57.7 (15.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median: 9 days</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>ECMO:</b> extracorporeal membrane oxygenation; <b>GFR:</b> glomerular filtration rate; <b>IMV:</b> invasive mechanical ventilation; <b>ITT:</b> intention‐to‐treat; <b>NIV:</b> non‐invasive ventilation; <b>SD:</b> standard deviation; <b>SoC:</b> standard of care. </p> </div> </div> <div class="table" id="CD015209-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Title</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>JAK inhibitors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants planned</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Prospective completion date</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective, Phase II, Randomized, Open‐label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS‐CoV2 Pneumonia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two intervention arms:</p> <p>1. Baricitinib</p> <p>2. Imatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0054" title="NCT04346147. Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of baricitinib, imatinib or supportive treatment in patients with SARS Cov2 pneumonia. www.clinicaltrials.gov/ct2/show/NCT04346147 (first received 15 April 2020). ">NCT04346147</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2021 (last update posted August 2021)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mulTi‐Arm Therapeutic Study in Pre‐ICu Patients Admitted With Covid‐19 ‐ Repurposed Drugs (TACTIC‐R) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two intervention arms:</p> <p>1. Baricitinib + SoC</p> <p>2. Ravulizumab + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0056" title="NCT04390464. mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R). www.clinicaltrials.gov/ct2/show/NCT04390464 (first received 12 May 2020). ">NCT04390464</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factorial, Multicentric, Randomized Clinical Trial of Remdesivir and Immunotherapy in Combination With Dexamethasone for Moderate COVID‐19 (the AMMURAVID Trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three intervetion arms:</p> <p>1. Baricitinib + SoC</p> <p>2. Remdesivir + SoC</p> <p>3. Baricitinib + Remdesivir + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC (with Dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0062" title="NCT04832880. Factorial, multicentric, randomized clinical trial of remdesivir and immunotherapy in combination with dexamethasone for moderate COVID-19 (the AMMURAVID Trial). www.clinicaltrials.gov/ct2/show/record/NCT04832880 (first received 6 April 2021). ">NCT04832880</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0063" title="NCT04891133. European DisCoVeRy for Solidarity: an Adaptive Pandemic and Emerging Infection Platform Trial. www.clinicaltrials.gov/ct2/show/NCT04891133 (first received 18 May 2021). ">NCT04891133</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>December 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACCORD‐2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID‐19 in Hospitalised Patients </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four intervetion arms:</p> <p>1. Bemcentinib</p> <p>2. MEDI3506 (human IgG mAB)</p> <p>3. Zilucoplan</p> <p>4. Acalabrutinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0053" title="EudraCT 2020-001736-95. ACCORD-2: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001736-95/GB (first received 23 April 2020). ">EudraCT2020‐001736‐95</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baricitinib in Hospitalized Covid‐19 Patients With Diabetes Mellitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0064" title="NCT04970719. Baricitinib in hospitalized Covid-19 patients with diabetes mellitus. www.clinicaltrials.gov/ct2/show/NCT04970719 (first received 21 July 2021). ">NCT04970719</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>December 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three intervetion arms:</p> <p>1. Ruxolitinib</p> <p>2. Colchicine</p> <p>3. Secukinumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0058" title="NCT04403243. COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT). www.clinicaltrials.gov/ct2/show/NCT04403243 (first received 27 May 2020). ">NCT04403243</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 2020 (last update posted May 2020)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised Multi‐arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID‐19 Pneumonia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two intervetion arms:</p> <p>1. Ruxolitinib</p> <p>2. Fostamatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0060" title="NCT04581954. Randomised multi-arm trial of ruxolitinib (RUX) and fostamatinib (FOS) for COVID-19 pneumonia. www.clinicaltrials.gov/ct2/show/NCT04581954 (first received 9 October 2020). ">NCT04581954</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>456</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>December 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS‐CoV2 (COVID‐19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial (TOFACoV‐2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tofacitinib + Hydroxychloroquine + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxychloroquine + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0055" title="NCT04390061. TOFAcitinib plus hydroxycloroquine vs hydroxycloroquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial (TOFACoV-2). www.clinicaltrials.gov/ct2/show/NCT04390061 (first received 13 May 2020). ">NCT04390061</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2020 (last update posted May 2020)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco‐hematological patients affected with COVID19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0052" title="EUCTR2020-001789-12. A phase I/II clinical trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: a structured summary of a study protocol for a randomised controlled trial. www.clinicaltrialsregister.eu/ctr-search/search/trial/2020-001789-12 (first received 5 Febuary 2021). [DOI: 10.1186/s13063-021-05072-4]">EUCTR2020‐001789‐12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baricitinib Compared to Standard Therapy in Patients With COVID‐19 (BARICIVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0057" title="NCT04393051. Baricitinib Compared to Standard Therapy in Patients With COVID-19 (BARICIVID-19). https://clinicaltrials.gov/ct2/show/NCT04393051 (first received 19 May 2020). ">NCT04393051</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2020</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID‐19 disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ruxolitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0059" title="EudraCT2020-001754-21. An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001754-21/FR (first received 17 April 2020). NCT04424056. A trial using anakinra, tocilizumab alone or in association with ruxolitinib in severe stage 2b and 3 of COVID 19-associated disease (INFLAMMACOV). www.clinicaltrials.gov/ct2/show/NCT04424056 (first received 9 June 2020). ">NCT04424056</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tocilizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0061" title="NCT04693026. Efficacy of ramdicivir and baricitinib for the treatment of severe COVID 19 patients. www.clinicaltrials.gov/ct2/show/NCT04693026 (first received 5 January 2021). ">NCT04693026</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2021</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>COVID‐19:</b> coronavirus disease 2019; <b>IgG:</b> immunoglobulin‐G;<b>mAB:</b> monoclonal antibody;<b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2;<b>SoC:</b> standard of care </p> </div> </div> </section> <section id="CD015209-sec-0059"> <h4 class="title">Included studies</h4> <section id="CD015209-sec-0060"> <h5 class="title">Designs of the studies and publication status</h5> <p>Please see Characteristics of included studies and <a href="#CD015209-tbl-0002">Table 1</a>.   </p> <p>We included six RCTs with 11,145 participants — ranging from n = 42 (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>) to n = 8156 (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>) — diagnosed with SARS‐CoV‐2 infection in this review (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>).  </p> <p>All studies had a parallel‐group design and were conducted either double‐blinded (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), single‐blinded (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>), or open‐label (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). Four studies were placebo‐controlled (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), in one study  vitamin C was administered as placebo (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>), and one study did not use placebo in addition to standard of care (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). All included studies were multi‐centre studies. Four of them were conducted internationally: <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> had 101 centre sites (Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Puerto Rico, Russia, South Korea, Spain, United Kingdom, USA); <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> had 9 centre sites (Ghana, India, Indonesia, Nepal, Pakistan, South Africa, Sri Lanka, United Kingdom, Vietnam); <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a> had 67 (Denmark, Japan, Mexico, Singapore, South Korea, Spain, United Kingdom, USA); and <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> had 18 (Argentina, Brazil, Mexico, USA). The two remaining studies were conducted nationally, with three centre sites in China (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>), and 15 centre sites in Brazil (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>), respectively.  </p> <p>All studies reported information on the responsible ethics committee and financial support. Three studies were funded by pharmaceutical companies, including Pfizer Inc. (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>), and Eli Lilly and Company (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). Three other studies were solely funded by departmental or governmental resources as well as non‐profit organisations: the National Institute of Allergy and Infectious Diseases (NIAID; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>); the Emergency Research Project of Tongji Hospital of Huazhong University of Science and Technology, and the Emergency Research Project of Hubei province (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>); the RECOVERY trial is supported by grants to the University of Oxford from UK Research and Innovation (UKRI) and NIHR (MC_PC_19056), the Wellcome Trust (Grant Ref: 480 222406/Z/20/Z) through the COVID‐19 Therapeutics Accelerator, by core funding provided by the NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth and Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). </p> <p>Five included studies (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>) were available as peer‐reviewed publications in indexed journals; one study was available as preprint only (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). Three studies had prospectively registered study protocols (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), another as part of a large platform study (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>, as an addendum to <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>, was not registered separately. One study had a retrospective trial registry entry (<a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>). </p> </section> <section id="CD015209-sec-0061"> <h5 class="title">Participants</h5> <p>All included studies were performed in hospitals, and included moderately and severely ill participants according to: WHO 4 (not receiving supplemental oxygen) to WHO 6 (defined as receiving supplemental oxygen through high‐flow devices) in <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; receiving supplemental oxygen through high‐flow devices or non‐invasive ventilation in <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a> and <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; WHO 4 to WHO 9 (receiving invasive mechanical ventilation (IMV) and/or extracorporeal membrane oxygenation (ECMO)) in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> and <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>. <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> included only participants receiving IMV or ECMO at study entry and randomisation. Considering all studies together, the largest subgroup (7220 participants) received supplemental oxygen through low‐flow devices (WHO 5), followed by the subgroup receiving supplemental oxygen through high‐flow devices or non‐invasive ventilation (WHO 6: 2555 participants) and the subgroup not receiving supplemental oxygen (WHO 4: 864 participants). Only 463 participants from three studies required invasive mechanical ventilation or ECMO when entering the study (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>). For seven participants, the level of respiratory support was not reported (<a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). </p> <p>SARS‐CoV‐2 infection was determined by polymerase chain reaction (PCR) prior to randomisation in five studies (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). Only the largest study, <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>, included participants with confirmed or suspected SARS‐CoV‐2 infection. At baseline, within this study population about 1% were SARS‐CoV‐2‐PCR negative and about 8% had an unknown PCR test result. Time from symptom onset to randomisation was 8 (<a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>), 9 (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>), 10 (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>), and 20 days (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>) (median), or 7 days or more in 83.5% and 93.9% of study participants in <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> and <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>, respectively.   </p> <p>The mean age of the included participants was 55.4 to 58.6 years (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). In the remaining study, the median of the participants' age was 63 (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>). Sixty‐three per cent of participants were male. Regarding all studies, the most common comorbidity was hypertension, where 54.5% (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>), 50.2% (<a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), 48% (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>), and 39% (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>) of study participants were assessed to be hypertensive. Obesity was the most common comorbidity in <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> (56.4%). <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> reported diabetes as the most common comorbidity (23%), while leaving the number of patients with hypertension or obesity unspecified. <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a> reported only the number of participants with none, one, or at least two comorbidities, respectively. Reported comorbidities and relevant risk factors are listed in the Characteristics of included studies section.  </p> <p>Exclusion criteria with respect to immunostatus were: immunocompromised status in general (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>); intake of different immunosuppressants in the four weeks prior to screening including anti‐IL‐6‐R‐antagonists (e.g. tocilizumab) (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>); or concomitant malignant tumour (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>). <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> excluded people with neutropenia or a "medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial" (detailed in the Characteristics of included studies section). </p> <p>Only one study provided information about the vaccination status of the participants, 42% of whom were vaccinated (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). </p> </section> <section id="CD015209-sec-0062"> <h5 class="title">Interventions and comparators </h5> <p>Studies investigated the selective Janus kinase (JAK) 1/JAK 2 inhibitors baricitinib (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), ruxolitinib (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>), and the JAK 1/JAK 3 inhibitor tofacitinib, with less activity against JAK 2 (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>). Baricitinib was given at a dose of 4 mg once a day (either orally (two 2‐mg tablets) or through a nasogastric tube) for up to 14 days or until hospital discharge, whichever occurred first. A dose of 2 mg once a day was given if the participant had a baseline estimated glomerular filtration rate (eGFR) of 30 to less than 60 mL/min/1.73 m<sup>2</sup> of body‐surface area as well as in case of decrease in GFR into this range during the course of the study, or also due to co‐medication with probenecid in one study (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). Ruxolitinib was given orally at a dose of 5 mg twice a day; the duration of the therapy was not reported. Tofacitinib was given at a dose of 10 mg twice a day for up to 14 days or until hospital discharge, whichever was earlier. A reduced‐dose regimen of 5 mg of tofacitinib twice a day was administered in participants with an eGFR of less than 50 mL/min/1.73 m<sup>2</sup> of body‐surface area, in those with moderate hepatic impairment, and in those with concomitant use of a strong cytochrome (CY) P3A4 inhibitor or a combination of a moderate CYP3A4 inhibitor and a strong CYP2C19 inhibitor. </p> <p>Four studies were double‐blinded and used placebo in addition to standard of care (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>). One study was designed single‐blinded and used 100 mg vitamin C as placebo (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>), which we deemed as equivalent to placebo. One study was open‐label and used standard of care alone as control condition (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). </p> <p>In all studies, standard of care followed local protocols and included the application of glucocorticoids, antibiotic agents, anticoagulants, and antiviral agents, as well as non‐pharmaceutical procedures, such as oxygen supplementation, non‐invasive and invasive ventilation, renal‐replacement therapy, and extracorporeal membrane oxygenation, if necessary. In two studies, participants in both study arms concomitantly received remdesivir in addition to standard of care (all in <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>, 20% in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>).   Systemic corticosteroids were administered in 95.3% (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>), 86.1% (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>), 79% (<a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), 78.5% (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>), and 70.7% of participants (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>). In one study (<a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>), glucocorticoids were permitted only for specific indications such as adrenal insufficiency, asthma exacerbation, laryngeal oedema, septic shock, and acute respiratory distress syndrome. In total, about 20% received corticosteroids. In four studies, previous (within four weeks prior to the study entry) or concomitant use of other JAK inhibitors, biologic agents, potent immunosuppressants, interleukin‐1 inhibitors, interleukin‐6 inhibitors, or potent CYP450 inducers was not allowed (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). In contrast,  <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> additionally reported concomitant application of or planned use of tocilizumab within the next 24 hours in 23% and 9% of participants, respectively. </p> </section> <section id="CD015209-sec-0063"> <h5 class="title">Outcomes</h5> <p>We defined a set of outcomes which are presented in the <a href="./full#CD015209-tbl-0001">summary of findings Table 1</a>. If data were available for those outcomes, we report the effect estimates in the <a href="#CD015209-sec-0072">Effects of interventions</a>. </p> <p>All‐cause mortality at day 28 was reported in all six included studies (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>); however, it was predefined as primary study outcome in one study only (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). Two studies reported all‐cause mortality at day 60 (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>).  </p> <p>The primary study outcome was time to clinical improvement in two studies (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>), while in <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> and <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> it was a secondary and in <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> an exploratory outcome. The studies’ definitions of time to clinical improvement varied. <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> defined it as the time from randomisation to an improvement of 2 points on a 7‐category ordinal scale or discharge alive from the hospital, and improvement rate of follow‐up CT scans at day 14. <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> defined it as overall improvement (assessed by odds of improvement in clinical status) and proportion of participants with at least a 1‐point improvement on the 8‐category National Institute of Allergy and Infectious Diseases ordinal scale (NIAID‐OS), or discharge alive from the hospital at days 4, 7, 10, 14, and 28, or as time to recovery. <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> specified it as time to discharge from hospital with the subsidiary clinical outcome of time to successful cessation of invasive mechanical ventilation and survival to 28 days. <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a> specified it as time to recovery, with the day of recovery defined as the first day, during the 28 days after enrolment, on which a participant attained category 1, 2, or 3 on the 8‐category ordinal scale. <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> did not provide an exact definition of time to recovery outcome. Number of ventilator‐free days as a surrogate of clinical improvement was reported by two studies (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). The primary study outcome was worsening of clinical status in <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a> and <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>, and was defined as the proportion of participants who progressed to high‐flow oxygen or non‐invasive ventilation (NIAID‐OS score 6), invasive mechanical ventilation or extracorporeal membrane oxygenation (NIAID‐OS score 7), or death (NIAID‐OS score 8) by day 28.  <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> reported worsening of clinical status as a secondary study outcome, and defined this outcome as new need for invasive mechanical ventilation or death. </p> <p>None of the included studies reported viral clearance.</p> <p>All included studies reported different types of safety outcomes (adverse events, serious adverse events, specific adverse events, suspected serious adverse reactions)(<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). Only the four double‐blinded randomised trials recorded and reported adverse events and serious adverse events according to the International Conference of Harmonisation Good Clinical Practice (ICH GCP) standards (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> reported adverse events and selected serious adverse events as total events rather than numbers of participants with any events. <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> did not record adverse events systematically. Hence, we only extracted and analysed safety data from the four double‐blinded RCTs (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). Specific adverse events — such as occurrence of signs of bone marrow suppression (anaemia, low lymphocyte or platelet count, pancytopenia), secondary infection, thromboembolic events, or intestinal perforation — were reported in some trials; secondary infection as a specific adverse event was reported in four trials (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). </p> <p>In <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>, all reported outcomes were exploratory outcomes. </p> </section> <section id="CD015209-sec-0064"> <h5 class="title">Ongoing studies</h5> <p>We classified 13 studies as ongoing: seven studies are evaluating baricitinib (<a href="./references#CD015209-bbs2-0052" title="EUCTR2020-001789-12. A phase I/II clinical trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: a structured summary of a study protocol for a randomised controlled trial. www.clinicaltrialsregister.eu/ctr-search/search/trial/2020-001789-12 (first received 5 Febuary 2021). [DOI: 10.1186/s13063-021-05072-4]">EUCTR2020‐001789‐12</a>; <a href="./references#CD015209-bbs2-0056" title="NCT04390464. mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R). www.clinicaltrials.gov/ct2/show/NCT04390464 (first received 12 May 2020). ">NCT04390464</a>; <a href="./references#CD015209-bbs2-0057" title="NCT04393051. Baricitinib Compared to Standard Therapy in Patients With COVID-19 (BARICIVID-19). https://clinicaltrials.gov/ct2/show/NCT04393051 (first received 19 May 2020). ">NCT04393051</a>; <a href="./references#CD015209-bbs2-0061" title="NCT04693026. Efficacy of ramdicivir and baricitinib for the treatment of severe COVID 19 patients. www.clinicaltrials.gov/ct2/show/NCT04693026 (first received 5 January 2021). ">NCT04693026</a>; <a href="./references#CD015209-bbs2-0062" title="NCT04832880. Factorial, multicentric, randomized clinical trial of remdesivir and immunotherapy in combination with dexamethasone for moderate COVID-19 (the AMMURAVID Trial). www.clinicaltrials.gov/ct2/show/record/NCT04832880 (first received 6 April 2021). ">NCT04832880</a>; <a href="./references#CD015209-bbs2-0063" title="NCT04891133. European DisCoVeRy for Solidarity: an Adaptive Pandemic and Emerging Infection Platform Trial. www.clinicaltrials.gov/ct2/show/NCT04891133 (first received 18 May 2021). ">NCT04891133</a>; <a href="./references#CD015209-bbs2-0064" title="NCT04970719. Baricitinib in hospitalized Covid-19 patients with diabetes mellitus. www.clinicaltrials.gov/ct2/show/NCT04970719 (first received 21 July 2021). ">NCT04970719</a>), three ruxolitinib (<a href="./references#CD015209-bbs2-0058" title="NCT04403243. COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT). www.clinicaltrials.gov/ct2/show/NCT04403243 (first received 27 May 2020). ">NCT04403243</a>; <a href="./references#CD015209-bbs2-0059" title="EudraCT2020-001754-21. An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001754-21/FR (first received 17 April 2020). NCT04424056. A trial using anakinra, tocilizumab alone or in association with ruxolitinib in severe stage 2b and 3 of COVID 19-associated disease (INFLAMMACOV). www.clinicaltrials.gov/ct2/show/NCT04424056 (first received 9 June 2020). ">NCT04424056</a>; <a href="./references#CD015209-bbs2-0060" title="NCT04581954. Randomised multi-arm trial of ruxolitinib (RUX) and fostamatinib (FOS) for COVID-19 pneumonia. www.clinicaltrials.gov/ct2/show/NCT04581954 (first received 9 October 2020). ">NCT04581954</a>); one tofacitinib (<a href="./references#CD015209-bbs2-0055" title="NCT04390061. TOFAcitinib plus hydroxycloroquine vs hydroxycloroquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial (TOFACoV-2). www.clinicaltrials.gov/ct2/show/NCT04390061 (first received 13 May 2020). ">NCT04390061</a>); one bemcentinib (<a href="./references#CD015209-bbs2-0053" title="EudraCT 2020-001736-95. ACCORD-2: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001736-95/GB (first received 23 April 2020). ">EudraCT2020‐001736‐95</a>); and one imatinib (<a href="./references#CD015209-bbs2-0054" title="NCT04346147. Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of baricitinib, imatinib or supportive treatment in patients with SARS Cov2 pneumonia. www.clinicaltrials.gov/ct2/show/NCT04346147 (first received 15 April 2020). ">NCT04346147</a>). These studies are evaluating primarily hospitalised participants, and anticipate including 60 to 4000 participants. According to the trial registries, the estimated completion dates have passed (2020 to March 2022) for seven studies or were projected to be within the remaining course of 2022 (three studies). One study is planned until 2025 and two studies did not provide the estimated completion date. Study details are summarised in <a href="#CD015209-tbl-0003">Table 2</a>. Within the ongoing studies, most include participants with COVID‐19 in an inpatient setting without further discriminating disease severity. However, according to their registration entries, one study will focus only on people with mild to moderate COVID‐19 (<a href="./references#CD015209-bbs2-0060" title="NCT04581954. Randomised multi-arm trial of ruxolitinib (RUX) and fostamatinib (FOS) for COVID-19 pneumonia. www.clinicaltrials.gov/ct2/show/NCT04581954 (first received 9 October 2020). ">NCT04581954</a>), and one only on people with moderate to severe COVID‐19 (<a href="./references#CD015209-bbs2-0063" title="NCT04891133. European DisCoVeRy for Solidarity: an Adaptive Pandemic and Emerging Infection Platform Trial. www.clinicaltrials.gov/ct2/show/NCT04891133 (first received 18 May 2021). ">NCT04891133</a>). </p> </section> <section id="CD015209-sec-0065"> <h5 class="title">Studies awaiting classification</h5> <p>We classified nine studies as awaiting classification. We identified six studies listed as "terminated" according to the trial registries (<a href="./references#CD015209-bbs2-0043" title="EudraCT2020-001367-88. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001367-88/results (first received 16 April 2020). ">EudraCT2020‐001367‐88</a>; <a href="./references#CD015209-bbs2-0046" title="NCT04373044. Baricitinib, placebo and antiviral therapy for the treatment of patients with moderate and severe COVID-19. www.clinicaltrials.gov/ct2/show/results/NCT04373044 (first received 4 May 2020). ">NCT04373044</a>; <a href="./references#CD015209-bbs2-0047" title="NCT04377620. Assessment of efficacy and safety of ruxolitinib in participants with COVID-19-associated ARDS who require mechanical ventilation (RUXCOVID-DEVENT). www.clinicaltrials.gov/ct2/show/NCT04377620 (first received 19 January 2022). ">NCT04377620</a>; <a href="./references#CD015209-bbs2-0048" title="NCT04404361. A phase 3 randomized, double-blind, placebo-controlled, multicenter study of pacritinib plus standard of care versus placebo and standard of care in hospitalized patients with severe COVID-19 with or without cancer. www.clinicaltrials.gov/ct2/show/NCT04404361 (first received 22 May 2020). ">NCT04404361</a>; <a href="./references#CD015209-bbs2-0050" title="NCT04477993. Ruxolitinib for acute respiratory disorder syndrome due to COVID-19 (RUXO-COVID). www.clinicaltrials.gov/ct2/show/NCT04477993 (first received 20 July 2020). ">NCT04477993</a>; <a href="./references#CD015209-bbs2-0049" title="NCT04415151. Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC). www.clinicaltrials.gov/ct2/show/NCT04415151 (first received 04 June 2020). ">NCT04415151</a>). One further study, published as a journal article, provided incomplete results (<a href="./references#CD015209-bbs2-0044" title="MurugesanH , CsG , NasreenHS , SanthanamS , GowrishankarM , RaviS , et al. An evaluation of efficacy and safety of tofacitinib, a JAK inhibitor in the management of hospitalized patients with mild to moderate COVID-19 - an open-label randomized controlled study. Journal of the Association of Physicians of India2022;69(12):11-2. [PMID: 35057599]">Murugesan 2022</a>). Two studies are listed as "completed" (<a href="./references#CD015209-bbs2-0045" title="NCT04362137. Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID). www.clinicaltrials.gov/ct2/show/NCT04362137 (first received 24 April 2020). ">NCT04362137</a> "RUXCOVID"; <a href="./references#CD015209-bbs2-0051" title="NCT04640168. A multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults (ACTT-4). www.clinicaltrials.gov/ct2/show/NCT04640168 (first received 23 November 2020). ">NCT04640168</a> "ACTT‐4").  </p> <p>Two of the studies described above — <a href="./references#CD015209-bbs2-0043" title="EudraCT2020-001367-88. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001367-88/results (first received 16 April 2020). ">EudraCT2020‐001367‐88</a> (six participants) and <a href="./references#CD015209-bbs2-0045" title="NCT04362137. Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID). www.clinicaltrials.gov/ct2/show/NCT04362137 (first received 24 April 2020). ">NCT04362137</a> (RUXCOVID; 432 participants) — have already published data in their trial registrations, but we found neither preprint data nor a peer‐reviewed publication. As the study registries provided insufficient data on the baseline characteristics, and because the overall effect estimate would not have changed by including these studies' results in our analysis, we decided to wait for complete publications before including these studies. </p> <p>The other five studies listed as "terminated" have not yet published data. <a href="./references#CD015209-bbs2-0046" title="NCT04373044. Baricitinib, placebo and antiviral therapy for the treatment of patients with moderate and severe COVID-19. www.clinicaltrials.gov/ct2/show/results/NCT04373044 (first received 4 May 2020). ">NCT04373044</a> had planned to compare baricitinib to placebo. Six participants were enrolled before study termination. The proportion of participants requiring invasive mechanical ventilation or dying within 14 days was specified as a primary outcome. <a href="./references#CD015209-bbs2-0047" title="NCT04377620. Assessment of efficacy and safety of ruxolitinib in participants with COVID-19-associated ARDS who require mechanical ventilation (RUXCOVID-DEVENT). www.clinicaltrials.gov/ct2/show/NCT04377620 (first received 19 January 2022). ">NCT04377620</a>, named "RUXCOVID‐DEVENT", had planned to compare two different doses of ruxolitinib with each other and placebo in participants requiring invasive mechanical ventilation and with at least mild acute respiratory distress syndrome. Mortality within 28 days was specified as the primary outcome. The study was terminated by the sponsor after enrolment of 211 participants. <a href="./references#CD015209-bbs2-0048" title="NCT04404361. A phase 3 randomized, double-blind, placebo-controlled, multicenter study of pacritinib plus standard of care versus placebo and standard of care in hospitalized patients with severe COVID-19 with or without cancer. www.clinicaltrials.gov/ct2/show/NCT04404361 (first received 22 May 2020). ">NCT04404361</a>, named "PRE‐VENT", had planned to compare baricitinib to placebo and to report the proportion of participants who progressed to IMV or ECMO, or both, or death during the 28 days following randomisation (primary outcome). Enrolment was closed soon after 200 participants were included. <a href="./references#CD015209-bbs2-0050" title="NCT04477993. Ruxolitinib for acute respiratory disorder syndrome due to COVID-19 (RUXO-COVID). www.clinicaltrials.gov/ct2/show/NCT04477993 (first received 20 July 2020). ">NCT04477993</a>, named "RUXO‐COVID", had planned to compare ruxolitinib to placebo in hospitalised participants without invasive ventilation. A composite endpoint of death, intensive care unit‐admission, or need for mechanical ventilation at day 14 was planned as the primary outcome. The study was terminated due to low accrual after enrolment of five participants. <a href="./references#CD015209-bbs2-0049" title="NCT04415151. Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC). www.clinicaltrials.gov/ct2/show/NCT04415151 (first received 04 June 2020). ">NCT04415151</a>, named "I‐TOMIC", was planned as a double‐blinded, randomised controlled trial comparing tofacitinib to placebo (and standard of care for both study arms) in hospitalised adults requiring oxygen. Its primary outcome was disease severity after 14 days. Enrolment was terminated after 24 participants due to decreased number of COVID‐19 infections. <a href="./references#CD015209-bbs2-0051" title="NCT04640168. A multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults (ACTT-4). www.clinicaltrials.gov/ct2/show/NCT04640168 (first received 23 November 2020). ">NCT04640168</a>, named "ACTT‐4", had planned to compare baricitinib plus remdesivir versus dexamethasone plus remdesivir in hospitalised people. Its primary outcome was the proportion of participants not meeting criteria for one of the following two ordinal scale categories at any time: 8) Death; 7) Hospitalised, on invasive mechanical ventilation or extracorporeal membrane oxygenation (day 1 to day 29). Enrolment was completed after including 1010 participants. We did not find a preprint or peer‐reviewed publication for this study. </p> </section> </section> <section id="CD015209-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 36 studies (37 references) that did not match our inclusion criteria for one or a combination of the following reasons (for details, see <a href="./references#CD015209-bbs1-0002" title="">Excluded studies</a>): </p> <p> <ul id="CD015209-list-0030"> <li> <p>11 studies had no control group;</p> </li> <li> <p>5 studies investigated JAK inhibitors in combination with other treatments;</p> </li> <li> <p>5 studies were open‐label and non‐randomised;</p> </li> <li> <p>4 studies were withdrawn before enrolment;</p> </li> <li> <p>4 studies investigated a different intervention;</p> </li> <li> <p>2 studies compared different dosages of JAK inhibitor with each other;</p> </li> <li> <p>2 studies were carried out retrospectively by chart analysis or cohort matching;</p> </li> <li> <p>2 studies investigated an ineligible population; and</p> </li> <li> <p>1 study had an observational study design.</p> </li> </ul> </p> </section> </section> <section id="CD015209-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed methodological quality and risk of bias for the results within the six included RCTs (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>), using the RoB 2 tool. We outline below the outcomes assessed, in accordance with our review protocol. Please refer to the <a href="./references#CD015209-sec-0128" title="">Risk of bias (tables)</a> for more detailed information on our risk of bias assessments for each outcome. The completed RoB 2 tool with responses to all assessed signalling questions is available online at <a href="https://doi.org/10.5281/zenodo.5719076" target="_blank">https://doi.org/10.5281/zenodo.5719076</a>. </p> <section id="CD015209-sec-0068"> <h4 class="title">Overall risk of bias: by study</h4> <p>Overall, we judged the risk of bias to range from low to high for the included studies. We see the lowest risk of bias in <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>, because we identified some concerns in only one domain for one outcome. We had some concerns about risk of bias, particularly for <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>, because neither a study protocol nor a statistical analysis plan exists, and it was a single‐blinded study. The <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> study showed high risk of bias in one domain and some concerns of bias in two domains. Specifically, we had general concerns about deviations from intended interventions (only 91% of all participants in the intervention group received baricitinib); further concerns about the open‐label design in general, which could have affected measurement of certain outcome parameters; and we had concerns about risk of bias due to missing outcome data because of an uncontrolled competing risk of death for the outcome 'Secondary infections'. We had some concerns regarding risk of bias for safety outcomes in four studies due to uncontrolled competing risk of death (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), and in one study, due to non‐blinded treating physicians (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>). </p> </section> <section id="CD015209-sec-0069"> <h4 class="title">Overall risk of bias: by outcome</h4> <p>The following section summarises the risk of bias per reported outcome for all primary outcomes included in the <a href="./full#CD015209-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015209-sec-0070"> <h5 class="title">JAK inhibitors plus standard of care compared to placebo plus standard of care or standard of care alone in individuals with moderate to severe disease </h5> <p>For the outcome ‘all‐cause mortality at day 28' (<a href="./references#CD015209-tblf-0030" title="">Risk of bias table for Analysis 1.1</a>), <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> showed some concerns in two domains in our risk of bias assessment. Since this is a dichotomous outcome, shortcomings in the blinding of the study and the lack of a statistical analysis should not affect this outcome. As <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> reported relevant deviations from intended intervention (only 3734 of 4084 participants (91%) with completed follow‐up at time of analysis received baricitinib), we assessed 'all‐cause mortality at day 28' as having a high risk of bias. Considering the possible direction of bias in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>, the effects of baricitinib on 28 day mortality could have been underestimated. Thus, we believe that there is risk of bias for the overall pooled result of this outcome. </p> <p>We have no concerns regarding risk of bias across studies for the outcome 'all‐cause mortality up to day 60' (<a href="./references#CD015209-tblf-0031" title="">Risk of bias table for Analysis 1.2</a>). </p> <p>Again, we detected an overall high risk of bias for the outcomes 'improvement in clinical status' and 'worsening of clinical status' in one study (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>), due to the described deviations from intended interventions. Additionally, due to the open‐label design, the measurement of the outcomes 'improvement in clinical status' and 'worsening of clinical status' might have been affected, because clinicians' knowledge about the treatment group could have influenced their decision‐making in terms of discharge (improvement) or endotracheal intubation (worsening), respectively (<a href="./references#CD015209-tblf-0034" title="">Risk of bias table for Analysis 1.5</a>, <a href="./references#CD015209-tblf-0035" title="">Risk of bias table for Analysis 1.6</a>). </p> <p>For the outcomes 'Adverse event (any grade)', 'Serious adverse events', and 'Secondary infection', we have some concerns of bias in five included studies caused by missing outcome data due to competing risk of death (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), and additionally, in the <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a> study, because data were not analysed as predefined (<a href="./references#CD015209-tblf-0036" title="">Risk of bias table for Analysis 1.7</a>; <a href="./references#CD015209-tblf-0038" title="">Risk of bias table for Analysis 1.9</a>; <a href="./references#CD015209-tblf-0039" title="">Risk of bias table for Analysis 1.10</a>). We detected high risk of bias for 'Secondary infections' in the <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> study for several reasons: first, in the open‐label context, it did not predefine an algorithm or definitions to screen for and assess secondary infection; second, because of competing risk of death; and third, due to deviations from intended interventions (<a href="./references#CD015209-tblf-0039" title="">Risk of bias table for Analysis 1.10</a>). For the smallest and single‐blinded trial (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>), we were concerned about the overall validity of the safety data, due to single‐blinded design, and the small number of participants and trial centres. Further, the authors reported adverse events and serious adverse events as numbers of total events rather than numbers of participants with any event. Thus, we could not extract this trial's safety data. </p> </section> <section id="CD015209-sec-0071"> <h5 class="title">JAK inhibitors plus standard of care compared to placebo plus standard of care or standard of care alone in individuals with asymptomatic or mild disease </h5> <p>We did not identify any study reporting on individuals with asymptomatic or mild disease.</p> </section> </section> </section> <section id="CD015209-sec-0072"> <h3 class="title" id="CD015209-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD015209-tbl-0001"><b>Summary of findings 1</b> JAK inhibitors plus standard of care compared to standard of care (plus/minus placebo) in individuals with moderate to severe COVID‐19</a> </p> <section id="CD015209-sec-0073"> <h4 class="title">Individuals with a suspected or confirmed diagnosis of asymptomatic or mild COVID‐19</h4> <p>We did not find RCTs comparing systemic JAK inhibitors plus standard of care versus standard of care (plus/minus placebo) or other interventions for the treatment of participants with asymptomatic SARS‐CoV‐2 infection or mild COVID‐19.  </p> </section> <section id="CD015209-sec-0074"> <h4 class="title">Individuals with a suspected or confirmed diagnosis of moderate to severe COVID‐19</h4> <p>We obtained data from five studies reporting on 2989 participants with laboratory‐confirmed moderate to severe COVID‐19 (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). The only study that included participants with clinically‐suspected or laboratory‐confirmed COVID‐19 diagnosis was <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>, reporting positive SARS‐CoV‐2 PCR results in about 3750 participants (90%) of the treatment group and 3655 participants (91%) of the standard of care group. All six studies compared JAK inhibitors plus standard of care to standard of care plus/minus placebo. The main findings for participants with moderate to severe COVID‐19 are summarised in the <a href="./full#CD015209-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015209-sec-0075"> <h5 class="title">Primary outcomes</h5> <section id="CD015209-sec-0076"> <h6 class="title">All‐cause mortality at day 28, day 60, and at hospital discharge</h6> <p><b>All‐cause mortality up to day 28</b> </p> <p>Considering the reported event rates within the studies, we estimated that 131 per 1000 participants died up to day 28 when treated without systemic JAK inhibitors. Systemic JAK inhibitors probably reduce all‐cause mortality up to day 28 (estimated 95 per 1000 participants (95% confidence interval (CI) 75 to 120 per 1000) died up to day 28) when compared to standard of care plus/minus placebo (risk ratio (RR) 0.72, 95% CI 0.57 to 0.91; I² = 50%; 6 studies, 11,145 participants; moderate‐certainty evidence). We downgraded the certainty of the evidence due to risk of bias (deviation from the intended interventions, unblinded trial design) in the largest trial (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; 73% of the total number of participants of this analysis) (see <a href="./references#CD015209-fig-0003" title="">Analysis 1.1</a>). </p> <p><b>All‐cause mortality up to day 60</b> </p> <p>An estimated 181 of 1000 participants treated without systemic JAK inhibitors died up to day 60. Systemic JAK inhibitors decrease all‐cause mortality up to day 60 (estimated 125 per 1000 participants (95% CI 102 to 156 per 1000)) when compared to placebo with standard of care alone (RR 0.69, 95% CI 0.56 to 0.86; I² = 0%; 2 studies, 1626 participants; high‐certainty evidence). We did not identify any limitations to the certainty of evidence in this result (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; see <a href="./references#CD015209-fig-0004" title="">Analysis 1.2</a>). </p> </section> <section id="CD015209-sec-0077"> <h6 class="title">Clinical status at day 28, day 60, and up to longest follow‐up</h6> <p><b>Improvement of clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care up to day 28</b> </p> <p>Clinical improvement was defined as participants discharged alive or hospitalised but meeting criteria for discharge (no longer requiring ongoing medical care) at up to day 28. When treated without systemic JAK inhibitors, 778 per 1000 participants experienced clinical status improvement within 28 days. Systemic JAK inhibitors probably make little or no difference in improvement of clinical status (estimated 801 per 1000 participants (95% CI 778 to 824 per 1000)) when compared to standard of care plus/minus placebo (RR 1.03, 95% CI 1.00 to 1.06; I² = 32%; 4 studies, 10,802 participants; moderate‐certainty evidence). Our main reason for downgrading the certainty of the evidence was serious indirectness, because of expected dissimilarities of the outcome measurements between the included studies impacting the transferability of results. We did not further downgrade for serious risk of bias (unblinded trial design and deviation from the intended interventions in the largest study (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>)), since the result of this study did not change the pooled effect estimate of the outcome but only narrowed the 95% confidence interval (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; see <a href="./references#CD015209-fig-0007" title="">Analysis 1.5</a>).  </p> <p><b>Worsening of clinical status: new need for invasive mechanical ventilation or death at day 28</b> </p> <p>Regarding the event rates, an estimated 172 per 1000 participants treated without systemic JAK inhibitors experienced a new need for invasive mechanical ventilation or death at day 28. Systemic JAK inhibitors probably decrease the risk of worsening of clinical status (estimated 154 per 1000 participants (95% CI 141 to 168 per 1000)) when compared to standard of care plus/minus placebo (RR 0.90, 95% CI 0.82 to 0.98; I² = 0%; 2 studies, 9417 participants; moderate‐certainty evidence). Our main reason for downgrading the certainty of the evidence was the high risk of bias in one of the two studies (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>), due to unblinded trial design (bias in measurement of the intervention provider decision outcome: invasive mechanical ventilation) and deviation from the intended intervention(see <a href="./references#CD015209-fig-0008" title="">Analysis 1.6</a>).  </p> </section> <section id="CD015209-sec-0078"> <h6 class="title">Adverse events (any grade)</h6> <p>When treated without systemic JAK inhibitors, an estimated 441 per 1000 participants experienced adverse events. Systemic JAK inhibitors probably make little or no difference in the rate of adverse events of any grade (estimated 427 per 1000 participants (95% CI 388 to 476 per 1000)) compared to placebo with standard of care alone (RR 0.97, 95% CI 0.88 to 1.08; I² = 27%; 3 studies, 1885 participants; moderate‐certainty evidence). We assessed the number of participants with one or more adverse events. Our reason for downgrading the certainty of the evidence was a risk of bias due to missing outcome data, because of missing data for adjustment for competing risk of death (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; see <a href="./references#CD015209-fig-0009" title="">Analysis 1.7</a>). <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> did not report serious adverse events adequately. </p> </section> <section id="CD015209-sec-0079"> <h6 class="title">Serious adverse events</h6> <p>When treated without systemic JAK inhibitors, an estimated 202 per 1000 participants experienced serious adverse events. Systemic JAK inhibitors probably decrease the risk for serious adverse events (estimated 160 per 1000 participants (95% CI 138 to 186 per 1000)) compared to placebo with standard of care alone (RR 0.79, 95% CI 0.68 to 0.92; I² = 0%; 4 studies, 2901 participants; moderate‐certainty evidence). Our reason for downgrading the certainty of the evidence was a risk of bias due to missing outcome data, because of missing data for adjustment for competing risk of death (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; see <a href="./references#CD015209-fig-0011" title="">Analysis 1.9</a>). <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> did not report serious adverse events adequately. </p> </section> <section id="CD015209-sec-0080"> <h6 class="title">Secondary infection</h6> <p>In the group treated without systemic JAK inhibitors, secondary infection occurred in an estimated 113 per 1000 people. JAK inhibitors may make little or no difference in the rate of secondary infection (estimated 111 per 1000 participants (95% CI 100 to 123 per 1000)) compared to standard of care plus/minus placebo (RR 0.98, 95% CI 0.89 to 1.09; I² = 0%; 4 studies, 10,041 participants; low‐certainty evidence). One reason for downgrading evidence certainty was serious indirectness, because of expected dissimilarities of study outcome measurements between included studies impacting the transferability of results. Additionally, we downgraded for serious risk of bias due to missing outcome data, because of missing data for adjustment for competing risk of death and deviations from intervention in the largest study of this analysis (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>; see <a href="./references#CD015209-fig-0012" title="">Analysis 1.10</a>). </p> </section> </section> <section id="CD015209-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD015209-sec-0082"> <h6 class="title">All‐cause mortality, time to event</h6> <p>Five studies provided data for time‐to‐event calculations over 28 days (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). Treatment with systemic JAK inhibitors compared to standard of care plus/minus placebo probably reduces all‐cause mortality when measured over time (hazard ratio (HR) 0.67, 95% CI 0.50 to 0.91; I² = 63%; 5 studies, 11,104 participants; <a href="./references#CD015209-fig-0005" title="">Analysis 1.3</a>). The HR over 60 days in two studies showed a consistent benefit for systemic JAK inhibitors (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>) (HR 0.61, 95% CI 0.47 to 0.78; I² = 0%; 2 studies, 1626 participants; <a href="./references#CD015209-fig-0006" title="">Analysis 1.4</a>).  </p> </section> <section id="CD015209-sec-0083"> <h6 class="title">Quality of life at up to 7 days, up to 28 days, and longest follow‐up available</h6> <p>None of the included studies reported quality of life outcomes.</p> </section> <section id="CD015209-sec-0084"> <h6 class="title">Adverse events (grades 3 or 4)</h6> <p>Systemic JAK inhibitors probably decrease the risk of suffering adverse events (grades 3 or 4) slightly (RR 0.87, 95% CI 0.76 to 1.00; estimated risk difference (RD) 61 fewer per 1000, 95% CI 112 fewer to 0 fewer; I² not applicable; 1 study, 1017 participants; <a href="./references#CD015209-fig-0010" title="">Analysis 1.8</a>). Only <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a> provided data for this outcome.  </p> </section> <section id="CD015209-sec-0085"> <h6 class="title">Other adverse events of special interest</h6> <p>Observed adverse events of special interest, apart from secondary infections, are to be found in <a href="./references#CD015209-fig-0013" title="">Analysis 1.11</a> based on three studies (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). </p> <p><b>Anaemia</b> </p> <p>Concerning the event rates for participants treated without systemic JAK inhibitors, an estimated 57 per 1000 experienced anaemia. Systemic JAK inhibitors may slightly decrease the rate of anaemia compared to placebo with standard of care alone (RR 0.74, 95% CI 0.45 to 1.19; estimated 42 fewer per 1000 participants, 95% CI 31 fewer to 11 more per 1000; I² = 0%; 2 studies, 1300 participants; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>).  </p> <p><b>Lymphocytopenia</b> </p> <p>Lymphocytopenia occurred in an estimated 38 per 1000 participants treated without systemic JAK inhibitors. It is uncertain whether systemic JAK inhibitors influence the rate of lymphocytopenia when compared to placebo with standard of care alone (RR 0.79, 95% CI 0.21 to 3.01; 30 per 1000, 95% CI 30 fewer to 77 more; I² = 57%; 2 studies, 1300 participants; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>).  </p> <p><b>Thrombocytopenia</b> </p> <p>This outcome was not reported as number of participants with at least one event in any of the included RCTs. However, <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> reported this outcome four times in the intervention group (n = 20) and three times in the control group (n = 21), but it remained unclear whether there were numbers of participants experiencing more than one event. </p> <p><b>Intestinal perforation</b> </p> <p><a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> reported that, in the entire study population (n = 1502), there was no intestinal perforation up to day 28, while <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> observed three bowel perforations believed to be related to baricitinib without making any statement about events within the standard of care group. </p> <p><b>Cardiac events and venous thrombosis</b> </p> <p>In December 2021, the US Food and Drug Administration (FDA) warned of an increased risk of major adverse cardiac events and venous thrombosis with the use of tofacitinib and baricitinib for the treatment of chronic inflammatory conditions (<a href="./references#CD015209-bbs2-0085" title="US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; December 2021. www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death (accessed 13 April 2022).">FDA 2021b</a>). The five included studies which recorded and reported on these adverse events did not find any relevant differences between treatment groups during their observation periods (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). </p> </section> <section id="CD015209-sec-0086"> <h6 class="title">Ventilator‐free days (defined as days alive and free from mechanical ventilation)</h6> <p>Two studies reported the number of ventilator‐free days (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). These studies investigated participants with different severities of disease (WHO 4 to 6 in <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> versus WHO 7 to 9 in <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>). Thus, we could not directly compare results of both studies. Nonetheless, the number of ventilator‐free days apparently did not differ significantly between intervention and control group in both studies: 8.1 ventilator‐free days on average with intervention compared to 5.5 ventilator‐free days without intervention (mean difference 2.36 days, 95% CI 1.4 to 6.1; P = 0.21; <a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>) and 24.5 ventilator‐free days with intervention compared to 23.7 ventilator‐free days without intervention (mean difference 0.75 days, 95% CI 0.0 to 1.5; P = 0.059; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>).  </p> </section> <section id="CD015209-sec-0087"> <h6 class="title">Viral clearance, assessed with reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 at baseline, and up to 3, 7, and 14 days </h6> <p>No study reported this outcome as defined. <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> reported the median time to viral clearance and found no significant difference between intervention (13 days) and control group (12 days), P = 0.649. </p> </section> </section> <section id="CD015209-sec-0088"> <h5 class="title">Subgroup analyses on all‐cause mortality at up to day 28 </h5> <section id="CD015209-sec-0089"> <h6 class="title">Type of JAK inhibitor</h6> <p>Four studies with 10,815 participants evaluated the effect of baricitinib on all‐cause mortality up to day 28 (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a> (n = 289) investigated the effect of tofacitinib, and <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> (n = 41) investigated the effect of ruxolitinib on this outcome parameter. The effect direction remained the same in all three different subgroups (see <a href="./references#CD015209-fig-0014" title="">Analysis 2.1</a>). Overall, there was no significant difference between these subgroups regarding all‐cause mortality at up to day 28 (P = 0.47).  </p> </section> <section id="CD015209-sec-0090"> <h6 class="title">Severity of condition </h6> <p>We obtained data from five studies (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), with 11,097 participants, reporting all‐cause mortality up to day 28, stratified by the need for respiratory support at baseline (no oxygen, low‐flow oxygen, NIV or high‐flow nasal oxygen (HFNO), IMV or ECMO; see <a href="./references#CD015209-fig-0015" title="">Analysis 3.1</a>).  The overall effect showed little heterogeneity (I<sup>2</sup> = 12%), the effect direction remained the same in all subgroups, and there are no statistically significant differences between the four different subgroups of disease severity at baseline regarding all‐cause mortality at up to day 28 (P = 1.00).  </p> </section> <section id="CD015209-sec-0091"> <h6 class="title">Age of participants </h6> <p>Only a few studies reported data for age‐specific results and within these studies, different strata were used (e.g. <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>); therefore, no subgroup analysis was possible.  </p> </section> </section> <section id="CD015209-sec-0092"> <h5 class="title">Sensitivity analyses</h5> <p>Please find our sensitivity analyses in <a href="#CD015209-tbl-0004">Table 3</a>. </p> <div class="table" id="CD015209-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses for the comparison: JAK inhibitor plus standard care versus standard care plus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Only peer‐reviewed articles</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Only studies judged to be of low risk of bias or some concerns</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Only placebo‐controlled studies, excluding vitamin C as placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect meta‐analysis</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality up to day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72 (95% CI 0.57 to 0.91), including 11,145 participants from six studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (95% CI 0.51 to 0.78), including 2989 participants from five studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (95% CI 0.51 to 0.78), including 2989 participants from five studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (95% CI 0.51 to 0.79), including 2948 participants from four studies<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.84 (95% CI 0.76 to 0.93), including 11,145 participants from six studies</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Exclusion of <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> (preprint article)<br/><sup>b</sup>Exclusion of <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> (used vitamin C as placebo) and <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> (no placebo was used) </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </div> </div> <section id="CD015209-sec-0093"> <h6 class="title">Comparison of preprints versus peer‐reviewed articles</h6> <p>Excluding the preprint article of <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>, the effect on mortality is stronger and remains statistically significant (RR 0.63, 95% CI 0.51 to 0.78). </p> </section> <section id="CD015209-sec-0094"> <h6 class="title">Comparison of studies with a low risk of bias or some concerns versus studies with a high risk of bias </h6> <p>As we assessed the outcome of 28‐day all‐cause mortality in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> at high risk of bias due to deviations from intended interventions in an open‐label study, we excluded this study and observed the same stronger effect as noted above (comparison excluding preprints).  </p> </section> <section id="CD015209-sec-0095"> <h6 class="title">Comparison of studies with placebo versus no placebo</h6> <p>As <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> used 100 mg vitamin C as a placebo and <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> compared baricitinib to standard care without the use of a placebo, we conducted a sensitivity analysis excluding these studies, revealing a RR of 0.63 (95% CI 0.51 to 0.78). Although a recently published systematic review found no differences in mortality and other outcomes when participants were treated with vitamin C versus standard of care (<a href="./references#CD015209-bbs2-0131" title="RawatD , RoyA , MaitraS , GulatiA , KhannaP , BaidyaDK . Vitamin C and COVID-19 treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews2021;15(6):102324. [DOI: https://doi.org/10.1016/j.dsx.2021.102324]">Rawat 2021</a>), we wanted to examine whether it could have influenced our outcomes.  </p> </section> <section id="CD015209-sec-0096"> <h6 class="title">Comparison of the fixed‐effect versus random‐effects statistical model</h6> <p>Performing a sensitivity analysis comparing the fixed‐effect and random‐effects models, we observed a reduction of the observed effect. Due to its size, the study gathering the most weight in the fixed‐effect model was <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>. However, this was an open‐label study with 9% of the participants not receiving baricitinib, with about 42% of the included participants being already vaccinated against SARS‐CoV‐2 and a relevant number of participants receiving further immunomodulatory anti‐COVID treatment strategies. Adding to its pragmatic platform trial design, <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> differs from the other larger, placebo‐controlled, double‐blind studies (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). Therefore, we decided to report our primary outcome analyses based on a random‐effects model.  </p> </section> <section id="CD015209-sec-0097"> <h6 class="title">Assessment of statistical heterogeneity (I² &gt; 80%)</h6> <p>For the outcome 'all‐cause mortality at up to day 28', there was no I<sup>2</sup> &gt; 80%; therefore, we did not conduct sensitivity analysis.  </p> </section> <section id="CD015209-sec-0098"> <h6 class="title">Comparison of premature termination of studies with completed studies</h6> <p>As we included no prematurely‐ended study, we did not conduct this sensitivity analysis.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015209-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015209-sec-0099"></div> <section id="CD015209-sec-0100"> <h3 class="title" id="CD015209-sec-0100">Summary of main results</h3> <p>This review included six studies, with 11,145 hospitalised participants with moderate to severe COVID‐19, investigating the effects of systemic treatment with different JAK inhibitors plus standard of care compared to standard of care alone (plus/minus placebo) (<a href="./full#CD015209-tbl-0001">summary of findings Table 1</a>). </p> <p>Moderate‐certainty evidence suggests that systemic JAK inhibitors probably decrease all‐cause mortality at up to 28 days, and high‐certainty evidence shows they decrease 60‐day mortality when compared to standard care in this population. Subgroup analyses could not determine whether effects differed by disease severity, as assessed by the need for respiratory support at baseline, or specific JAK inhibitors. However, about 88% of all included participants in our analysis needed low‐flow or high‐flow oxygen therapy or non‐invasive ventilation (NIV) at baseline, and about 97% of all participants received baricitinib. </p> <p>Moderate‐certainty evidence indicates that systemic JAK inhibitors probably decrease the risk of worsening of clinical status, assessed by new need for invasive mechanical ventilation or death at up to day 28. Moderate‐certainty evidence shows that systemic JAK inhibitors probably make little or no difference to improvement in clinical status, assessed as participants discharged alive (or hospitalised, but no longer requiring medical care) at up to day 28. Systemic JAK inhibitors probably decrease the occurrence of serious adverse events and probably make little or no difference in the rate of any adverse event. Systemic JAK inhibitors may make little or no difference in the rate of secondary infections compared to standard care. </p> </section> <section id="CD015209-sec-0101"> <h3 class="title" id="CD015209-sec-0101">Overall completeness and applicability of evidence</h3> <p>Our review summarises the study data on the effects of systemic JAK inhibitor treatment against COVID‐19. The six included studies were conducted in 15 different countries, mainly from high‐income (Germany, Italy, Japan, Korea, Puerto Rico, Singapore, Spain, United Kingdom, USA) and upper‐middle‐income countries (Argentina, Brazil, China, Mexico, Russian Federation), but also from one lower‐middle‐income country (India) (<a href="./references#CD015209-bbs2-0166" title="World Bank. GNI per capita, Atlas method (current US$) World Bank national accounts data, and OECD National Accounts data files. data.worldbank.org/indicator/NY.GNP.PCAP.CD (accessed prior to 8 March 2022).">World Bank</a>).  </p> <p>The systematic search revealed nine trials awaiting classification that have completed recruitment, but have not yet published their results. As of 24 February 2022, two of these studies — a randomised controlled trial on ruxolitinib with 432 included participants (<a href="./references#CD015209-bbs2-0045" title="NCT04362137. Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID). www.clinicaltrials.gov/ct2/show/NCT04362137 (first received 24 April 2020). ">NCT04362137</a>) and a randomised controlled trial on baricitinib with six participants (<a href="./references#CD015209-bbs2-0043" title="EudraCT2020-001367-88. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001367-88/results (first received 16 April 2020). ">EudraCT2020‐001367‐88</a>) — have uploaded first results on a clinical trial register platform (ClinicalTrials.gov). Nonetheless, due to incompleteness and missing baseline characteristics of included participants, we have not included the data of these two studies in our analysis so far.  </p> <p>We also identified 13 ongoing studies. Hence, in future, we expect more relevant data that could help to clarify the currently unanswered questions on potential different therapeutic effects, depending on JAK subtype, disease severity, or the combination of JAK inhibitors with other COVID‐19 therapies. </p> <p>The median duration from symptom onset to the start of therapy ranged between 7 and 20 days. In the context of clinical practice, the results reflect effects of systemic JAK inhibitor treatment on an early to intermediate phase in the time course of the disease, mainly between the end of the first and the third week of symptomatic infection.  </p> <p>The studies included in this review used tofacitinib, primarily inhibiting JAK 1 and JAK 3, and baricitinib and ruxolitinib, primarily inhibiting JAK 1 and JAK 2, which are approved for different autoimmune and haematologic diseases. We excluded studies of inhaled JAK inhibitors, considering inhalation of these substances as topic treatment. Our subgroup analysis of the primary outcome 'all‐cause mortality at up to 28 days' did not show statistically significant differences between the effects of the different JAK inhibitors, but it is important to consider that the majority of data included in this review came from studies that used baricitinib (10,815 of 11,145 participants). Due to this relevant difference in the quantity of data between the different types of JAK inhibitors in COVID‐19 therapy, the results of the current version of this review should not be used directly to predict the efficacy and safety of the entire group of JAK inhibitors. Current guideline groups have already addressed this issue by developing different recommendations favouring baricitinib over other JAK inhibitors in COVID‐19 therapy (<a href="./references#CD015209-bbs2-0164" title="World Health Organization guideline development group. Therapeutics and COVID-19 living guideline. Ninth version, published 3 March 2022. Available at www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.3.">WHO 2022</a>). Although our analysis now includes a much higher number of participants than the network meta‐analysis of the WHO guideline group, we think that due to the limited quantity of efficacy data and heterogeneous quality of safety data (see below), we cannot draw a final conclusion about relevant clinical differences in efficacy and safety between the different types of JAK inhibitors from our current analysis.  Furthermore, ongoing therapy with anti‐IL‐6‐R‐antagonists (e.g. tocilizumab) represented a major exclusion criterion in four of the included studies. The large RECOVERY platform trial <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>, in which combinations of baricitinib and IL‐6‐R antagonists were not excluded, did not report adverse events or serious adverse events systematically; hence, there are no data to assess benefits or harms of the combination of systemic JAK inhibitor therapy with this different type of immunomodulatory therapy in the treatment of COVID‐19.<b> </b> </p> <p>More generally, future studies on pharmacological interventions for the treatment of symptomatic COVID‐19 may need to take into account combination or sequential applications of such therapies. </p> <p>For this series of living systematic reviews on COVID‐19 treatments, we considered the degree of respiratory support applied to the participants at baseline as a surrogate of disease severity, focused on pulmonary organ dysfunction. Participants of all six included studies were hospitalised for moderate to severe COVID‐19; thus, there are no available data from people with mild COVID‐19 or from outpatient settings. Our current analysis did not reveal statistically significant differences between subgroups of disease severity represented by different levels of respiratory support. Therefore, we cannot identify a specific subgroup of COVID‐19 severity in which people might benefit from treatment with systemic JAK inhibitors.  </p> <p>Nevertheless, about 88% of the hospitalised participants of the six included studies initially received low‐flow (about 65%) or high‐flow oxygen therapy, or received non‐invasive mechanical ventilation (about 23%). Compared to the data from meta‐analyses of study results on corticosteroids and tocilizumab as COVID‐19 treatments, in which about 35% (systemic corticosteroids, <a href="./references#CD015209-bbs2-0151" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963]">Wagner 2021</a>) and 57% (tocilizumab, <a href="./references#CD015209-bbs2-0089" title="GhosnL , ChaimaniA , EvrenoglouT , DavidsonM , GrañaC , SchmuckerC , et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD013881. [DOI: 10.1002/14651858.CD013881]">Ghosn 2021</a>) of the participants, respectively, were in need of advanced respiratory support (high‐flow oxygen, non‐invasive ventilation, invasive ventilation, and/or ECMO‐treatment) at baseline, the disease severity of the participants of the six studies on systemic JAK inhibitor treatment is lower on average. Thus, the majority of participants of the studies on systemic JAK inhibitors probably suffered less severe COVID‐19 in terms of need for respiratory or ventilatory support at baseline/at randomisation, compared to the studies on the anti‐inflammatory agents corticosteroids or IL‐6‐R‐antagonists. This assumption is supported by the observation that the reported 28 day all‐cause mortality of the standard of care group in this meta‐analysis of systemic JAK inhibitor study data is much lower (13.1%) compared to the aggregated data of standard of care groups of the studies on corticosteroids (27.5%) and IL‐6‐R‐antagonists (29.1%). </p> <p>With regard to the safety of JAK inhibitor therapy in clinical practice, the extent and the quality of the safety data from the included studies is still limited (moderate‐ to low‐certainty evidence). Thus far, these data have not revealed clinically relevant negative effects on the primary outcomes of this analysis: adverse events, serious adverse events, and secondary infections. In contrast, the FDA recently issued a warning on long‐term treatment, usually at least 24 weeks of therapy versus 14 days of therapy (<a href="./references#CD015209-bbs2-0084" title="US Food and Drug Administration. Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib); December 2021. www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis?utm_medium=email&amp;utm_source=govdelivery (accessed 13 April 2022).">FDA 2021a</a>). This warning was based on long‐term (up to 72 months) safety data of tofacitinib in people with rheumatoid arthritis, compared to tumour necrosis factor (TNF)‐alpha blockers and using methotrexate as part of standard of care in both groups (<a href="./references#CD015209-bbs2-0118" title="NCT02092467. Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis. www.clinicaltrials.gov/ct2/show/NCT02092467 (accessed 24 November 2021).">NCT02092467</a>). There were increased risks of death, major adverse cardiac events (MACE), malignancies, and venous thrombosis associated with long‐term treatment with tofacitinib (5 mg or 10 mg twice daily) compared to TNF‐alpha blocker treatment. As baricitinib has a similar mechanism of action, the FDA also takes an increased risk for this drug into account. As it is not used in the treatment of arthritis or any inflammatory disease in general, ruxolitinib has not been included in the warning. Nevertheless, the administration regimen (standard of care without methotrexate) and especially the duration (maximum of 14 days of treatment) are remarkably different in the assessed therapeutic strategy against COVID‐19. Therefore, the reported harmful effects of JAK inhibitors cannot be transferred directly to the application of these drugs in the context of COVID‐19 therapy. Regarding MACE and venous thrombosis with the use of tofacitinib and baricitinib for the treatment of chronic inflammatory conditions (<a href="./references#CD015209-bbs2-0085" title="US Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; December 2021. www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death (accessed 13 April 2022).">FDA 2021b</a>), our five included studies (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>) did not reveal any relevant differences between treatment groups.  </p> <p>In summary, safety data on JAK inhibitor therapy against COVID‐19 do not show relevant harmful effects of these drugs in this specific and time‐limited application so far, but the extent and quality of the safety data are limited. Thus, potential adverse events should be monitored carefully for all JAK inhibitors and be reported to pharmacovigilance authorities. </p> <p>Having been included in February 2020 (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>), May to July 2020 (<a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>), June 2020 to January 2021 (<a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>), September to December 2020 (<a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>), and December 2020 to April 2021 (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>), most participants in these studies had been infected by the wild‐type SARS‐CoV‐2. While we are uncertain as to the applicability of the study results to COVID‐19 caused by SARS‐CoV‐2 variants, this source of uncertainty is shared with most current pharmacological treatment options for people with COVID‐19. Additionally, recruitment to the included studies had largely been finalised prior to the worldwide deployment of vaccines against COVID‐19. Moreover, neither of the two studies that included participants in early 2021 reported on potentially vaccinated study participants. In contrast, 42% of the study participants in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> were vaccinated against SARS‐CoV‐2.  We cannot draw any robust conclusions with respect to the impact of vaccination on the efficacy of JAK inhibitors. </p> </section> <section id="CD015209-sec-0102"> <h3 class="title" id="CD015209-sec-0102">Quality of the evidence</h3> <p>We included data from six RCTs to assess the effects of JAK inhibitors for the treatment of moderate to severe COVID‐19 when compared to placebo or standard care alone. We evaluated the certainty of the evidence using the GRADE approach, with any downgrading substantiated (see <a href="./full#CD015209-tbl-0001">summary of findings Table 1</a>). </p> <p>We have moderate to high certainty in the identified evidence for effectiveness outcomes (all‐cause mortality up to day 28 and day 60; improvement in clinical status (discharged alive or hospitalised, but no longer requiring ongoing medical care) and worsening of clinical status (new need for mechanical ventilation or death)), and low to moderate certainty in the identified evidence for safety outcomes (any grade and serious adverse events, and secondary infection). Our main concerns for effectiveness outcomes were serious risk of bias due to <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>'s unblinded trial design and deviation from the intended interventions (10% deviation in the study mainly impacting the certainty because of its weight), and serious indirectness because of dissimilarities between outcome measurements between studies impacting the transferability of results. For any grade and serious adverse events, we identified serious risk of bias due to missing outcome data because of the competing risk of death. For the outcome 'secondary infections', we downgraded one level for serious indirectness, because of expected dissimilarities between outcome measurement between studies concerning the definitions of different types of infections, and one level for serious risk of bias due to missing outcome data because of the competing risk of death and deviations from intended intervention. </p> <p>We did not identify any study that evaluated JAK inhibitors in people with asymptomatic or mild disease. </p> </section> <section id="CD015209-sec-0103"> <h3 class="title" id="CD015209-sec-0103">Potential biases in the review process</h3> <p>This review is part of a Cochrane Living Systematic Reviews Series on different interventions for treatment of COVID‐19, established and performed by the CEOsys (COVID‐19 Evidence‐Ecosystem) consortium. CEOsys is a consortium of clinical and methodological experts supported by the German Federal Ministry of Education and Research to synthesise clinical evidence during this global pandemic. In general, our evidence synthesis approach for each topic is based on a rigorous search of electronic databases, including preprint servers and clinical trial registries, as well as additional screening of reference lists of included studies and comparison of search results with those from the living network meta‐analysis (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0120" target="_blank">COVID‐NMA</a>). Therefore, we are confident that we identified all relevant studies for this Cochrane Review. We also updated search results and the number of included studies within the review process prior to finalising the review. We aim to closely monitor ongoing studies, as well as full publications of preprints, after the publication of this version of the review. </p> <p>In addition to peer‐reviewed, full‐text articles, we also included one preprint with preliminary results for baricitinib (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>). We interpreted results of this preprint publication carefully, as there might be changes once the peer‐reviewed journal publication becomes available. We are convinced that including all eligible data in a highly dynamic situation, such as the COVID‐19 pandemic, is necessary in order to provide timely information on potentially promising treatment options. We compared journal publications and corresponding preprint articles for consistency, and did not find relevant inconsistencies. We assessed all study results for risk of bias. In case of study endpoints with missing or incomplete data, we attempted to contact corresponding authors for clarification. We received responses for two studies; these responses confirmed previously extracted data and did not provide significant new data. </p> <p>The nine trials we assessed as awaiting classification have completed recruitment, but final publication of results is still pending. Two of these studies — an RCT with a total of 432 included participants (<a href="./references#CD015209-bbs2-0045" title="NCT04362137. Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID). www.clinicaltrials.gov/ct2/show/NCT04362137 (first received 24 April 2020). ">NCT04362137</a>) and an RCT including six participants (<a href="./references#CD015209-bbs2-0043" title="EudraCT2020-001367-88. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001367-88/results (first received 16 April 2020). ">EudraCT2020‐001367‐88</a>) — recently released first results in their respective trials register platforms, ClinicalTrails.gov (<a href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a>) and EudraCT (<a href="https://eudract.ema.europa.eu/" target="_blank">https://eudract.ema.europa.eu/</a>). Although we specified in the <a href="#CD015209-sec-0017">Types of studies</a> section that results published in trial registries were eligible for inclusion, the data so far presented by these studies do not meet the requirement to provide "sufficient information [...] on study design, characteristics of participants, interventions and outcomes" to warrant inclusion. We will closely monitor these trials for publication in the near future. </p> <p>To avoid potential bias in the review process, we followed published guidance provided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0129" target="_blank">Higgins 2020a</a>). Initially, a common core outcome set was established for all reviews in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for COVID‐19 patients (<a href="./references#CD015209-bbs2-0080" title="COMET Initiative. Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020). [DOI: www.comet-initiative.org/Studies/Details/1538]">COMET 2020</a>; <a href="./references#CD015209-bbs2-0113" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>). Subsequently, additional outcomes have been prioritised by consumer representatives and the German guideline panel for inpatient therapy of people with COVID‐19 (<a href="./references#CD015209-bbs2-0067" title="AWMF. Recommendations on inpatient treatment of patients with COVID-19; March 2022 [S3-Leitlinie - Empfehlungen zur stationären Therapie von Patienten mit COVID-19]. www.awmf.org/uploads/tx_szleitlinien/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-03.pdf (accessed 14 Apri 2022).">AWMF 2022</a>). We adapted prespecified outcomes in the protocol template to address issues of competing risks associated with certain outcomes describing the clinical status of people with COVID‐19: these issues are extensively discussed in previous reviews (<a href="./references#CD015209-bbs2-0066" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>; <a href="./references#CD015209-bbs2-0151" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963]">Wagner 2021</a>). To overcome competing risks, we added outcomes for hospitalised and ambulatory managed patients that aim to simultaneously capture all participants of the population with clinical worsening and all participants with clinical improvement. This was possible by using composite outcomes: for example, by combining 'new need for invasive mechanical ventilation' and 'death' as clinical worsening for hospitalised individuals. Clinical improvement for hospitalised participants was represented by the number of participants discharged alive within the same time period used for clinical worsening. We analysed all outcomes defined in the protocol on clinical status assessed by need for respiratory support as secondary outcomes. In order to avoid biases in the generation of the manuscript, we performed all important review steps (i.e. screening of records, GRADE assessment, risk of bias assessment) independently in multiple centres, and in duplicate. The review author team discussed outstanding topics of the review process in at least weekly online meetings. </p> <p>None of the members of the review author team has any affiliation with any stakeholder group that favours or disapproves of any JAK inhibitor or the comparators used in relevant studies. </p> </section> <section id="CD015209-sec-0104"> <h3 class="title" id="CD015209-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>A first meta‐analysis on the topic was based on four studies (<a href="./references#CD015209-bbs2-0126" title="PatouliasD , DoumasM , PapadopoulosC , KaragiannisA . Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clinical Rheumatology2021;40(11):4671-4. [DOI: 10.1007/s10067-021-05884-4]">Patoulias 2021</a>), three of which are included in this review (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>). The fourth study included in <a href="./references#CD015209-bbs2-0126" title="PatouliasD , DoumasM , PapadopoulosC , KaragiannisA . Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clinical Rheumatology2021;40(11):4671-4. [DOI: 10.1007/s10067-021-05884-4]">Patoulias 2021</a> included 25 participants that had received the inhalative JAK inhibitor nezulcitinib (<a href="./references#CD015209-bbs2-0140" title="SinghD , BogusM , MoskalenkoV , LordR , MoranE , CraterGD , et al. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. European Respiratory Journal2021;58(4):2100673. [DOI: 10.1183/13993003.00673-2021]">Singh 2021</a>). We decided to exclude studies applying inhalative JAK inhibitors from our review as, in our opinion, these represent a significantly distinctive mode of action. This exclusion was not prespecified and thus deviates from the primary study protocol. Consequently, this review refers to systemically applied JAK inhibitors only. Finally, <a href="./references#CD015209-bbs2-0126" title="PatouliasD , DoumasM , PapadopoulosC , KaragiannisA . Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clinical Rheumatology2021;40(11):4671-4. [DOI: 10.1007/s10067-021-05884-4]">Patoulias 2021</a> pooled data of 1388 hospitalised participants with COVID‐19. The reduction for risk of progression of disease to mechanical ventilation or ECMO treatment (RR 0.64, CI 0.47 to 0.89) as well as death related to COVID‐19 (RR 0.57, CI 0.37 to 0.89) pointed to a clear benefit when treatment was added to standard of care, comparable to our results.  </p> <p>The same conclusion was drawn by a second published systematic review (<a href="./references#CD015209-bbs2-0074" title="ChenCY , ChenWC , HsuCK , ChaoCM , LaiCC . Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: a systematic review and meta-analysis of randomized controlled trials. International Immunopharmacology2021;99:108027. [DOI: 10.1016/j.intimp.2021.108027]">Chen CY 2021</a>). This review was based on the three trials with oral JAK inhibitors (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>), with a total of 1363 included participants. In line with our findings, the <a href="./references#CD015209-bbs2-0074" title="ChenCY , ChenWC , HsuCK , ChaoCM , LaiCC . Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: a systematic review and meta-analysis of randomized controlled trials. International Immunopharmacology2021;99:108027. [DOI: 10.1016/j.intimp.2021.108027]">Chen CY 2021</a> review found that JAK inhibitors demonstrated a favourable safety profile, with no significant difference between control and intervention groups regarding the incidence of any adverse event, as well as anaemia and lymphocytopenia in particular.  </p> <p>Limen and colleagues performed another systematic review and meta‐analysis on 14 observational and clinical trials (<a href="./references#CD015209-bbs2-0107" title="LimenRY , SedonoR , SugiartoA , HariyantoTI . Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis. Expert Review of Anti-infective Therapy 2021 Sep 29 [Epub ahead of print]. [DOI: 10.1080/14787210.2021.1982695]">Limen 2021</a>), among them three RCTs which are included in this review (<a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a>; <a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a>). The authors reported clinical benefits, such as a shortened time to recovery, a reduction in the risk of clinical deterioration, and a reduction in the mortality rate, due to systemically applied JAK inhibitors. The reduction in the mortality rate was confirmed by our meta‐analysis based on randomised controlled trials. </p> <p>Our review adds new data from three more recently published RCTs (<a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a>; <a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> (both of which are part of the COV‐BARRIER study), and <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>, part of the RECOVERY platform study). Compared to both prior meta‐analyses, this review has eightfold the number of enrolled participants (n = 11,145). In line with these previous reviews, our review confirms the benefits of systemic JAK inhibitors in the treatment of moderately to severely ill participants hospitalised with COVID‐19 especially in terms of reducing mortality (number needed to treat for an additional beneficial outcome = 28). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015209-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-FIG-01" target="_blank"><b></b></a></p> </div><img alt="WHO clinical progression scale (from: Marshall 2020)ECMO: extracorporeal membrane oxygenation; FiO2:fraction of inspired oxygen; NIV: non‐invasive ventilation; pO2:partial pressure of oxygen; SpO2:oxygen saturation. *If hospitalised for isolation only, record status as for ambulatory patient." data-id="CD015209-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-FIG-01.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>WHO clinical progression scale (from: <a href="./references#CD015209-bbs2-0113" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>) </p> <p>ECMO: extracorporeal membrane oxygenation; FiO<sub>2</sub>:fraction of inspired oxygen; NIV: non‐invasive ventilation; pO<sub>2</sub>:partial pressure of oxygen; SpO<sub>2</sub>:oxygen saturation. *If hospitalised for isolation only, record status as for ambulatory patient. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-FIG-02" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD015209-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 1: All‐cause mortality up to day 28" data-id="CD015209-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 1: All‐cause mortality up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 2: All‐cause mortality up to day 60" data-id="CD015209-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 2: All‐cause mortality up to day 60 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 3: All‐cause mortality within 28 days (time to event)" data-id="CD015209-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 3: All‐cause mortality within 28 days (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 4: All‐cause mortality within 60 days (time to event)" data-id="CD015209-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 4: All‐cause mortality within 60 days (time to event) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 5: Improvement in clinical status: discharged alive (up to day 28)" data-id="CD015209-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 5: Improvement in clinical status: discharged alive (up to day 28) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 6: Worsening of clinical status: new need for invasive mechanical ventilation or death at day 28" data-id="CD015209-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 6: Worsening of clinical status: new need for invasive mechanical ventilation or death at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 7: Adverse events (any grade)" data-id="CD015209-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 7: Adverse events (any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 8: Adverse events grade 3 and 4" data-id="CD015209-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 8: Adverse events grade 3 and 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 9: Serious adverse events" data-id="CD015209-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 9: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 10: Secondary infection" data-id="CD015209-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 10: Secondary infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 11: Adverse events of special interest" data-id="CD015209-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 11: Adverse events of special interest </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis ( type of JAK inhibitor ): baricitinib or tofacitinib or ruxolitinib versus standard of care alone (plus/minus placebo), Outcome 1: All‐cause mortality up to day 28" data-id="CD015209-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis ( type of JAK inhibitor ): baricitinib or tofacitinib or ruxolitinib versus standard of care alone (plus/minus placebo), Outcome 1: All‐cause mortality up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015209-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/urn:x-wiley:14651858:media:CD015209:CD015209-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis (severity of condition): systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 1: All‐cause mortality up to day 28" data-id="CD015209-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_t/tCD015209-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis (severity of condition): systemic JAK inhibitors versus standard of care alone (plus/minus placebo), Outcome 1: All‐cause mortality up to day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015209/media/CDSR/CD015209/image_n/nCD015209-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015209-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">JAK inhibitors plus standard of care compared to standard of care (plus/minus placebo) in individuals with moderate to severe COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>JAK inhibitors plus standard of care compared to standard of care (plus/minus placebo) in individuals with moderate to severe COVID‐19</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: hospitalised people with confirmed SARS‐CoV‐2 infection</b> <br/><b>Setting: hospitalised participants</b> <br/><b>Intervention: Janus kinase inhibitors plus standard of care</b> <br/><b>Comparator: standard of care alone (plus/minus placebo)</b> </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes<br/><i>(Time frame of absolute effects)</i> </b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>95% CI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Plain language summary</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard of care alone (plus/minus placebo)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Janus kinase inhibitors</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality (<i>up to day 28)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000<br/>(75 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72<br/>(0.57 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,145 (6 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably decrease all‐cause mortality at up to day 28</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality <i>(up to day 60)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>181 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000<br/>(102 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69<br/>(0.56 to 0.86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1626 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊕<br/>High </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors decrease all‐cause mortality at up to day 60</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care </p> <p><i>(up to day 28)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>778 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>801 per 1000<br/>(778 to 824) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03<br/>(1.00 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,802 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably make little or no difference in improvement in clinical status (discharged alive or hospitalised, but no longer requiring ongoing medical care) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worsening of clinical status: new need for invasive mechanical ventilation or death</p> <p><i>(at day 28)</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000<br/>(141 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90<br/>(0.82 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9417 (2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably decrease the risk of worsening of clinical status (new need for invasive mechanical ventilation or death at up to day 28) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events (any grade)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>427 per 1000<br/>(388 to 476) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97<br/>(0.88 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1885 (3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably make little or no difference in the rate of adverse events (any grade) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/>(138 to 186) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79<br/>(0.68 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2901 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊕ ⊖<br/>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors probably decrease the occurrence of serious adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary infection</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/>(100 to 123) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98<br/>(0.89 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,041 (4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊕ ⊖ ⊖<br/>Low<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>JAK inhibitors may make little or no difference to the rate of secondary infections</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><b>CI:</b> confidence interval; <b>JAK inhibitors:</b> Janus kinase inhibitors; <b>NE:</b> not estimable; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. <br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Reasons for downgrading:</b> </p> <p><sup>a</sup>Downgraded one level for serious risk of bias, because of unblinded trial design, deviation from the intended interventions (only 91% of participants allocated to baricitinib received treatment) in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> </p> <p><sup>b</sup>Downgraded one level for serious indirectness, because of expected dissimilarities between outcome measurement between studies impacting the transferability of results; no further downgrade for serious risk of bias (unblinded trial design and deviation from the intended interventions in the largest study (<a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a>), since the result of this study did not change pooled effect estimate of the outcome but only narrowed 95% confidence interval </p> <p><sup>c</sup>Downgraded one level for serious risk of bias, because of unblinded trial design (bias in measurement of the intervention provider decision outcome: invasive mechanical ventilation) and deviation from the intended intervention (91% allocated to baricitinib received treatment) in <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> </p> <p><sup>d</sup>Downgraded one level for serious risk of bias, because of missing data to adjust for competing risk of death </p> <p><sup>e</sup>Downgraded one level for serious indirectness, because of expected dissimilarities between outcome measurement (definitions of different types of infections) between studies and one level for serious risk of bias because of missing data to adjust for competing risk of death and deviations from intended intervention </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">JAK inhibitors plus standard of care compared to standard of care (plus/minus placebo) in individuals with moderate to severe COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015209-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number</b> </p> <p><b>of participants (ITT)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Severity of condition in regard to respiratory support, n (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Age, years</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time from symptom onset to randomisation</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ruxolitinib 5 mg twice a day orally (duration not reported)</p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo twice a day (vitamin C) orally + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 20</p> <p>Control: 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Supplemental oxygen<br/>through low‐flow devices = 36 (87.8) </p> <p>Supplemental oxygen<br/>through high‐flow devices / NIV = 5 (12.2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (range) 63 (58 ‐ 68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 20 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0003" title="GuimarãesPO , QuirkD , FurtadoRH , MaiaLN , SaraivaJF , AntunesMO , et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine2021;385(5):406-15. ">Guimarães 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tofacitinib 10 mg twice a day orally (reduced dose: 5 mg twice a day) for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo twice a day orally + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 144</p> <p>Control: 145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen = 71 (24.6)</p> <p>Supplemental oxygen<br/>through low‐flow devices = 181 (62.6) </p> <p>Supplemental oxygen<br/>through high‐flow devices = 37 (12.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 56 (± 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 10 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0005" title="KalilAC , PattersonTF , MehtaAK , TomashekKM , WolfeCR , GhazaryanV , et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine2021;384(9):795-807. [DOI: 10.1056/NEJMoa2031994]">Kalil 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4 mg once a day (reduced dose: 2 mg once a day) for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC (including remdesivir in all participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo once a day + SoC (includig remdesivir in all participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 515</p> <p>Control: 518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen = 142 (13.7)</p> <p>Supplemental oxygen<br/>through low‐flow devices = 564 (54.6) </p> <p>Supplemental oxygen<br/>through high‐flow devices / NIV = 216 (20.9) </p> <p>IMV = 111 (10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 55.4 (± 15.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median: 8 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0006" title="MarconiVC , RamananAV , deBonoS , KartmanC , KrishnanV , LiaoR , et al. Baricitinib plus standard of care for hospitalized adults with Covid-19. medRxiv [Preprint] 03 May 2021. [DOI: 10.1101/2021.04.30.21255934]MarconiVC , RamananAV , deBonoS , KartmanCE , KrishnanV , LiaoR , et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Medicine2021;9(12):1407-18. [DOI: 10.1016/S2213-2600(21)00331-3]">Marconi 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4 mg once a day orally (reduced dose: 2 mg once a day) for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo once a day orally + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 764</p> <p>Control: 761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen = 186 (12.2)</p> <p>Supplemental oxygen<br/>through low‐flow devices = 962 (63.1) </p> <p>Supplemental oxygen<br/>through high‐flow devices / NIV = 370 (24.3) </p> <p>Unknown = 7 (0.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 57.6 (± 14.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 7 days in 83.5% of participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0002" title="ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzeliML , et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2022 Feb 3 [Epub ahead of print]. [DOI: 10.1016/S2213-2600(22)00006-6]ElyEW , RamananAV , KartmanCE , deBonoS , LiaoR , PiruzwliML , et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv [Preprint] 09 November 2021. [DOI: 10.1101/2021.10.11.21263897]">Ely 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4 mg once a day (reduced dose when GFR ≥ 30 to<br/>&lt; 60 mL/min/1.73 m<sup>2</sup> : 2 mg once a day) by nasogastric tube delivery (or<br/>given orally when feasible); for up to 14 days or until hospital discharge </p> <p>+</p> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo once a day by nasogastric tube delivery (or<br/>given orally when feasible) + SoC </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 51</p> <p>Control: 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMV = 101 (100)</p> <p>ECMO = 4 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) 58.6 (± 13.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 7 days in 93.9% of participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib 4mg once a day for up to 10 days or until hospital discharge (reduce dose if eGFR ≥30 &lt;60 mL/min/1.73m2: 2 mg once daily, if eGFR ≥15 &lt;30 mL/min/1.73m2: 2 mg on alternate days) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: 4148</p> <p>Control: 4008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No supplemental oxygen: 465 (6%)</p> <p>Simple oxygen: 5513 (68%)</p> <p>NIV: 1927 (24%)</p> <p>IMV: 251 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>intervention: 58.5 (15.4) vs control 57.7 (15.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median: 9 days</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>ECMO:</b> extracorporeal membrane oxygenation; <b>GFR:</b> glomerular filtration rate; <b>IMV:</b> invasive mechanical ventilation; <b>ITT:</b> intention‐to‐treat; <b>NIV:</b> non‐invasive ventilation; <b>SD:</b> standard deviation; <b>SoC:</b> standard of care. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015209-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of ongoing studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Title</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>JAK inhibitors</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of participants planned</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Prospective completion date</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective, Phase II, Randomized, Open‐label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS‐CoV2 Pneumonia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two intervention arms:</p> <p>1. Baricitinib</p> <p>2. Imatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0054" title="NCT04346147. Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of baricitinib, imatinib or supportive treatment in patients with SARS Cov2 pneumonia. www.clinicaltrials.gov/ct2/show/NCT04346147 (first received 15 April 2020). ">NCT04346147</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2021 (last update posted August 2021)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mulTi‐Arm Therapeutic Study in Pre‐ICu Patients Admitted With Covid‐19 ‐ Repurposed Drugs (TACTIC‐R) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two intervention arms:</p> <p>1. Baricitinib + SoC</p> <p>2. Ravulizumab + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0056" title="NCT04390464. mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R). www.clinicaltrials.gov/ct2/show/NCT04390464 (first received 12 May 2020). ">NCT04390464</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Factorial, Multicentric, Randomized Clinical Trial of Remdesivir and Immunotherapy in Combination With Dexamethasone for Moderate COVID‐19 (the AMMURAVID Trial) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three intervetion arms:</p> <p>1. Baricitinib + SoC</p> <p>2. Remdesivir + SoC</p> <p>3. Baricitinib + Remdesivir + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC (with Dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0062" title="NCT04832880. Factorial, multicentric, randomized clinical trial of remdesivir and immunotherapy in combination with dexamethasone for moderate COVID-19 (the AMMURAVID Trial). www.clinicaltrials.gov/ct2/show/record/NCT04832880 (first received 6 April 2021). ">NCT04832880</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0063" title="NCT04891133. European DisCoVeRy for Solidarity: an Adaptive Pandemic and Emerging Infection Platform Trial. www.clinicaltrials.gov/ct2/show/NCT04891133 (first received 18 May 2021). ">NCT04891133</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>December 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACCORD‐2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID‐19 in Hospitalised Patients </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four intervetion arms:</p> <p>1. Bemcentinib</p> <p>2. MEDI3506 (human IgG mAB)</p> <p>3. Zilucoplan</p> <p>4. Acalabrutinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0053" title="EudraCT 2020-001736-95. ACCORD-2: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001736-95/GB (first received 23 April 2020). ">EudraCT2020‐001736‐95</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baricitinib in Hospitalized Covid‐19 Patients With Diabetes Mellitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0064" title="NCT04970719. Baricitinib in hospitalized Covid-19 patients with diabetes mellitus. www.clinicaltrials.gov/ct2/show/NCT04970719 (first received 21 July 2021). ">NCT04970719</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>December 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three intervetion arms:</p> <p>1. Ruxolitinib</p> <p>2. Colchicine</p> <p>3. Secukinumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0058" title="NCT04403243. COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT). www.clinicaltrials.gov/ct2/show/NCT04403243 (first received 27 May 2020). ">NCT04403243</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>August 2020 (last update posted May 2020)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised Multi‐arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID‐19 Pneumonia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two intervetion arms:</p> <p>1. Ruxolitinib</p> <p>2. Fostamatinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0060" title="NCT04581954. Randomised multi-arm trial of ruxolitinib (RUX) and fostamatinib (FOS) for COVID-19 pneumonia. www.clinicaltrials.gov/ct2/show/NCT04581954 (first received 9 October 2020). ">NCT04581954</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>456</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>December 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS‐CoV2 (COVID‐19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial (TOFACoV‐2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tofacitinib + Hydroxychloroquine + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydroxychloroquine + SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0055" title="NCT04390061. TOFAcitinib plus hydroxycloroquine vs hydroxycloroquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial (TOFACoV-2). www.clinicaltrials.gov/ct2/show/NCT04390061 (first received 13 May 2020). ">NCT04390061</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>September 2020 (last update posted May 2020)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco‐hematological patients affected with COVID19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0052" title="EUCTR2020-001789-12. A phase I/II clinical trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: a structured summary of a study protocol for a randomised controlled trial. www.clinicaltrialsregister.eu/ctr-search/search/trial/2020-001789-12 (first received 5 Febuary 2021). [DOI: 10.1186/s13063-021-05072-4]">EUCTR2020‐001789‐12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baricitinib Compared to Standard Therapy in Patients With COVID‐19 (BARICIVID‐19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0057" title="NCT04393051. Baricitinib Compared to Standard Therapy in Patients With COVID-19 (BARICIVID-19). https://clinicaltrials.gov/ct2/show/NCT04393051 (first received 19 May 2020). ">NCT04393051</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>June 2020</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID‐19 disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ruxolitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SoC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0059" title="EudraCT2020-001754-21. An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001754-21/FR (first received 17 April 2020). NCT04424056. A trial using anakinra, tocilizumab alone or in association with ruxolitinib in severe stage 2b and 3 of COVID 19-associated disease (INFLAMMACOV). www.clinicaltrials.gov/ct2/show/NCT04424056 (first received 9 June 2020). ">NCT04424056</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>November 2022</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tocilizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015209-bbs2-0061" title="NCT04693026. Efficacy of ramdicivir and baricitinib for the treatment of severe COVID 19 patients. www.clinicaltrials.gov/ct2/show/NCT04693026 (first received 5 January 2021). ">NCT04693026</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2021</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><b>COVID‐19:</b> coronavirus disease 2019; <b>IgG:</b> immunoglobulin‐G;<b>mAB:</b> monoclonal antibody;<b>SARS‐CoV‐2:</b> severe acute respiratory syndrome coronavirus 2;<b>SoC:</b> standard of care </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of ongoing studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015209-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses for the comparison: JAK inhibitor plus standard care versus standard care plus placebo</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Main analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Only peer‐reviewed articles</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Only studies judged to be of low risk of bias or some concerns</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Only placebo‐controlled studies, excluding vitamin C as placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fixed‐effect meta‐analysis</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality up to day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.72 (95% CI 0.57 to 0.91), including 11,145 participants from six studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (95% CI 0.51 to 0.78), including 2989 participants from five studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (95% CI 0.51 to 0.78), including 2989 participants from five studies<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.63 (95% CI 0.51 to 0.79), including 2948 participants from four studies<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.84 (95% CI 0.76 to 0.93), including 11,145 participants from six studies</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Exclusion of <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> (preprint article)<br/><sup>b</sup>Exclusion of <a href="./references#CD015209-bbs2-0001" title="CaoY , WeiJ , ZouL , JiangT , WangG , ChenL , et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology2020;146(1):137-46.e3. [DOI: 10.1016/j.jaci.2020.05.019]">Cao 2020</a> (used vitamin C as placebo) and <a href="./references#CD015209-bbs2-0004" title="HorbyP , EmbersonJR , MafhamM , ThwaitesG , HaynesR , LandrayMR , et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 Posted 03 March 2022. [DOI: 10.1101/2022.03.02.22271623]">Horby 2022</a> (no placebo was used) </p> <p><b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses for the comparison: JAK inhibitor plus standard care versus standard care plus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/full#CD015209-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015209-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic JAK inhibitors versus standard of care alone (plus/minus placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality up to day 60 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.56, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality within 28 days (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality within 60 days (time to event) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.47, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Improvement in clinical status: discharged alive (up to day 28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [1.00, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Worsening of clinical status: new need for invasive mechanical ventilation or death at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse events grade 3 and 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2901</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Secondary infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Adverse events of special interest <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.45, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Lymphocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.21, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Intestinal perforation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic JAK inhibitors versus standard of care alone (plus/minus placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015209-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis ( type of JAK inhibitor ): baricitinib or tofacitinib or ruxolitinib versus standard of care alone (plus/minus placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Baricitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.58, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Tofacitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.16, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Ruxolitinib</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 2.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis ( type of JAK inhibitor ): baricitinib or tofacitinib or ruxolitinib versus standard of care alone (plus/minus placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015209-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis (severity of condition): systemic JAK inhibitors versus standard of care alone (plus/minus placebo)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 All‐cause mortality up to day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.71, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 No oxygen at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.40, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Low‐flow oxygen at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.52, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 NIV or HFNO at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.65, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 IMV or ECMO at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.59, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis (severity of condition): systemic JAK inhibitors versus standard of care alone (plus/minus placebo)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#CD015209-tbl-0007">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Cao 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using permuted blocks of four. The process of randomisation was masked to all treating physicians. There are no significant differences between intervention and control group. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Treating physicians aware of group assignment.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from 41 Participants were reported (= modified ITT‐population).</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a binary outcome. There is only one way do measure this ouctome.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>With the available data, it cannot be decided whether the planning of the statistical analysis was completed before unblinding. The authors write that the study was terminated before the planned number of participants (n=70) was reached because recruitment of participants became impossible due to the pandemic slowdown. However, since the outcome is binary, a missing SAP does not have a significant impact on the way the outcome is recorded. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Ovearall, we judged some concerns due to the unblinded study design.</p> </td> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before start of participants recruitment for this addendum. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was double‐blinded and an appropriate analysis was used.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was analysed in accordance with a pre‐specified statistical analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There were slight discrepancies between study groups concerning pre‐existing conditions and age deviation but randomisation process apeared appropriate. Outcome measurement was carried out according to a pre‐specified protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial design and chance of underestimation of baricitinib effects because only 91% patients in the intervention group received Baricitinib (ITT analysis used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Follow‐up form was completed for 4084 (98%) patients in the baricitinib group and 3950 (99%) patient in the control group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>no relevant issues</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol provided details of time points and analysis. Mortality was analysed in accordance with a prespecified analysis plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concerns due to bias from relevant deviation from intended intervention in the treatment group </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged a low risk of bias. Although it is possible that participants were already receiving remdesivir before inclusion in the study, any resulting risk of bias should be considered "low". To estimate the effect of assingment the intention‐to‐treat population was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data are reported for the entire 'intention‐to‐treat' population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an statistical analysis plan available. There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the ITT‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP was completed before unblinding.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause mortality up to day 60</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before start of participants recruitment for this addendum. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias. Mortality at day 60 was a prespecified exploratory endpoint, however introduced with an amendment during study. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. However, this endpoint was added, based on a regulatory feedback, in a protocol amendment (Amendment D, 20.10.2020). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias. Mortality at day 60 was a prespecified exploratory endpoint, however introduced with an amendment during study. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause mortality up to day 60</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 All‐cause mortality within 28 days (time to event)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>To estimate the effect of assingment the intention‐to‐treat population was used. Matching placebos were used and the study was carried out double blinded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for all participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. There are no substantial differences at baseline. To estimate the effect of assingment the ITT‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Carers and participants were unaware of the assigned interventions and the ITT was reported. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. Same methods used for both groups. Assessors were unaware of the intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Analysis was performed in accordance with a pre‐specified SAP. Outcome was measured in accordance to the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with concealed Web‐based randomisation system, baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Chance of underestimation of baricitinib effects because only 91% patients in the intervention group received Baricitinib (ITT analysis used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>no relevant issues; Follow‐up form was completed for 4084 (98%) patients in the baricitinib group and 3950 (99%) patient in the control group. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>no relevant issues</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>outcome parameter prespecified as primary outcome in study protocol</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concerns due to relevant noncompliance in the treatment group</p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged a low risk of bias. Although it is possible that participants were already receiving remdesivir before inclusion in the study, any resulting risk of bias should be considered "low", because the period during which deviations from the protocol were possible was very short. To estimate the effect of assingment the intention‐to‐treat population was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data are reported for the entire 'intention‐to‐treat' population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring was appropriate. Same methods for both groups used. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an statistical analysis plan available that was released after the enrolment had been terminated. In the trial protocol, only percentages of deceased participants (d14, d 28) were planned, although assessment of changes in ordinal scales was planned, too. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns. There are only minor differences at baseline. This is a double blinded trial. To estimate the effect of assingment the intention‐to‐treat population was used. The method of measuring the outcome was appropriate.<br/>There is an statistical analysis plan available. However, the statistical analysis plan was available after enrolment of all participants. In the pre‐specified protocol (NCT04401579), there were only TTE‐analyses planned, that concerned cinical improvement. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. To estimate the effect of intervention the 'as‐treated' population was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The entire ITT was reported. Additionally, there was a low rate of "lost to follow‐up"s.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measurement of the outcome was adequate, with planned study visits at Study Day 4, Day 7, Day 10, Day 14, and Day 28 and a follow‐up visit at Day 60 and assessors were blinded. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome measurement and analysis were carried out as pre‐defined in study protocol/SAP.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 All‐cause mortality within 28 days (time to event)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 All‐cause mortality within 60 days (time to event)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>To estimate the effect of assingment the intention‐to‐treat population was used. Matching placebos were used and the study was carried out double blinded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for all participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was analysed in accordance with a pre‐specified statistical analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study is judged to be at low risk of bias for all domains for this result. There are no substantial differences at baseline. To estimate the effect of assingment the ITT‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. However, this endpoint was added, based on a regulatory feedback, in a protocol amendment (Amendment D, 20.10.2020). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality at day 60 was a prespecified exploratory endpoint, however introduced with an amendment during study. Overall, we judged low risk of bias. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 All‐cause mortality within 60 days (time to event)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Improvement in clinical status: discharged alive (up to day 28)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study was doouble‐blinded and verum and placebo were packaged indistinguishably in identical containers. Hence, an unintentional unblinding was almost impossible. To estimate the effect of intervention the 'intention‐to‐treat' population was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified 'intention‐to‐treat' population was used.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before start of participants recruitment for this addendum. There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial design and chance of underestimation of baricitinib effects because only 91% patients in the intervention group received Baricitinib (ITT analysis used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Length of hospital stay might have been prolonged by treating physician.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Differences of protocol and publication do not directly influence our analysis of the aggregated raw dichotomous outcome, but are relevant in general. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concerns about deviation from intended interventions and measurement of outcome in an unblinded trial. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was double‐blinded and an appropriate analysis was used.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was available for nearly all participants and competing risk of death was addressed.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was analysed in accordance with a pre‐specified statistical analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There were slight discrepancies between study groups concerning pre‐existing conditions but randomisation process appeared appropriate. Outcome measurement was carried out according to a pre‐specified analysis plan. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study was doouble‐blinded and verum and placebo were packaged indistinguishably in identical containers. Hence, an unintentional unblinding was almost impossible. To estimate the effect of intervention the 'intention‐to‐treat' population was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified 'intention‐to‐treat' population was used: LOCF (=Last Observation Carried Forward) popoulation. Definition: All ITT participants with non‐missing baseline NIAID‐OS score and at least one post‐baseline NIAID‐OS score (intervention: 758 participants, control: 754 participants). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. The study protocol states: "... The SAP will be finalized prior to unblinding. ..." There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Improvement in clinical status: discharged alive (up to day 28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Worsening of clinical status: new need for invasive mechanical ventilation or death at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial design and chance of underestimation of baricitinib effects because only 91% patients in the intervention group received Baricitinib (ITT analysis used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Initiating invasive ventilation is a intervention provide decision outcome. the decision to start invasive ventilation could be influenced by the knowledge of treating physician about treatment group. But the decision making process to start invasive ventilation is guided by well accepted reference values/guideline recommendations for treating intensive care physicians and the individual decision making physician is unlikely to have an interest to adjust decision according to treatment group allocation. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol provided details of time points and analysis. "New need for mechanical ventilation or death" was analysed in accordance with a prespecified analysis plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concerns due to deviation from intended interventions and due to measurement of outcome in an unblinded trial. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Study was double‐blinded and verum and placebo packaged indistinguishably in identical containers. Hence, an unintentional unblinding was almost impossible. To estimate the effect of intervention a modified 'intention‐to‐treat' population was analysed: "Last Observation Carried Forward" population. Participants who develop a worsening condition after discharge and were readmitted may not be recorded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A modified 'intention‐to‐treat' population was used: LOCF (=Last Observation Carried Forward) population. Definition: All ITT participants with non‐missing baseline NIAID‐OS score and at least one post‐baseline NIAID‐OS score (intervention: 758 participants, control: 754 participants). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP is available in the online appendix and was completed before unblinding. The study protocol states: "... The SAP will be finalized prior to unblinding. ..." </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Protocol was amended and composite end‐point modified during study (from day 10 to day 28) based on external trial; risk of bias, nevertheless, is regarded as low. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Worsening of clinical status: new need for invasive mechanical ventilation or death at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Adverse events (any grade)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind study; to estimate the effect of intervention the safety population (participants that received at least one dose) was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The 'as‐treated' population was used. There is an uncertain amount of missings due to competing risk of death and a possible underreporting of AE due to consideration as a result of covid progression. Only treatment‐emergent adverse events were reported. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate (could not have differed between groups, same methods where use in both groups outcome assessors were unaware of the intervention recieved by study participants). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before start of participants recruitment for this addendum. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns. There were slight deviations between study groups concerning age but randomisation process apeared appropriate. There is an uncertain amount of missings due to competing risks. </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was carried out double‐blinded and the outcome was assessed by safety set.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an uncertain amount of missings due to competing risk of death. It is uncertain, whether the result is biased or not. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were unaware of the treatment assignments and could not have been affected by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was reported but not analysed according to a study protocol providing details of comparison of adverse events between study groups. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to competing risk of death and deviations from protocol‐defined analyses. The as‐treated population was analysed. Slight differences in baseline characteristics a likely to be random. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind study; to estimate the effect of intervention the safety population (participants that received at least one dose) was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The 'as‐treated' population was used (intervention: 750 participants, control: 752 participants). There is an uncertain amount of missings due to competing risk of death and a possible underreporting of AE due to consideration as a result of covid progression. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate (could not have differed between groups, same methods where use in both groups outcome assessors were unaware of the intervention recieved by study participants). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. The study protocol states: "... The SAP will be finalized prior to unblinding. ...". However, this endpoint was added, based on a regulatory feedback, in a protocol amendment (Amendment D, 20.10.2020). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns. There were slight deviations between study groups concerning age but randomisation process apeared appropriate. There is an uncertain amount of missings due to competing risks. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.7 Adverse events (any grade)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Adverse events grade 3 and 4</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a double blinded trial. Analysis was appropriate. As‐treated‐populatien was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for all 1016 participants are reported. Adverse effects were reported only when they occurred in at least 5 patient participants. Therefore, the maximum rate of unreported adverse effects is very small. The bias due to competing risk of death was minimized by application of the Fine‐Gray approach. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. Outcome assessors were unaware of treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>A statistical analysis plan was available before the actual analysis was performed. The data were analysed in accordance with a pre‐SAP. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the as‐treated‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.8 Adverse events grade 3 and 4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. To estimate the effect of intervention the safety population was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The 'as‐treated' population was used. There is an uncertain amount of missings due to competing risk of death and a possible underreporting of SAE due to consideration as a result of covid progression.Only treatment‐emergent severe adverse events were reported. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate (could not have differed between groups, same methods where use in both groups outcome assessors were unaware of the intervention recieved by study participants). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before start of participants recruitment for this addendum. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns. There were slight deviations between study groups concerning age but randomisation process apeared appropriate. There is an uncertain amount of missings due to competing risks. </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was carried out double‐blinded and the outcome was assessed by safety set.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an uncertain amount of missings due to competing risk of death. It is uncertain, whether the result is biased or not. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to exclusion of defined serious adverse events, bias in measurement can not be precluded. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was reported but not analysed according to a study protocol providing details of comparison of adverse events between study groups. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to concerns in measurement with exclusion of disease‐related serious adverse events. There were slight discrepancies between study groups concerning pre‐existing conditions and age deviation but randomisation process appeared appropriate. There is an uncertain amount of missings due to competing risk of death. Outcome was assessed blinded for the safety set population with minor deviation from study protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a double blinded trial. Analysis was appropriate. As‐treated‐populatien was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>By applying the Fine‐Gray approach, the risk of bias in the results due to competing risk was minimized. Therefore judged low risk of bias. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. Outcome assessors were unaware of treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was analysed in accordance with a pre‐specified SAP.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the as‐treated‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. To estimate the effect of intervention the safety population was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The 'as‐treated' population was used (intervention: 750 participants, control: 752 participants). There is an uncertain amount of missings due to competing risk of death and a possible underreporting of SAE due to consideration as a result of covid progression. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate (could not have differed between groups, same methods where use in both groups outcome assessors were unaware of the intervention recieved by study participants). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. Protocol Section 10.3.2 defines what is to be recorded as SAE. There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns. There were slight deviations between study groups concerning age but randomisation process apeared appropriate. There is an uncertain amount of missings due to competing risks. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.9 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Secondary infection</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. To estimate the effect of intervention the safety population was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The 'as‐treated' population was used. There is an uncertain amount of missings due to competing risk of death. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate (could not have differed between groups, same methods where use in both groups outcome assessors were unaware of the intervention recieved by study participants). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. Outcome was measured and analysed as planned. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns. There were slight deviations between study groups concerning age but randomisation process apeared appropriate. There is an uncertain amount of missings due to competing risks. </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was carried out double‐blinded and the outcome was assessed by safety set.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence that the result was not biased by missings due to competing risk of death and early drug discontinuation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were unaware of the treatment assignments and could not have been affected by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were unaware of the treatment assignments and could not have been affected by knowledge of intervention, but data was not fully reported and not analysed according to a study protocol providing details of comparison between study groups. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall jugded some concerns due to competing risk of death and deviations from protocol‐defined analyses. The as‐treated population was analysed. Slight differences in baseline characteristics a likely to be random. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Unblinded trial design and chance of underestimation of baricitinib effects because only 91% patients in the intervention group received Baricitinib (ITT analysis used). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an uncertain amount of missings due to competing risks. It is uncertain, whether the result is biased or not. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>In this open‐label trial without further algorithms or procedures in place to actively screen for certain infections the assessor could have let infections or suspected infections undocumented. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issues with selection of the reported result.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Concerns due to deviation from intended interventions and due to measurement of outcome in an unblinded trial. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. To estimate the effect of intervention the safety population was analysed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The 'as‐treated' population was used (intervention: 750 participants, control: 752 participants). There is an uncertain amount of missings due to competing risk of death. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate (could not have differed between groups, same methods where use in both groups outcome assessors were unaware of the intervention recieved by study participants). </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. Outcome was measured and analysed as planned. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns. There were slight deviations between study groups concerning age but randomisation process apeared appropriate. There is an uncertain amount of missings due to competing risks. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.10 Secondary infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Adverse events of special interest</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.1 Anaemia</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was carried out double‐blinded and the outcome was assessed by safety set.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an uncertain amount of missings due to competing risk of death. It is uncertain, whether the result is biased or not. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were unaware of the treatment assignments and could not have been affected by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was not fully reported and not analysed according to a study protocol providing details of comparison between study groups. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to competing risk of death and deviations from protocol‐defined analyses. The as‐treated population was analysed. Slight differences in baseline characteristics a likely to be random. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a double blinded trial. Analysis was appropriate. As‐treated‐populatien was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>By applying the Fine‐Gray approach, the risk of bias in the results due to competing risk was minimized. Therefore judged low risk of bias. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because same methods were used in both the intervention an control group there is a low risk of bias. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was analysed in accordance with a pre‐specified SAP.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the as‐treated‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.2 Lymphocytopenia</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col6" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was carried out double‐blinded and the outcome was assessed by safety set.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an uncertain amount of missings due to competing risk of death. It is uncertain, whether the result is biased or not. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were unaware of the treatment assignments and could not have been affected by knowledge of intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was not fully reported and not analysed according to a study protocol providing details of comparison between study groups. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged some concerns due to competing risk of death and deviations from protocol‐defined analyses. The as‐treated population was analysed. Slight differences in baseline characteristics a likely to be random. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>This is a double blinded trial. Analysis was appropriate. As‐treated‐populatien was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>By applying the Fine‐Gray approach, the risk of bias in the results due to competing risk was minimized. Therefore judged low risk of bias. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Because same methods were used in both the intervention an control group there is a low risk of bias. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data was analysed in accordance with a pre‐specified SAP.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the as‐treated‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.11.3 Intestinal perforation</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double blind study. Safety population anaysed.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The 'as‐treated' population was used (intervention: 750 participants, control: 752 participants). There are no missing data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome was assessed equally in both groups, assessors were blinded.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before unblinding. The study protocol states: "... The SAP will be finalized prior to unblinding. ...". However, this endpoint was added, based on a regulatory feedback, in a protocol amendment (Amendment D, 20.10.2020). </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>IAEs were not separately classified, although we rate a low risk of bias.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.11 Adverse events of special interest</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 All‐cause mortality up to day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.1 No oxygen at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was double‐blinded and an appropriate analysis was used.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was analysed in accordance with a pre‐specified statistical analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There were slight discrepancies between study groups concerning pre‐existing conditions and age deviation but randomisation process apeared appropriate. Outcome measurement was carried out according to a pre‐specified protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Relevant lack of the intervention in the intervention group.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was performed according to a pre‐defined study protocol and appropriate. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality was analysed in accordance with a prespecified analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mainly deviations from the intended intervention introduce risk of bias in a possible influence on the effect. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged a low risk of bias. Although it is possible that participants were already receiving remdesivir before inclusion in the study, any resulting risk of bias should be considered "low". To estimate the effect of assingment the intention‐to‐treat population was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data are reported for the entire 'intention‐to‐treat' population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an statistical analysis plan available. There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the ITT‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP was completed before unblinding.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.2 Low‐flow oxygen at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was double‐blinded and an appropriate analysis was used.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was analysed in accordance with a pre‐specified statistical analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There were slight discrepancies between study groups concerning pre‐existing conditions and age deviation but randomisation process apeared appropriate. Outcome measurement was carried out according to a pre‐specified protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Relevant lack of the intervention in the intervention group.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was performed according to a pre‐defined study protocol and appropriate. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality was analysed in accordance with a prespecified analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mainly deviations from the intended intervention introduce risk of bias in a possible influence on the effect. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged a low risk of bias. Although it is possible that participants were already receiving remdesivir before inclusion in the study, any resulting risk of bias should be considered "low". To estimate the effect of assingment the intention‐to‐treat population was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data are reported for the entire 'intention‐to‐treat' population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an statistical analysis plan available. There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the ITT‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP was completed before unblinding.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.3 NIV or HFNO at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Guimarães 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study was double‐blinded and an appropriate analysis was used.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was available for all participants randomized.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was appropriate. The outcome was assessed using standardised methods and assessors were unaware of the treatment assignments. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data was analysed in accordance with a pre‐specified statistical analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There were slight discrepancies between study groups concerning pre‐existing conditions and age deviation but randomisation process apeared appropriate. Outcome measurement was carried out according to a pre‐specified protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Relevant lack of the intervention in the intervention group.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was performed according to a pre‐defined study protocol and appropriate. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality was analysed in accordance with a prespecified analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mainly deviations from the intended intervention introduce risk of bias in a possible influence on the effect. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged a low risk of bias. Although it is possible that participants were already receiving remdesivir before inclusion in the study, any resulting risk of bias should be considered "low". To estimate the effect of assingment the intention‐to‐treat population was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data are reported for the entire 'intention‐to‐treat' population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an statistical analysis plan available. There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the ITT‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> <tr class="study-data"> <td> <p>Marconi 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed according to standard and concealed. There were slight discrepancies between study groups which did not imply a general problem with the randomisation process. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP was completed before unblinding.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 3.1.4 IMV or ECMO at baseline</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Ely 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Randomisation was performed using an interactive web‐response system. The differences in baseline characteristics are likely to be random and do not suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Double‐blind trial. Verum and placebo were packaged indistinguishably for participants in identical containers. The tablets used were visually indistinguishable. Hence, an unintentional unblinding was almost impossible. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data from all participants were available.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate and was assessed using standard methods, while assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The SAP available in the online appendix was completed before start of participants recruitment for this addendum. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall, we judged low risk of bias (randomization with interactive web‐response system (IWRS), baseline differcences likely to be random, double blinded study, ITT analysed and data from all participants available, outcome measuring appropriate, analysis using a pre‐specified SAP). </p> </td> </tr> <tr class="study-data"> <td> <p>Horby 2022</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No significant or relevant differences.</p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Relevant lack of the intervention in the intervention group.</p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No issue with missing data.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Measuring of the outcome was performed according to a pre‐defined study protocol and appropriate. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mortality was analysed in accordance with a prespecified analysis plan.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Mainly deviations from the intended intervention introduce risk of bias in a possible influence on the effect. </p> </td> </tr> <tr class="study-data"> <td> <p>Kalil 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no evidence to suggest a risk of bias in the randomisation process. Differences in baseline characteristics are likely to be random. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged a low risk of bias. Although it is possible that participants were already receiving remdesivir before inclusion in the study, any resulting risk of bias should be considered "low". To estimate the effect of assingment the intention‐to‐treat population was used. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data are reported for the entire 'intention‐to‐treat' population.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The method of measuring the outcome was appropriate. This outcome is a binary outcome and was assessed using standard methods. The outcome assessors were unaware of the intervention recieved by study participants. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is an statistical analysis plan available. There is only one way to measure the outcome. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Overall judged low risk of bias. There are no substantial differences at baseline. To estimate the effect of assingment the ITT‐population was used. The data were analysed in accordance with a pre‐specified SAP. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 All‐cause mortality up to day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015209/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015209&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD015209-note-0069">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015209-note-0055">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015209-note-0062">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015209-note-0048">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD015209-note-0041">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD015209-note-0034">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD015209-note-0027">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015209-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015209-note-0020">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015209\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015209"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015209\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015209\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015209"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015209\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015209"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015209\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015209\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015209"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Qh5938oe&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015209&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015209';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015209/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015209/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015209%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726750819"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015209/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726750823"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015209/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9b411b7f9368',t:'MTc0MDcyNjc1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 